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Eukaryotic organisms, including human, require molecular oxygen (O2) to survive. During 
periods of low O2 availability (hypoxia), a family of protein transcription factors become 
stabilised (Hypoxia Inducible Factors, HIF) and allow the adaption to hypoxia by regulating 
gene expression. Hypoxic adaption is required for cellular survival and is considered a 
hallmark of cancer. HIF is a heterodimeric protein consisting of a stable beta subunit (HIF-
1β) and an O2 labile alpha subunits (HIF-1α  or HIF-2α). The two HIFα isoforms share ~50% 
sequence homology, yet have different target genes, O2 sensitivity and sub-nuclear 
localisation. The O2-dependent stability of HIFα subunits is due to an O2 dependent, proline 
hydroxylation post translational modification (PTM) resulting in degradation. The current 
understanding of post-translational regulation beyond the O2 dependent hydroxylation are 
poorly understood. Previous published studies aiming to identify HIF PTMs did it using a 
targeted/biased approach and failed to compare isoforms. Therefore, the primary aim of 
this work was to expand the understanding of the regulatory network of HIFα proteins, by 
obtaining an unbiased identification of PTMs and binding partners using a proteomics 
approach. We have performed an in-depth analysis of PTMs across ~90% of the total 
protein sequence for HIF-1α and HIF-2α in response to hypoxia, with a specific focus on 
phosphorylation. In total, ~50 different PTMs were confidently identified (~25 of which 
were phosphorylation) for each HIFα proteins, with the majority of these PTM sites being 
novel. Identified PTM sites were investigated through a combination of hypoxia regulation, 
evolutionary analysis, domain localisation and crystal structure modelling to identify 
potentially interesting sites to prioritise functional characterisation. This led to the 
discovery of HIF-1α Serine 31 phosphorylation, a previously superficially investigated site, 
as a potentially important mechanism to fully abolish HIF-1α-mediated transcription by 
preventing its binding to DNA. In addition, HIFα binding partners in response to hypoxia 
were identified. We demonstrated that many more proteins interact with HIFα proteins 
than currently known. The binding partner profiles were hypoxia-dependent, especially for 
HIF-2α which had >10 fold more binding partners confidently identified in hypoxia than 
normoxia. Combined with Gene ontology (GO) analysis, the binding partners identified 
strongly suggest a role for HIFα with mitochondria. Whilst we have discovered many novel 
data, this project has opened many avenues for further investigation. Overall, it is clear that 
the current understanding of HIF mediated hypoxia signalling is incomplete, and that the 
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1.1. Cellular adaptation and the requirement 
aaaiof cell signalling 
All living organisms, either single or multi-cellular, need to be able adapt to their changing 
environment in order to survive. Because various environmental signals (stimuli) are 
possible, organisms require mechanisms to sense specific environmental stimuli and 
transduce the signal to promote the appropriate adaptive response. Over a prolonged time 
period, the adaption process to the environment drives the evolution of species, 
highlighting its significance. For multicellular organisms, adaption at the cellular level 
permits cells to function as independent cell types to form highly complex systems. 
 
An extracellular signal needs be transduced intracellularly to promote an adaptive 
response, known as cell signalling. The adaptive response is ultimately achieved by a 
change in the gene expression programme. The steps required involve protein complexes 
and a range of chemical reactions to convey the message to the DNA binding proteins. The 
mechanisms evolved by cells to identify a specific stimuli and regulate protein interactions, 
for the appropriate response, are highly varied. A generalised principle is that the stimuli is 
detected by specialised receptor proteins localised on cellular membranes and result in 
protein structural changes, permitting the interaction with other target proteins (known as 
effector proteins) which may then lead to gene expression regulation. However, certain 
stimuli can freely diffuse into cells allowing intracellular protein receptors to induce a 
signalling response, such as Estrogen signalling (Björnström et al., 2005). 
 
One important aspect of cell signalling is the ability to switch off the adaptive response 
once the cell has responded to the stimulus, or once the stimulus is no longer present, to 
prevent excessive response. Hence, effector proteins generally result in the expression of 
inhibitor proteins that inactivate the cellular signalling pathways, as part of a negative 
feedback loop system. A very common mechanism to regulate effector proteins is the cyclic 
protein accumulation/degradation in response to stimuli. Besides being highly metabolically 
inefficient, this mechanism can result in delays between stimulus detection and gene 
expression changes. Therefore, cells have evolved mechanisms to rapidly modify an already 
translated protein to swiftly alter its structural and functional properties, known as post 
translation modification (PTM). PTMs can be reversible and irreversible modifications. Thus, 
PTMs permit cell signalling without the accumulation/degradation cycling, providing a 




1.1.1. Post translational modification (PTM) 
PTM is a process that results in the covalent modification of a specific amino acid residue 
within the protein sequence. Thus, PTM alters the modified residues biochemical properties 
by size, and potentially charge, which can act as a switch to alter protein binding partners 
and function; thereby enabling signal transduction. As singular entities, PTMs are highly 
varied with >400 different types of PTM recorded in the UniProt database 
(The UniProt Consortium, 2017), highlighting the range of different strategies that have 
evolved to regulate protein function. The same PTM on different proteins does not 
necessarily result in the same functional outcome, nor does the same PTM of different sites 
within a given protein. Furthermore, identical residues can be modified by different PTMs, 
depending on the signal, and result in different regulatory roles. PTMs do not generally 
occur as single events but rather are highly abundant in ‘decorating’ the protein at sub-
stoichiometric levels below total protein. Thus, PTMs result in the simultaneous fine tuning 
of signalling pathways and allow for a single protein to participate in multiple different 
regulatory pathways at once (Mann et al., 2003). Therefore, a protein can be viewed as 
separate ‘proteoforms’, each having a different PTM map and function. Because of the 
large number of PTMs possible, only a few relevant PTMs to my work are discussed below. 
 
1.1.1.1. Phosphorylation 
Phosphorylation is a reversible PTM that involves the functional attachment of a negatively 
charged phosphate group to a residue, performed by a kinase and hydrolysed by a 
phosphatase (Figure 1.1). Phosphorylation is highly abundant within cells with >500 
different human kinases identified, equating to ~2% of the proteins encoded by the human 
genome (Manning et al., 2002), that are regulated by different cell signals and/or target 
different sequences for PTM within a protein. For scale, it is predicted that at any one 
moment approximately a third of all proteins in the cellular protein complement are 
phosphorylated (Cohen, 2001 & Olsen et al., 2006). Phosphorylation canonically occurs on 
Serine (S), Threonine (T) and Tyrosine (Y) residues at a ratio of ~86% : 12% : 2% (Olsen et al., 
2006), however more recent studies identify that Histidine (H), Arginine (R), Lysine (K), 
Aspartic acid (D), Glutamic acid (E) and Cysteine (C) are also extensively phosphorylated in 





Figure 1.1: The structure of non-phosphorylated and phosphorylated Serine, Threonine and Tyrosine residues. 
 
The relatively large and negatively charged phosphate group has been shown to have 
various effects to a modified protein, either by protein structural changes or acting as a 
docking site (to promote) or blocking agent (to prevent) additional binding partners from 
associating. Functionally, phosphorylation has been shown to regulate protein function by 
many mechanisms including the aforementioned binding partner role, altering the sub-
cellular localisation of a protein and/or stability roles (reviewed by Hunter et al., 1992). 
With such a vast a role in cellular signal transduction, aberrant 
phosphorylation/phosphatase expression (or function) is linked to many diseases and 
represents one of the largest markets for drug discovery (Cohen, 2001 & Cohen, 2002). 
 
1.1.1.1. Lysine PTMs 
Lysine is a positively charged amino acid that has been identified to undergo multiple PTM 
states including acetylation, methylation, ubiquitination and SUMOylation (Figure 1.2). 
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Many more lysine PTMs exist and have functionally important roles, however only the 
aforementioned PTMs are described here. Lysine acetylation, performed by acetyl-
transferases and removed by de-acetylases, results in the addition of an acetyl group to the 
positively charged amino-group side chain of lysine and resulting in charge neutralisation. 
Acetylation has been shown to have various roles in protein regulation, similar to 
phosphorylation. Although acetylation has been identified as an essential signalling 
mechanism on a large proportion of human proteins, and at multiple different sites, the 
number of acetyl-transferases in the human genome (~20, Drazic et al., 2016) is much 
smaller than the number of kinases identified. Dysregulation of acetylation is linked with 
multiple diseases (Drazic et al., 2016 & Timmermann et al., 2001). 
 
Figure 1.2: The structure of a selection of lysine PTMs. 
 
Most of the investigation into the role of lysine methylation has been conducted on DNA 
bound proteins such as histones. These studies show that lysine can be mono-, di- and tri- 
methylated, each known to have different regulatory roles. Unlike acetylation, methylation 
does not result in charge neutralisation (Figure 1.2), hence is suggested to play a role 
primarily acting as docking/blocking site to change protein binding partners (Lanouette et 
al., 2014 & Blanc et al., 2017). Recent studies demonstrated the key role of methylation in 
cellular signalling pathways, as, for example, for the Epidermal growth factor receptor 
(EGFR) pathway (Hsu et al., 2011), and for regulating transcription factor function by 
binding partners and/or stability means (Huang et al., 2007 & Lee et al., 2017). Because of 
the relatively recent discovery of their role beyond histone proteins, few methylated 
proteins have been identified, however the role of methylation in cancer progression is well 




Ubiquitin (Ub in Figure 1.2) is an example of a PTM that involves the covalent addition of a 
small (~8.5 kDa) protein tag to lysine residues. Ubiquitination is a 3-stage process involving 
a ubiquitin activating (E1), ubiquitin conjugating (E2) and ubiquitin ligase (E3) enzyme, thus 
providing the mechanism to target multiple different lysine residues (Komander et al., 
2012). Ubiquitination is a highly complex PTM, the ubiquitin molecule itself contains 7 
different lysine residues which can undergo sequential ubiquitination PTMs leading to the 
formation of highly branched, poly-ubiquitin chains (Komander et al., 2012). Ubiquitination 
is a reversible PTM by the function of de-ubiquitinase enzymes. There are ~80 encoded de-
ubiquitinases in the human genome, highlighting the complexity of ubiquitin mediated 
signalling (Komander et al., 2009). Poly-ubiquitination is generally associated with a 
catabolic role, increasing the rate that tagged proteins are degraded by the 26S 
proteasome. However, the different branching patterns of poly-ubiquitination are 
suggested to have different roles, and have been shown to stabilise proteins too (Komander 
et al., 2012 & Sun et al., 2004). 
 
Similar to ubiquitin, Small Ubiquitin related Modifier (SUMO, Figure 1.2) is a 12 kDa protein 
tag that involves a 3-stage activation process for lysine modification (SUMOylation), and is 
reversible by SUMO-specific proteases (Flotho et al., 2013). SUMOylation can result in 
complex SUMO chains, similar to ubiquitin (Flotho et al., 2013). Humans encode 4 different 
SUMO isoforms (SUMO-1/2/3/4), where the SUMO-1 has poor sequence similarity to the 
highly conserved SUMO-2/3/4 isoforms (Flotho et al., 2013). SUMOylation has varied roles 
dependent on the target and location (similar to phosphorylation and acetylation), but 
generally alters binding partners by acting as a docking or blocking site. 
  
1.1.1.2. Redox sensitive PTMs 
General cellular processes such as mitochondrial function result in the production of highly 
reactive free radical species, known as reactive oxygen and nitrogen species (ROS/RNS). 
ROS/RNS can non enzymatically react with multiple amino acids including methionine, 
phenylalanine, tryptophan, histidine and cysteine (Sharma et al., 2010). Cysteine is 
particularly prone to ROS/RNS reaction by containing a free thiol group and results in 
multiple different reversible and irreversible PTM states known to regulate cellular 
signalling (Hess et al., 2005 & Chung et al., 2013).  
 
Under severe oxidative stress, cysteine can undergo irreversible oxidation into 2+ and 3+ 
oxidative states, sulfinic acid and sulfonic acid respectively (Figure 1.3). Although not well 
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studied, these irreversible oxidative cysteine states are known to be important PTMs for 
modulating protein structure (Vivancos et al., 2005, Blackinton et al., 2009 & Fujiwara et al., 
2007). Additionally, enzymes have also been identified that utilise O2 as a cofactor to 
hydroxylate specific residues including lysine, tryptophan, asparagine and proline (Figure 
1.3). The role of hydroxylation is context specific, playing a major role in collagen structure 
but having different roles intracellularly on different proteins, from degradation to altering 
binding partners (Tak et al., 2019 & Zurlo et al., 2016). Recent studies suggest that 
intracellular proline hydroxylation is highly specific to a single family of proteins that are 
known to be stability regulated by O2 tension (Cockman et al., 2019). 
 
Figure 1.3: The structure of residues that can undergo redox sensitive PTMs. 
Hydroxylation of proline, asparagine and tryptophan are enzyme mediate and are reversible. Cysteine oxidation 




1.2. Oxygen-dependent signalling 
For eukaryotic organisms, one example of an environmental stimuli that cells monitor is the 
availability of molecular oxygen (O2). Eukaryotic organisms, including humans, are known as 
obligate aerobes and require O2 to survive. O2 is used in a process called oxidative 
phosphorylation, where O2 is reduced into water (H2O) to yield high quantities of ATP 
(Adenosine triphosphate), a chemical energy storage molecule. ATP is ubiquitously used by 
all organisms and cells to provide an energy source to promote chemically unfavourable 
reactions, including some PTMs. Although O2 is essential for life, both over oxygenation 
(hyperoxia) and under oxygenation (hypoxia) can result in cellular stress, and are 
potentially lethal for organisms. Thus, cells have evolved highly specific O2 sensing 
mechanisms to stringently monitor available O2 and allow the adaption to changes in 
environmental O2 tension. Therefore, beyond its role in metabolism, O2 is a signalling 
molecule. Low O2 levels in the cells surroundings (hypoxia) trigger a range of intracellular 
events, known as hypoxia signalling. This signalling pathway is the focus of this thesis.  
 
1.3. Hypoxia 
The definition of hypoxia is when the O2 demand by a cell outweighs the available O2 supply 
to that cell. Simply, if the O2 supply to a tissue or cell is insufficient for regular metabolic 
activity then they are deemed hypoxic. Table 1.1 contains a summary of organs and 
required O2 tension for normal function.  
 
Table 1.1: Examples of O2 tension in regular organs and associated tumours.  
Median values of O2 tension shown, data collected from Muz et al., 2015 & Carreau et al., 2011. 
 
In response to hypoxia, cells trigger pathways to ultimately promote the restoration of 
normal O2 tension and O2 independent energy metabolism, increasing cell survival rates 
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during periods of prolonged hypoxia. For example, hypoxia promotes the upregulation of 
genes encoding proteins that are involved with iron metabolism (Transferrin, Rolfs et al., 
1997), erythropoiesis (EPO, Wang et al., 1993), angiogenesis (VEGF, Forsythe et al., 1996), 
and the anaerobic stages of energy metabolism- glycolysis (Chen et al., 2001 & Marsin et 
al., 2002). Thus, pathways aim to increase the available O2 saturation per unit of blood and 
permit increased rates of O2 independent energy metabolism during hypoxia, however 
inefficiently. 
 
Physiologically, hypoxia can be separated into two categories: global and localised hypoxia. 
Mild global hypoxia is an essential factor for correct embryonic development (where O2 
availability is limited by placental diffusion, (Dunwoodie, 2009), and adaptions to high 
altitudes (where the partial pressure of O2 in the air is limited, Frisancho, 2013). While 
pathologies can induce global hypoxia, such as anaemia where there is a lack of 
haemoglobin containing iron to carry O2, pathologies generally result in localised hypoxia by 
blocking the delivery of O2 to tissues/cells, for example in heart attacks and strokes where 
blockages in blood vessels directly disrupts the supply of oxygenated blood to tissues and 
cells. 
 
1.4. Hypoxia and cancer 
Due to the rapid replication rate of tumours/cancers, the cell masses created are usually 
large in size and have a poor vasculature network, resulting in localised hypoxic cores 
within the tumour microenvironment (Figure 1.4). Table 1.1 has examples of the median O2 
tension of different tumour cell types compared to their normal cellular state. Since the 
first draft of “The Hallmarks of Cancer” in 2000, the increased rate of angiogenesis was a 
known characteristic that promotes cancer survival (Hanahan et al., 2000). In 2011, an 
updated draft of The Hallmarks of Cancer was published which included the upregulation of 
glycolytic pathways (Hanahan et al., 2011). Significantly, both of these pathways related to 
tumour survival are canonically hypoxia upregulated pathways, highlighting the potential 
importance of hypoxia in cancer. 
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Figure 1.4: Hypoxia and the tumour microenvironment. 
 A large tumour mass combined with poor vasculature can cause hypoxic tumour cores, as low as 0.1% O2. 
 
Infact, it has been shown that an extended, or unregulated, hypoxic response can result in 
multiple of the hallmarks of cancer becoming upregulated (Figure 1.5), including: 1) 
Activating invasion and metastasis, through the upregulation of extracellular metabolism 
proteins such as matrix metalloproteases (MMPs, Ben-Yosef et al., 2002) and uPA/uPAR 
(Urokinase Plasminogen Activator and receptor, Gupta et al., 2011). 2) Sustaining 
proliferative signalling, through regulating autocrine signalling proteins such as 
Transforming Growth Factor –α (TGFα, Krishnamachary et al., 2003) and Insulin-like Growth 
Factor 2 (IGF2, Feldser et al., 1999). 3) Resisting cell death, through various mechanisms 
including the reduced expression of proteins involved with apoptosis pathways (Erler et al., 
2004) and upregulation of Multi-Drug Resistance (MDR) proteins; resulting chemo-
resistance (Comerford et al., 2002). Thus tumour/cancer hypoxia is a poor prognostic 












Figure 1.5: The hypoxia regulated hallmarks of cancer survival and progression.  
Each section of the wheel contains a hallmark trait which promotes cancer survival and progression. *indicates 
primary targets of hypoxic regulation, **indicates secondary targets of extended hypoxia regulation. Modified 
from Hanahan et al., 2011. 
 
1.5. Hypoxia Inducible Factor- The master 
aaairegulator of the hypoxic response 
In 1995, the Greg Semenza lab discovered an O2 dependent, labile protein transcription 
factor was responsible for the hypoxic induced expression of erythropoietin (EPO), and 
subsequent increased rate of angiogenesis, termed the Hypoxia Inducible Factor (HIF, Wang 
et al., 1995). Wang and co-workers were able to identify that the active HIF transcription 
factor was a basic Helix-Loop-Helix (bHLH), Per-Arnt-Sim (PAS) domain containing, 
heterodimeric complex consisting of the O2 dependently degraded protein (termed HIF-1α) 
and an O2 insensitive protein (termed HIF-1β, also known as Aryl hydrocarbon Nuclear 
Translocator (ARNT)) (Wang et al., 1995 & Wang et al., 1995). Thus, in response to hypoxia 
(limited O2 availability) HIF-1α is no longer degraded, permitting the formation of the active 
HIFαβ dimer that can regulate gene expression. 
 
1.1.2. HIFα isoforms 
Further characterisation of the HIF-1α protein (Pugh et al., 1997 & Jiang et al., 1997) 
identified three additional functional domains, and their minimalistic sequences: the 
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Oxygen Dependent Degradation domain (ODDD), the Amino-terminal Transactivation 
domain (NTAD) and Carboxyl-terminal Transactivation domain (CTAD), with the 2 TAD 
domains having distinctly different functions (schematically depicted in Figure 1.6). 
Figure 1.6: Schematic diagram of the HIF-1α and HIF-2α domain structure.  
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At the same time, a second hypoxia inducible transcription factor, with high sequence 
homology to HIF-1α, was simultaneously identified by four separate laboratories, thus the 
multiple names associated to it: Endothelial PAS domain protein -1 (EPAS1, Tian et al., 
1997), HIF-1α Like Factor (HLF, Ema et al., 1997), HIF Related Factor (HRF, Flamme et al., 
1997) and Member Of PAS Superfamily 2 (MOPS2, Hogenesch et al., 1997). Later studies 
identified that this second hypoxia responsive protein, though slightly larger than HIF-1α, 
could be functionally compartmentalised into bHLH, PAS, ODDD, NTAD and CTAD domains, 
identically to HIF-1α (Figure 1.6); thus this protein was termed HIF-2α (Wiesener et al., 
1998 and O’Rourke et al., 1999). 
 
A third HIFα gene locus exists (HIF-3α), which exhibits high rates of multiple splicing, giving 
rise to over six separate protein isoforms that generally contain an ODDD and NTAD in 
combination with different domains (Maynard et al., 2003 & Gu et al., 1998). The most 
predominant HIF-3α isoform is a 307 amino acid protein with extremely high sequence 
homology to the bHLH and PAS domains of HIF-1α and HIF-2α and functions in a dominant 
negative mechanism to inhibit HIFα signalling, termed Inhibitory PAS domain protein (IPAS, 
Makino et al., 2001 & Makino et al., 2002). Thus HIF-3α was not a target for this study, 
which solely focuses on HIF-1α and HIF-2α. 
 
1.1.3. HIF-1α versus HIF-2α 
Although HIF-1α and HIF-2α are expressed almost ubiquitously by cells in vivo (Stroka et al., 
2001, Wiesener et al., 2003 & Rosenberger et al., 2002) and have an overall high sequence 
homology of ~50% (Tian et al., 1997), their functional characteristics and downstream roles 
are different. For example, their target genes regulated, their O2 sensitivity and their sub-
nuclear localisation are different between the two HIFα isoforms (discussed below). 
 
1.1.3.1. Target genes 
Many studies have determined the promoter region where active HIF dimers bind, 
irrespective of HIFα isoform, as 5’-RCGTG-3, termed the Hypoxia responsive element (HRE, 
Wenger et al., 2005 & Schödel et al., 2011). The HRE is highly abundant within the human 
genome, however HIF-1α and HIF-2α occupy <1% (~500) of the total HREs available in 
response to hypoxia (Mole et al., 2009). Significantly, <20% of HREs identified can be 
occupied by both HIFα isoforms, thus many HREs have HIF-1α or HIF-2α exclusivity, 
suggesting differential roles for HIF-1α and HIF-2α in response to hypoxia (Mole et al., 
2009). This conclusion is further supported by additional genome wide Chromatin 
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Immunoprecipitation assays (Schödel et al., 2011 & Smythies et al., 2019), microarray 
analysis (Hu et al., 2003) and biochemical approaches (Raval et al., 2005 & Lau et al., 2007) 
which all identified HIF-1α and HIF-2α specific target gene regulation. For example, HIF-1α 
specifically regulates genes encoding enzymes of the glycolytic pathway (Hu et al., 2003), 
while HIF-2α specifically regulates the Transforming growth factor alpha gene (TGFα, Raval 
et al., 2005),  yet both HIFα isoforms regulate genes encoding proteins involved with 
angiogenesis (Hu et al., 2003). Recently, the gene specificity of HIFα isoforms has been 
shown to be due to specific binding locations of HIFα in respect to the hypoxia regulated 
gene, with HIF-1α predominately binding at HREs in close proximity to gene promoters 
while HIF-2α binds predominately at distant gene enhancer HREs (Smythies et al., 2019). 
 
1.1.3.2. Stability  
Since its discovery, HIF-1α protein stability has been known to be O2 dependent, only 
stabilising at 1% O2 (Wang et al., 1995). HIF-1 α is rapidly degraded upon reoxygenation, 
with a half-life of ~5 min (Moroz et al., 2009). Although many published data show a similar 
O2 dependent stability profile for HIF-2α, there is growing evidence that HIF-2α stability is 
less sensitive to O2 tensions than HIF-1α. Many published data show that HIF-2α is strongly 
stabilised at 2-5% O2 (Holmquist-Mengelbier et al., 2006 & Nilsson et al., 2005) and more 
recent data report that HIF-2α is actually stable at atmospheric O2 (21%), with only 
marginal increase in stability at 1% O2 (Hara et al., 1999, Fujita et al., 2012, Uchida et al., 
2004, Xie et al., 2018, Bagnall et al., 2014 & Taylor et al., 2016). As suggested by these 
publications, HIF-2α protein stability is probably cell-line dependent. This is supported by 
Bracken et al., 2006, who demonstrated that HIF- 1α and HIF-2α protein stability and 
transcriptional function vary dramatically by cell line. 
 
1.1.3.3. Nuclear localisation 
HIF-1α appears as a homogenous distribution throughout the nucleus, while HIF-2α 
localises to distinct punctate during hypoxia (Hara et al., 1999). Later studies even suggest 
that HIF-2α is physically trapped within these fine punctate, potentially by nuclear tethering 




Figure 1.7: The nuclear localisation of HIF-1α and HIF-2α tagged with EGFP.  
HIF-1α homogenously distributed throughout the nucleus, while HIF-2α is non-homogenously distributed as 
intense punctate (taken from Taylor et al., 2016). 
 
Although the exact role played by sub-nuclear localisation in regulation/differentiating HIF-
1α and HIF-2α is not fully determined, a recent study has shown that transcription factors 
can form concentrated hubs via, which have the potential to phase-separate at higher 
concentrations (Chong et al., 2018). In this study the authors postulated that the weak, 
dynamic, and transient contacts between transcription factors within the hubs, play a role 
in disease-causing dysregulation of gene expression. In the HIF context, they might 
underpin some target gene expression regulatory differences.  
 
1.1.4. HIFα domain function 
As stated, both HIF-1α and HIF-2α can be compartmentalised into five distinct functional 
domains: bHLH, PAS, ODDD, NTAD and CTAD (Figure 1.6). Sequence alignment comparisons 
between HIF-1α and HIF-2α (Tian et al., 1997) identified that the bHLH and PAS domains 
share the highest degree of sequence homology of all domains at 85% and 70% 
respectively. This is unsurprising considering their importance for DNA binding and HIF-1β 
binding. Tian et al., 1997 also identified that the CTAD also has significant sequence 
homology at ~70%, while the ODDD and NTAD have minimal sequence homology (~40% 
and ~20% respectively, Figure 1.6). Later studies characterising the domains of HIFα 
proteins identified that the CTAD is required for binding to the histone acetyltransferase 
proteins CREB binding protein (CBP) and p300, the CBP/p300 complex (Ema et al., 1999). 
The HIF-p300/CBP binding axis is well known to be essential for the HIF dependent 
transcriptional response to hypoxia, likely by chromosomal remodelling (Ema et al., 1999 & 
Kallio et al., 1998). The ODDD between HIFα isoforms shares ~40% sequence homology, 
however it appears to have a similar role in the O2 dependent degradation of both HIF-1α 
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and HIF-2α (discussed further in the O2 dependent regulation section 1.6). The NTAD shares 
the least sequence homology between HIFα isoforms and was initially thought to explain 
the gene targeting differences observed by HIF-1α and HIF-2α (Hu et al., 2003). In 2007, the 
NTAD was proved to control gene specific targeting of HIFα isoforms. Using mutational 
analysis (where the HIF-2α NTAD was inserted into HIF-1α, and vice versa), it was 
demonstrated that mutant HIF-1α could express HIF-2α specific genes, and vice versa (Hu et 
al., 2007 & Lau et al., 2007). It was also found that secondary, isoform specific, cofactor 
binding partners bound within the NTAD and were responsible for isoform specific gene 
regulation; including ETS like protein 1 (ELK) for HIF-2α (Hu et al., 2007). 
 
1.6. O2 dependent regulation 
The O2-dependent regulation mechanism is shown in Figure 1.8. A class of enzymes, the 
Prolyl Hydroxylases (PHDs), encoded by the EGLN genes, utilise molecular O2 and iron as 
cofactors to result in the proline hydroxylation of HIFα subunits (Epstein et al., 2001 & 
Bruick et al., 2001). Proline hydroxylation occurs within the ODDD at the specific residues: 
HIF-1α P402/P564 and HIF-2α P405/531 (Jaakkola et al., 2001, Ivan et al., 2001 & Masson et 
al., 2001). HIFα Proline hydroxylation acts as a recognition site for binding of the Von 
Hippel-Lindau E3 ubiquitin ligase complex (pVHL), resulting in the poly-ubiquitination of 
HIFα and subsequent protein degradation through the 26S proteasome (Ivan et al., 2001, 





























Figure 1.8: The canonical oxygen dependent regulation pathway of HIFα during hypoxia and normoxia. 
In normoxia (right hand side), available O2 is used as a cofactor for PHDs to hydroxylate HIFα proline residues 
(HIF-1α P402/P564 and HIF-2α P405/P531), resulting in the recognition and poly-ubiquitination by VHL and 
subsequent degradation by the 26S proteasome. FIH also hydroxylates HIFα on an Asparagine residue (HIF-1α 
N803 and HIF-2α N847) causing the inhibition of essential interactions with CBP/p300. During hypoxia (left hand 
side), a lack of O2 inhibits both PHDs and FIH, thus resulting in the accumulation and translocation of HIFα into 
the nucleus where dimerization with HIF-1β and complexing with the essential co-factors CBP/p300 occur; 
resulting in transcriptional regulation.  
 
As shown in Figure 1.8, a second O2 dependent regulatory pathway has also been 
discovered. Factor Inhibiting HIF-1 (FIH-1) is an asparaginyl hydroxylase protein, using 
molecular O2 to hydroxylate a single asparagine residue within the CTAD of both HIF-1α 
(N803) and HIF-2α (N847). FIH-1 maintains function at much lower O2 tensions than PHDs, 
as low as 0.5% O2, and is responsible for abolishing transcriptional activity independently of 
protein stability by blocking the essential cofactor interactions with CBP/p300 (Lando et al., 




Overall, in normoxia HIFα proteins are rapidly degraded and transcriptionally inactivated by 
hydroxylation through the function of PHDs and FIH-1, both requiring O2 as a cofactor. 
Thus, when there is a lack of O2, the activity of PHDs and FIH-1 become greatly reduced; 
allowing the accumulation and translocation of HIFα into the nucleus, where the active HIF 
transcription factor forms and regulates gene expression. 
 
1.7. O2 independent regulation 
Many PTMs do not require O2 directly as a co-factor, as is the case for hydroxylation. For 
example, phosphorylation, acetylation, methylation, ubiquitination and SUMOylation are all 
O2 independent. Thus, many PTMs can regulate protein function independently of O2 
tension. These PTMs have all been shown to regulate HIFα proteins in hypoxia, or hypoxia 
mimicking conditions, by 3 mechanisms: 1) PTM occurs directly on the HIFα proteins 
(discussed below). 2) PTM occurs on a secondary binding partner, thus indirectly regulating 
HIFα proteins (Kewley et al., 2005). 3) PTM occurs on proteins that do not interact with 
HIFα, yet result in the elevated translation rate of HIFα proteins (Page et al., 2002). 
 
Because of the important association of HIF with cancer progression, many different 
pathways have been identified as essential regulators of the HIFα proteins, such as the 
MAPK cascade and PI3K-mTOR pathway. However, importantly, the exact mechanisms by 
which these pathways regulate HIF is unclear, with many pathways being found to regulate 
HIFα proteins both directly and indirectly (Reviewed by: Kietzmann et al., 2016, Dengler et 
al., 2014, Lee et al., 2004 & Semenza, 2003). Additionally, many of the studies that show 
direct regulation of HIFα by PTMs fail to identify the exact site of modification, an essential 
aspect of functional outcomes, but rather narrow PTM location to a specific domain. 
Therefore, only PTMs that have been localised to a specific residues of HIF-1α or HIF-2α are 
discussed here. A summary of the modifications previously described is depicted in Figure 






































































































































 Table 1.2: Known post translational modifications of HIF-1α. 
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Table 1.3: Known post translational modifications of HIF-2α. 
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It is clear from Figure 1.9 and Table 1.2 & Table 1.3 that many more PTMs have been 
identified of HIF-1α than HIF-2α, possibly because of its earlier discovery. The functional 
consequences of these PTMs are discussed below. 
 
1.1.5. HIFα phosphorylation 
Phosphorylation has been shown to regulate both HIFα isoforms, in terms of protein 
stability, transactivation and nuclear localisation. A total of 28 different phosphorylation 
sites have been identified for HIF-1α, although not all are considered to have functional 
effects, and 5 different sites for HIF-2α. 
 
1.1.5.1. Stability 
The phosphorylation status of HIF-1α has been shown to have large effects on protein 
stability, both positively and negatively, although no phosphorylation mediated stability 
roles have yet been defined for HIF-2α. Two separate studies have identified Glycogen 
Synthase Kinase 3β (GSK3β) phosphorylation at HIF-1α sites: T498, S502, S505, T506, S510, 
S551, T555 and S589, resulting in protein degradation (Flügel et al., 2007 & Cassavaugh et 
al., 2011). Infact, mutation of these GSK3β phosphorylation sites to phospho-null alanine 
residues increased protein stability >10 fold in normoxia (Flügel et al., 2007 & Cassavaugh 
et al., 2011), highlighting the importance that PTMs can play. Polo-like Kinase 3 (Plk3) has 
also been demonstrated to have a role in the degradation of HIF-1α, by phosphorylation at 
S576 and S657. In C. elegans, the redox sensitive AMP-activated protein kinase (AMPK) was 
shown to phosphorylate HIF-1α S419 leading to its degradation (Hwang et al., 2014). 
However, human cell line studies conflict this and suggest AMPK induces HIF-1α protein 
stability, mediated through JNK signalling pathways (Jung et al., 2008).  
 
Phosphorylation at different sites of HIF-1α has been demonstrated to have stabilising 
roles. Bullen et al., 2016 identified that Protein Kinase A (PKA) could multiply phosphorylate 
HIF-1α at 10 different sites in vitro, but found that only T63 and S692 phosphorylation 
increased protein stability. A role for Cyclin Dependent Kinases (CDK) in promoting HIF-1α 
stability has also been identified. CDK1 was shown to phosphorylate HIF-1α at S668, and 
CDK5 at S687, both resulting in increased protein stability. Cam et al., 2010 also report that 
Ataxia telangiectasia Mutated (ATM) can phosphorylate HIF-1α at S696 to result in 






There is a single reported case of phosphorylation-induced global transcriptional 
inactivation for HIF-1α and HIF-2α, S247 (Kalousi et al., 2010) and T844 (Gradin et al., 2002) 
respectively. Casein Kinase 1δ (CK1δ) was shown to phosphorylate HIF-1α at S247, 
preventing the formation of HIFαβ dimers and thus inhibiting transcriptional roles without 
affecting protein stability (Kalousi et al., 2010). Gradin et al., 2002 did not identify a kinase 
that causes the phosphorylation, but rather mutated serine and threonine residues within 
the CTAD to determine a potential role for phosphorylation. However, phospho-null 
mutants of T844 to alanine resulted in the inability to bind p300/CBP thereby inhibiting 
transcription. 
 
Phosphorylation has also been demonstrated to have a role in differentiating HIF-1α and 
HIF-2α binding partners for gene specificity (To et al., 2006). To et al., 2006 identified that 
HIF-2α T324 can be phosphorylated by Protein Kinase D1 (PKD1), which prevents the SP1 
transcription factor from binding. HIF-1α contains a sequence variation that prevents PKD1 
phosphorylation, thus SP1 can bind and mediate a specific set of gene targets. 
 
1.1.5.3. Nuclear localisation 
Phosphorylation has been shown to regulate the nuclear localisation of both HIF-1α and 
HIF-2α proteins, without affecting protein stability. Extracellular signal Regulated protein 
kinases 1 & 2 (ERK1/2) have been demonstrated to phosphorylate both HIF-1α (at S641 and 
S643) and HIF-2α (at S672) (Mylonis et al., 2006, Mylonis et al., 2008 & Gkotinakou et al., 
2019). Phosphorylation at these sites was shown to promote nuclear accumulation, while 
phospho-null mutations were exclusively cytoplasmic, this was identified as the result of 
preventing interactions with the nuclear exporter protein CRM-1. Additionally, CK1δ 
phosphorylation of HIF-2α S383 and T528 results in nuclear accumulation, similarly by 
blocking CRM-1 mediated nuclear export (Pangou et al., 2016). 
 
1.1.6. HIFα acetylation 
Acetylation has been shown to regulate both HIFα isoforms, regulating protein stability and 
transactivation. Although acetylation status of HIFα is much less studied compared to 







The first reported acetyl-transferase to have function in regulating HIF-1α was Arrest 
Defective Protein 1 (ARD-1, an acetyl transferase protein), which resulted in the acetylation 
of K532 (Jeong et al., 2002). It was demonstrated that K532 acetylation was essential for 
the O2 dependent, VHL mediated degradation post proline hydroxylation, and that 
acetylation-null mutations to arginine residues were stable in normoxia (Jeong et al., 2002 
& Lee et al., 2010). However, two separate studies (albeit in different cell lines, Murray-
Rust et al., 2006 & Arnesen et al., 2005) have failed to identify ARD-1 mediated HIF-1α 
acetylation. This therefore could suggest that acetylation mediated degradation may be cell 
line dependent. 
 
Geng et al., 2012 identified that p300 dependent acetylation of HIF-1α at K709 results in 
increased protein stability. This study also identified reduced rates of ubiquitination by less-
conservative acetylation-null K709 mutations to alanine, suggesting potential PTM 
competition where acetylation prevents ubiquitination mediated protein degradation. A 
previous study by the same group used multi-site acetylation-null mutations of the lysine 
residues in the bHLH domain (K10, K11, K12, K19 and K21) to demonstrate acetylation 
induced HIF-1α degradation (Geng et al., 2011). The methodology employed by Geng et al., 
2011 did not identify an acetyl-transferase protein responsible for the modification nor the 
role of individual sites, hence it is possible only 1 site requires acetylation for degradation. 




Acetylation has also been reported to affect HIF-1α and HIF-2α transactivation, by both 
global and specific gene targeting mechanisms. p300/CBP associated factor (PCAF) was 
demonstrated to acetylate HIF-1α at 2 separate sites to regulate transactivation. Lim et al., 
2010 identified K674 as an acetylation site that results in the global upregulation of HIF-1α 
target genes, however did not identify an explanation for this observation. While Xenaki et 
al., 2008 demonstrated that PCAF acetylation at K389 resulted in the differential regulation 
of specific HIF-1α target genes, such as the upregulation of Carbonic anhydrase-IX and 
downregulation of Lactate dehydrogenase, highlighting a gene specific targeting 
mechanism of acetylation. A single publication has shown the role of acetylation on HIF-2α 
activity. Dioum et al., 2009 identified the acetylation sites K385, K685 and K741 on O2 stable 
HIF-2α (P405A/P531A), and used multi-site acetylation-null mutation analysis to 
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demonstrate HIF-2α acetylation increased transcriptional function without affecting protein 
stability. 
 
1.1.7. HIFα methylation 
Most research on methylation as a PTM has been conducted on DNA bound proteins such 
as histones, where it is known to regulate secondary protein binding by either acting as a 
docking site (to promote) or blocking agent (to prevent) protein interactions (reviewed by 
Lanouette et al., 2014 & Blanc et al., 2017). More recently, methylation has been identified 
as a key PTM in regulating protein function in signal transduction pathways, including the 
EGFR – ERK pathway (Hsu et al., 2011), and for regulating transcription factor function, such 
as p53 (Huang et al., 2007). Methylation has also been shown to regulate both protein 
stability and transactivation of HIF-1α and HIF-2α. 
 
1.1.7.1. Stability 
Methylation has been suggested to be an important PTM for regulating HIF-1α protein 
stability. Lee et al., 2017 demonstrated that SET9 could methylate HIF-1α K391 and was 
required for the efficient normoxic proline hydroxylation by PHDs, with methylation null 
mutations to arginine being stable in normoxia. Thus, Lee et al., 2017 suggest that K391 
methylation may be an important pre-requisite for the O2-dependent PHD mediated 
degradation pathway. 
 
HIF-1α methylation at K32 has also been identified by 2 separate groups, however have 
conflicting evidence regarding the functional outcomes (Kim et al., 2016 & Liu et al., 2015). 
Kim et al., 2016 shows that the overexpression of a methyl-transferase protein (SET7/9) 
results in the increased degradation rate of HIF-1α, while Liu et al., 2015 use the same assay 
to report transcriptional inhibition independent of HIF-1α protein degradation. Liu et al., 
2015 also identified that the respective HIF-2α site (K29) is also a methylation site with 
identical functional outcomes. 
 
1.1.7.2. Transactivation  
Bao et al., 2018 identified K674 as a target for mono- and di- methylation by Histone-lysine 
N-methyltransferase EHMT2 (G9a) and G9a Like protein (GLP). K674 methylation was 
demonstrated to inhibit HIF-1α dependent transcription, independent of protein stability. 
This observation is particularly interesting considering acetylation at K674 was shown to 
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have identical regulatory roles (Lim et al., 2010), potentially suggesting a mechanism of 
regulation that is more dependent on charge neutralisation of K674 than the PTM type. 
 
1.1.8. HIFα SUMOylation 
The role of SUMOylation in HIF-1α dependent signalling is controversial, multiple studies all 
identify the identical SUMOylation sites yet report a different functional outcome by PTM. 
Initially, Bae et al., 2004 identified HIF-1α K391 and K477 as SUMOylation sites for the 
SUMO-ligase Ubc9, and demonstrated that SUMOylation induced protein stability. 
However, a second independent group identified PIASy as the SUMO-ligase of HIF-1α K391 
and K477 sites, and demonstrated SUMOylation induced degradation (Cheng et al., 2007 & 
Kang et al., 2010). While a third independent group identify RanBP2/NUP538 as the SUMO-
ligase responsible for modifying HIF-1α K391 and K477 sites and could not identify a protein 
stability role of SUMOylation, yet showed transcriptional inactivation by SUMOylation. 
Again, the conflicting reports for SUMOylation of the same sites, might be due to the 
different cell lines used, but also to the use of different SUMO-ligases and HIF-1α 
recombinant fragments. A single publication has reported SUMOylation of HIF-2α at K394 
(van Hagen et al., 2010). van Hagen et al., 2010 identified SUMOylation motifs with HIF-2α 
and used SUMOylation-null arginine mutations to show that K394 SUMOylation induced 
protein degradation. 
 
1.1.9. HIFα Ubiquitination 
As described earlier, the canonical pathway of O2 dependent degradation involves the 
hydroxylation of proline residues followed by poly-ubiquitination, resulting in rapid 
proteasomal degradation (Ivan et al., 2001,  Jaakkola et al., 2001, Masson et al., 2001). 
Tanimoto et al., 2000 sequentially mutated all K residues within the HIF-1α ODDD to 
identify K532 as the major site responsible for O2 dependent ubiquitination and 
degradation. Using similar techniques, Paltoglou et al., 2007 identified that HIF-1α K532, 
K538 and K542 (and respective HIF-2α sites K497, K503 and K512) could also be 
ubiquitinated in normoxic conditions. Because my work focuses on the role of specific sites 
of PTM, only ubiquitination that has been associated to specific HIFα residues are 
discussed. However it is important to mention that the ubiquitination status of HIFα is a 
highly studied field and has been shown to be a much more complex regulatory system 
than only proline hydroxylation based degradation by involvement of different ubiquitin 
ligases and de-ubiquitinating enzymes (reviewed by Schober et al., 2016). One interesting 
43 
 
example of ubiquitination is a possible role in switching between HIF-1α to HIF-2α 
dependent signalling in prolonged hypoxia. Koh et al., 2008 identified a novel E3 ubiquitin 
ligase termed Hypoxia Associated Factor (HAF) which specifically poly-ubiquitinates HIF-1α 
only, resulting in the rapid degradation by the 26S proteasome. Later studies from the same 
group found that HAF could bind to HIF-2α at the CTAD, promoting transcriptional function 
of HIF-2α target genes by promoting DNA binding at HREs (Koh et al., 2011 & Koh et al., 
2014). 
 
1.1.10. HIFα nitrosylation 
All modifications discussed so far were enzyme driven. However, PTMs can occur through 
non-enzyme mediated reactions. For example, the production of reactive oxygen, or 
nitrogen, species (ROS/RNS) can react with free thiol groups of cysteine residues, resulting 
in multiple different cysteine PTM modifications that are both reversible and irreversible 
(Reviewed by Hess et al., 2005 & Chung et al., 2013). ROS/RNS production occurs 
endogenously through general mitochondrial function and cell signalling pathways, and is 
greatly increased in response to hypoxia (Chandel et al., 1998 & Bell et al., 2007). Nitric 
Oxide (NO) is a RNS that has been shown to modify HIF-1α C800, with contradictory reports 
regarding its function. Initially, Yasinska et al., 2003 has shown that S-nitrosylation of C800, 
by chemical or signalling meditated strategies, resulted in a HIF-1α CTAD mutated fragment 
(N803A, to prevent asparagine hydroxylation) binding strongly to p300/CBP. Whereas, a 
later study by Cho et al., 2007 used a non-mutated variant of the same CTAD fragment to 
show that S-nitrosylation-null mutants to alanine bound stronger to p300/CBP, the 
opposite effect of the previous study. 
 
1.8. Limitations of previous studies 
HIF-1α, and to a lesser extent HIF-2α, have been shown to be regulated by various PTMs, 
impacting either protein stability, transactivation or nuclear localisation. An important 
consideration is that many of these studies relied on the use of recombinant fragment 
based approaches coupled with in vitro assays to identify PTMs (Table 1.2 & Table 1.3). 
These strategies however have multiple intrinsic issues: 1) recombinant proteins, 
particularly small fragments, may not fold correctly. 2) A reported PTM site discovered on a 
small fragment, may be buried within the full length protein, and hence physically blocked 
by internal stoichiometric mechanisms. 3) Proteins tend to form large protein complexes 
for regulation, a fragment may lack many protein interactions in neighbouring regions of 
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the protein which could block the reported PTM site 4) The ratios used by in vitro assays 
might force interactions, resulting in modification that would not otherwise be observed in 
cellulo. Overall, the false discovery (and false negative) rate of these techniques can be 
potentially quite high and may not reflect true in vivo regulatory mechanisms.  
 
Additionally, for hypoxic conditions, studies generally used hypoxia mimicking drugs such as 
DMOG (Dimethyloxalylglycine), DFO (Deferoxamine), DFX (Deferasirox) and CoCl2 (cobalt 
chloride), which are PHD inhibitors (directly, by iron chelation or iron replacement). 
Therefore, hypoxia mimicking drugs do not necessarily reflect the true effects observed by 
a lack of O2. For example, DFO based iron chelation, used to increase HIFα stability, has 
additionally been shown to induce cell cycle arrest at the G1/S boundary by reducing the 
protein levels of cyclin D1 and p21; by inhibiting their mRNA cytoplasmic translocation and 
increased non-ubiquitin dependent proteasomal degradation (Fu et al., 2007 & Nurtjahja-
Tjendraputra et al., 2007).  
 
Furthermore, the use of multiple different cancer cell lines, many with important regulatory 
proteins and modifying proteins deleted or mutated, may explain some of the observed 
discrepancies (Bracken et al., 2006). This is particularly evident for HIF-1α K532 acetylation 
(Jeong et al., 2002, Lee et al., 2010, Arnesen et al., 2005 & Murray-Rust et al., 2006) and 
HIF-1α K391 and K477 SUMOylation (Bae et al., 2004, Berta et al., 2007, Cheng et al., 2007 
& Kang et al., 2010). 
 
Finally, all these studies were performed in a targeted manner, aimed at identifying a single 
PTM through in vitro assays, motif analysis and PTM-null mutations. Thus, these studies 
lack any perspective into how multiple PTMs may affect overall protein function inside cells, 
a potentially important aspect for fine tuning regulatory responses (Mann et al., 2003 & 
Lanucara et al., 2013). Unbiased PTM discovery is therefore critical to understand how the 
PTM map of HIF-1α and HIF-2α changes in response to true O2 deprivation. Such 
investigation is essential for the discovery of novel regulatory mechanisms and to unravel 
the signalling strategies that coordinate the hypoxic response. One method to explore the 







The term proteome was used originally to describe all expressed proteins within a cell at a 
given time. However, it has evolved to also include all proteoforms (differentially PTM 
forms of the same protein), a reflection that the functional aspect of proteins are orders of 
magnitude more complicated than simply the complement of expressed genes (Tyers et al., 
2003), as exemplified with HIFα PTMs discussed above. Many more PTMs exist than have 
been discussed above in the context of HIFα, including glycosylation, sulphation and 
acylation (Mann et al., 2003). Additionally, PTMs can occur in a combinatorial fashion which 
may regulate protein function differently than either PTM alone (Mann et al., 2003). As 
many PTMs are reversible, often occurring at sub-stoichiometric levels compared to total 
protein, this allows the simultaneous co-existence of multiple functionally distinct subsets 
of the same protein within a cell (Mann et al., 2002); hence can pose a challenge for 
proteomics analysis. With the advancements in technology over the past 25 years, mass 
spectrometry (MS) has become an essential component of proteomics analysis. MS can be 
used not only for protein identification and to determine PTM status of proteins, but also to 
quantify protein levels, sub-cellular protein localisation, protein interactions and protein 
structures (Reviewed by Han et al., 2008, Aebersold et al., 2016, Mallick et al., 2010, 
Schneider et al., 2018 & Lanucara et al., 2014). 
 
1.1.11. Bottom-Up Proteomics 
Although MS-based proteomics analysis can be performed on full length proteins (Top-
Down proteomics) there are many technical challenges to this, including: 1) A lack of 
fractionation techniques to decrease the complexity of samples. 2) The inefficiency of 
protein fragmentation in a gaseous phase, required to identify the protein. 3) Difficulty in 
the ionisation of proteins (Lanucara et al., 2013 & Zhang et al., 2013). Peptides, made from 
the proteolysis of proteins, are much smaller and circumvent the problems associated with 
analysis of intact proteins. Thus a ‘Bottom-Up’ approach is common, where proteins 
undergo proteolysis and protein identity is inferred from peptide sequence. Bottom-Up 
proteomics approaches are also referred to as shotgun proteomics due to its similarity to 
shotgun genomic sequencing (Lanucara et al., 2013 & Zhang et al., 2013).  
 
For a typical Bottom-Up approach, proteins are extracted from the system of interest, 
followed by denaturation, reduction of disulphide bonds and alkylation of cysteine residues 
to prevent reformation of disulphide bonds, before proteolysis. Proteolysis most commonly 
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uses Trypsin as a protease because it has a highly specific cleavage pattern at the C-
terminus of Arginine (R) and Lysine (K) residues (unless the K/R +1 position is proline (P)). 
Electrospray ionisation (ESI, section 1.1.15) of tryptic digested products thus typically 
results in doubly protonated peptide ions, which is beneficial in terms of analysing large 
peptides with mass analysers (section 1.1.16) of smaller m/z ratios (Paizs et al., 2005, Zhang 
et al., 2013 & Michalski et al., 2012). 
 
However, proteolysis exponentially increases sample complexity. Thus, for highly complex 
samples there can be competitive/preferential ionisation of peptides combined with an 
inability for the MS to analyse all peptides available at any one time. Hence, low abundance 
proteins, and different PTM proteoforms, are challenging to analyse without prior 
fractionation techniques, purification or enrichment strategies being additionally employed 
(Mann et al., 2002). Consequently, peptides are separated by Reverse-Phase 
chromatography prior to MS analysis. Immunoprecipitation (IP) of target proteins or PTM 
enrichment can also aid in analysis. 
 
1.1.12. IP-coupled Proteomics 
A cells proteins do not function as separate entities but rather form highly complex, multi-
protein complexes that result in protein function (Alberts, 1998), for example the HIF-1α – 
HIF-1β complex (Wang et al., 1995). Additionally, for a PTM to occur a modifying enzyme 
must come into contact with the target protein, even if transiently. Thus, protein binding 
partners result in an additional layer of complexity when attempting to understand cellular 
regulatory mechanisms, thus is an important aspect to investigate. 
 
A method to investigate binding partners, and simultaneously solve the problem of 
potential low abundance proteins, is to specifically purify the protein of interest prior to 
proteomics analysis. The most common method for protein purification is to use an 
antibody to the target protein, that is bound to a solid phase, thus purifying the protein of 
interest and, under the correct conditions, any interacting proteins at a specific time (Co-IP) 
away from the whole cell proteome (Dunham et al., 2012). Thus Co-IP reduces sample 
complexity, increases the relative abundance of the target protein and allows identification 
of target protein interactors (Mallick et al., 2010). Although it is possible to identify protein 
interactors post IP through alternative techniques to proteomics, such as western blotting, 
these are largely Low Throughput (LTP) and are inherently biased by the requirement of 
prior knowledge of potential binding partners to investigate. Proteomics analysis provides a 
47 
 
High Throughput (HTP), unbiased identification approach, significantly improving 
understanding of protein interaction networks (Dunham et al., 2012 & Mallick et al., 2010). 
 
1.1.13. Phospho-Proteomics 
As mentioned, the proteome is highly fluidic in nature, in part due to the dynamic nature of 
PTMs (Mann et al., 2002). Due to the sub-stoichiometric levels of PTMs, and the fact that 
certain regions of the protein will not be analysable by MS following tryptic digest, it can be 
difficult to identify and locate the site of a PTM using standard Bottom-Up proteomics 
approaches, even following IP. Thus, enrichment strategies have been developed that can 
enrich for a specific PTM in the background of unmodified peptides. Many enrichment 
strategies for phosphorylation have been developed, including antibody-based techniques 
and targeting the charge introduced by phosphorylation. IP using anti phospho-tyrosine 
antibodies is fairly efficient. However phospho -serine and –threonine antibodies are highly 
dependent on the sequence surrounding the PTM site (Fíla et al., 2012), thus are not 
particularly useful for the vast majority of the phospho-proteome. 
 
Alternatively, using metal cations bound to a solid matrix, known as Immobilised Metal Ion 
Affinity Chromatography (IMAC), results in the enrichment of peptides that contain the 
negatively charged phosphate moiety. Thus, IMAC reduces sample complexity for more in 
depth analysis of phospho-peptides (Mann et al., 2002 & Rainer et al., 2015). The most 
commonly used phospho-peptide enrichment method is by Titanium dioxide (TiO2). 
 
1.1.14. Liquid Chromatography Mass Spectrometry 
As mentioned, MS has become an integral part of proteomics, however sample complexity 
is often too high for in-depth MS analysis alone. To deconvolute sample complexity, a prior 
Liquid Chromatography (LC) separation step is commonly coupled prior to MS analysis, 
where peptides are bound to a C18 column and eluted using an increasing acetonitrile 
concentration gradient, separating peptides based on their hydrophobicity. The LC system 
is coupled in-line with the ESI source of the mass spectrometer, thus as peptides are eluted 
off the LC column, they directly enter the mass spectrometer for analysis. The reduced 
complexity at any given time thus dramatically increases the depth of coverage of MS-
based proteomics analysis. 
 
In order to determine peptide primary sequence for protein identification, tandem MS 
(MS/MS) is generally performed. At any given time, the m/z ratio is recorded for all peptide 
48 
 
ions eluting from the LC column in an MS1 scan. Subsequently, the most intense, or 
desired, ions are sequentially isolated and fragmented. Fragment ions are then analysed by 
a second round of MS, and the m/z ratios of the product ions identified, generating an MS2 
spectrum. To prevent the same precursor m/z ion from MS1 being selected for multiple 
rounds of fragmentation and MS2 analysis, MS/MS is generally performed in a data 
dependent-acquisition mode (DDA) combined with an exclusion time window. Thereby, a 
‘Top X’ approach can be adopted to obtain tandem mass spectra analysis of a defined 
number of most intense precursor ions from the MS1 scan.  
 
A typical mass spectrometer consists of three essential components: an ionisation source, a 
mass analyser and a detector, although the exact components will vary depending on the 
type of instrument. For LC-MS/MS, the ionisation source is coupled to the LC elution and 
ionises peptides into a gaseous phase to enter the mass spectrometer. A mass analyser 
manipulates ions according to m/z ratios and a detector records the signal of ions when 
ejected from the mass analyser. Mass spectra are created from a MS scan by plotting 
detected m/z ratio against relative intensity of all ions in each respective MS scan. Tandem 
mass spectra can thus be used to determine the primary sequence of a peptide, which is 
searched against a database of all potential proteins in a sample. In this manner, a tandem 
mass spectrum can be used to identify a peptide and the gene product it was derived from. 
 
1.10.  Thermo Orbitrap Fusion Tribrid 
The continued development of MS techniques has led to the generation of multiple mass 
analysers, and peptide ion fragmentation techniques. The most advanced mass 
spectrometers combine these technologies into hybrid systems to provide extensive 
flexibility for MS/MS analysis. The Thermo Orbitrap Fusion Tribrid mass spectrometer is an 
example of this, combining a quadrupole, linear ion trap and Orbitrap mass analyser (Figure 
1.10, Senko et al., 2013). Utilising multiple mass analysers, it is possible to perform mass 
analysis (MS1, MS2 or MSn) in either the Orbitrap or the Iontrap, thus maximising efficiency. 
Additionally, this allows MS/MS analysis to be performed in a time-dependent mode, rather 
than a Top X mode, where a maximal (undefined) number of precursor ions can be analysed 
in the Orbitrap while product ions are detected in the Iontrap (Senko et al., 2013). The 
Thermo Orbitrap Fusion Tribrid mass spectrometer also incorporates multiple different 
fragmentation strategies (see section 1.1.17), thus making its use in proteomics highly 
advantageous for both in-depth protein identification and phospho-proteome analysis.  
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Figure 1.10: Schematic view of the Thermo Orbitrap Fusion Tribrid Mass Spectrometer. 
All major components of the MS are labelled, including: ion guides, mass analysers, ETD source and electrospray 
ionisation source. Taken from Senko et al., 2013. 
 
1.1.15. Electrospray Ionisation 
To analyse large biomolecules (peptides), ‘soft’ ionisation mechanisms are required to 
ensure that ions produced are not simultaneously fragmented. Electrospray ionisation (ESI) 
is the most commonly used ‘soft’ ionisation technique used for proteomics analysis. During 
ESI, a sample in a volatile solvent (acetonitrile) is passed through a high voltage capillary, 
generating a highly charged droplet cloud, of equal charge to the capillary (Fenn et al., 
1989). Charged droplets are heated to high temperatures (~300 oC) as they enter a high-to-
low pressure gradient, resulting in the desolvation of droplets and creating multiply 
charged gaseous ions, which can be analysed by MS (Fenn et al., 1989 & Kebarle et al., 
1993). ESI produces ions in the form of [Mass+nH]n+ where n = the number of protons 
added. 
 
1.1.16. Mass analysers 
Upon entering the mass spectrometer, ions are guided into a mass analyser. Mass analysers 
use a variable magnetic and/or electric field to eject ions and allow all ions of a single m/z 
ratio to be detected. There are multiple types of mass analyser, each with inherent 
properties to analyse different m/z ranges, sensitivity, resolution and mass accuracy (Haag, 
50 
 
2016 & Yates et al., 2009). The Thermo OrbiTrap Fusion Tribrid primarily consists of two 
main mass analysers, an Iontrap and an Orbitrap, with the quadrupole typically being used 
in a m/z filtering mode only. 
 
1.1.16.1. Iontrap 
Iontrap mass analysers rely on a high frequency, oscillating electric field to spatially capture 
all ions within electrodes. The application of a varying radio frequency (RF) voltage to the 
capturing electrodes results in the selective resonance of a particular m/z ion, resulting in 
its ejection from the Iontrap and detection by the detector; thus ejection/detection is 
dependent upon m/z ratio (Stafford et al., 1984). Two main types of Iontrap mass analysers 
have been developed: 3D (also known as Paul’s) Iontrap and 2D linear Iontrap (Figure 1.11).  
 
Figure 1.11: Schematic view of Iontrap mass analysers. 
A) 3D (Paul) Iontrap, consisting of two hyperbolic end cap electrodes (at the same AC voltage) surrounding a 
ring electrode (exhibits the varying RF frequency) to trap ions in a figure of 8. B) 2D Linear Iontrap, consisting of 
four parallel, oppositely charged, hyperbolic pole electrodes (that exhibit varying RF frequencies) with capping 
electrodes (exhibit DC voltages) to trap ions within an internal cavity cloud. The end caps and central trap can 
each experience different DC voltages. Detectors are perpendicular to the length of the Iontrap. 
 
A 3D Iontrap consists of a ring electrode surrounded by two hyperbolic electrode plates 
(Figure 1.11 A). All ions that enter into the 3D Iontrap are trapped spatially in a 3D figure-of-
eight trajectory, and experience resonance ejection from the ion cloud by changing the RF 
voltage applied to the central ring electrode (Stafford et al., 1984 & Williams et al., 1994). A 
2D linear Iontrap applies the same basic principles as a 3D Iontrap, however has a different 
structural layout. A 2D linear Iontrap consists of four parallel hyperbolic pole electrodes, of 
opposite changes, surrounded by end cap electrodes, thus trapping ions linearly (Figure 
1.11 B). The RF voltage is applied to the end caps of the 2D linear Iontrap, resulting in the 
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selective resonance ejection of a particular m/z ratio, perpendicularly to the Iontrap 
direction, enabling detection (Schwartz et al., 2002). Because a 2D linear Iontrap has a large 
internal capacity between electrodes, compared to other mass analysers, it allows for the 
large accumulation of ions before space-charge ion effects occur, thus providing the ability 
to achieve high sensitivity. However, Iontraps lack mass accuracy and resolving power 
compared to more advanced mass analysers such as the Orbitrap (Douglas et al., 2005) 
 
1.1.16.2. Orbitrap 
The Orbitrap is another type of ion-trapping mass analyser that was used in this project. An 
Orbitrap consists of a spindle-like pole electrode encapsulated by concave electrodes to 
form a barrel-like structure (Figure 1.12, Makarov, 2000). A linear electric field is applied 
between electrodes which causes ions to oscillate bi-spatially, orbitally around and axially 
along the inner spindle-like electrode, with frequency of oscillations being independent of 
each other (Makarov, 2000). The frequency at which a particular ion axially oscillates is 
directly proportional to the m/z ratio of the ion. When a mixture of ions is detected, a 
complex, repeating wave is generated over time. Fourier Transformation (FT) can then be 
used to convert the complex repeating wave into its component wave frequencies, which 
are proportionate to the m/z ratios and their respective intensities, to generate a mass 
spectrum (Scigelova et al., 2011). As frequency of oscillation can be detected much more 
accurately than time, Orbitrap mass analysers provide very high mass accuracy and 
resolution. However, they are more prone to space-charge effects, resulting in decreased 
sensitivity (Scigelova et al., 2011 & Makarov, 2000). 
Figure 1.12: Schematic view of an Orbitrap mass analyser.  
Consisting of two concave electrodes forming a barrel around a central spindle electrode. Ions are injected in 
time interval ‘packets’ through a whole in an outer electrode and ions oscillate both orbitally around and axially 







1.1.17. Peptide fragmentation 
Peptide sequence determination requires peptide ion fragmentation and MS2 (MS/MS) 
analysis. For peptide analysis, multiple fragmentation methods have been developed which 
primarily result in fragmentation along the peptide backbone (Figure 1.13 , Hunt et al., 
1986, Johnson et al., 1988, Zubarev et al., 1998, Syka et al., 2004 & Frese et al., 2012). 
 
Figure 1.13: Nomenclature of peptide fragment ions. 
a, b and c ions are different fragmentations of the peptide backbone, numbered sequentially from the amino-
terminus of peptides. x, y and z ions are respective counterparts, of a, b, c ions, and labelled from the carboxy-
terminus of peptides. R groups are of unknown amino acid side chains. CID/HCD predominantly results in b, y 
ions, ECD/ETD predominantly results in c, z ions and EThcD results in all four ion types. Taken from Paizs et al., 
2005. 
 
1.1.17.1. Collisional-induced dissociation 
The most commonly used fragmentation technique is collision-induced dissociation (CID). 
CID involves selectively exciting a specific m/z ratio and allowing it to collide with an inert 
gas to promote fragmentation. Generally, CID fragmentation occurs along the amide bond, 
producing a heterogeneous mixture of b and y ions, depending on how the charge localises 
post fragmentation (Figure 1.13). b –ions are derived from N-terminal peptide ion 
fragments, and y –ions are derived from C-terminal peptide ion fragments (Johnson et al., 
1988). By deducing the exact mass of b/y ions, it is possible to determine the primary 
sequence of the peptide by calculating mass changes between identified m/z ratio peaks at 
MS2 (Johnson et al., 1988 & Hunt et al., 1986).  
 
There are 2 general types of CID, resonance CID (performed in Iontraps, Johnson et al., 
1988) and beam type CID, also known as higher energy collisional dissociation (HCD, 
performed in a specialised collision cell, Olsen et al., 2007). Resonance CID, involves the 
selective resonance excitation of a single m/z ratio (by changing the RF voltage), leading to 
their increased collision rate with the inert gas (commonly helium) and fragmentation 
(Johnson et al., 1988). Thus, upon a single fragmentation event, a different m/z ratio is 
generated and the ions are no longer excited, hence MS2 spectra can be information 
limited. HCD involves filtering a specific m/z ratio into a specialised collision cell which has a 
variable RF voltage applied to accelerate ions into a high pressure of inert gas (commonly 
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nitrogen) to promote fragmentation (Olsen et al., 2007). Because HCD does not require 
resonance excitation, fragment ions undergo secondary fragmentation events to provide 
greater depth of b/y ion production, allowing the more efficient determination of peptide 
primary sequence (Olsen et al., 2007). However, a particular problem of CID is the 
susceptibility of phosphorylation to both CID and HCD methods (Zhang et al., 2009). 
 
1.1.17.2. Electron mediated dissociation 
Another commonly used fragmentation technique is through the absorption of thermal 
electrons by multiply protonated, charged peptide ions. Electron Transfer Dissociation 
(ETD) utilises a chemical anion vehicle to introduce electrons efficiently to peptide ions in a 
gaseous state (Syka et al., 2004). The absorption of electrons by ions results in the 
spontaneous fragmentation of electron hypervalent species, primarily at the N-Cα bond; 
producing a heterogeneous mixture of c and z ions (Figure 1.13, McLafferty et al., 2001 & 
Zubarev et al., 1998). c –ions are derived from N-terminal peptide ion fragments, and z –
ions are derived from C-terminal peptide ion fragments (Zubarev et al., 1998). In a similar 
manner to CID/HCD, deducing the exact mass of c/z ions allows for the determination of 
peptide primary sequence. ETD results in peptide fragmentation in a non-energetic 
reaction, thus preserving PTM localisation data. However these fragmentation strategies 
are limited to multiply charged species (3+), due to the electron-induced charge reduction 
and inability to fragment singly charged (1+) ions (Sobott et al., 2009). 
 
1.1.17.3. Dual fragmentation 
More recently, a combined dual fragmentation approach has been developed which utilises 
both HCD and ETD fragmentation strategies (EThcD, Frese et al., 2012). EThcD 
fragmentation creates a highly heterogeneous mixture of b, y, c and z ions in order to 
obtain more in-depth data to determine primary sequence while maintaining an increased 
chance that the PTM is not lost (Frese et al., 2012 & Frese et al., 2013). 
 
1.11. Data analysis 
In order to identify peptides, and thus proteins, from MS/MS analysis, search engines can 
be used to search obtained spectra against a database consisting of all potential proteins in 
the sample, for example the human protein complement. Three search engines are relevant 
to this project: MASCOT (Perkins et al., 1999), PEAKS DB (Zhang et al., 2012) and 
Andromeda (Cox et al., 2011). Search engines use complex algorithms to match MS2 
spectra (also known as peptide spectral matches (PSMs)) against the database to determine 
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primary peptide sequence and infer protein identity. As a peptide can be unique to a single 
protein or found within multiple proteins, inferred protein identities are scored based on 
the total number of PSMs that match to a specific protein. 
 
To estimate the false-positive rate of PSMs randomly matching a target database, all PSMs 
are subject to a second-round search against a fictional decoy database of equal size, which 
is usually the primary database with the sequence of proteins reversed. Comparison of the 
total number of matching PSMs from the desired and decoy databases allows the 
determination of a false discovery rate (FDR). Thus, FDR reflects the probability that any 
given PSM that matches the desired database is due to chance. Hence, a FDR cut-off can be 
applied, generally at 1%, to statistically control the number of false positive protein 
identifications per sample. 
 
For PTM discovery, data analysis needs to account for the known mass change introduced 
at the peptide level in the MS1 spectrum and the amino acid level in the MS2 spectrum, to 
determine the PTM site (Perkins et al., 1999). However, as stated, fragmentation 
techniques can result in the neutral loss of PTMs and difficulty in localising its site (Mann et 
al., 2002), essential information to characterise the biological function of a PTM. Therefore, 
common proteomics practise is to provide a site localisation confidence score of identified 
PTMs, determined through bioinformatics approaches. phosphoRS (ptmRS, Taus et al., 
2011) is a tool that analyses specific product ions to predict PTM site localisation, and has 
been used here with MASCOT as part of the Proteome Discoverer pipeline. Similar 
approaches are applied for PEAKS PTM and Ascore (part of the PEAKS pipeline, Han et al., 
2011), and Andromeda with PTM score (part of the MaxQuant pipeline, Cox et al., 2011). 
 
1.1.18. Quantitative proteomics 
In response to a specific stimulus, PTMs and protein interactions can change, thus altering 
the functions of the protein of interest. It is therefore relevant to define quantitatively the 
changes, in order to further understand the proteome. However, MS analysis is not 
inherently quantitative due to differences in ionisation efficiency of peptides (Bantscheff et 
al., 2007).Therefore, multiple strategies have been developed to quantify proteins, either in 
relative terms (fold change comparisons between treatments) or absolute terms (the 
number of copies a cell has of a single protein). Relative quantification can be further 
divided into two distinct techniques: label-free or labelled approaches (Bantscheff et al., 
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2007 & Bantscheff et al., 2012). Here, relative quantification was performed using a label-
free approach, described below. 
 
1.1.18.1. Label free quantification 
Label-free quantification is a less accurate approach compared to label based techniques as 
the samples are prepared and analysed independently, resulting in increased experimental 
and analytical variation (Bantscheff et al., 2007 & Bantscheff et al., 2012). Whilst highly 
flexible and theoretically able to compare an unlimited number of samples, label free 
quantification requires extensive normalisation techniques to compensate for experimental 
error. Commonly used normalisations include LC elution time correction and signal intensity 
correction against house-keeping proteins, both of which are assumed to be near identical 
for different samples (Gillet et al., 2016 & Välikangas et al., 2018). Thus, although not the 
most powerful technique for quantification, label free techniques provide a rapid and low-
cost strategy to simultaneously extract semi-quantitative information from proteomics 
datasets. 
 
Two strategies have been developed to infer protein abundance from peptides: Spectral 
counting and peptide intensity averaging. Spectral counting relies on the fact that for a 
given protein, a greater number of PSMs will be identified for a protein of greater 
abundance, when normalising for protein length (Washburn et al., 2001, Arike et al., 2014, 
Old et al., 2005 & Bantscheff et al., 2007). However, spectral counting approaches are 
relatively controversial due not measuring any physical traits of identified peptides and is 
further complicated by the inclusion of dynamic exclusion windows which prevent the same 
m/z ratio being sent for MS2 analysis multiple times, thus limiting the number of PSMs (Old 
et al., 2005). 
 
Alternatively, a more computationally intensive, intensity-based quantification is possible. 
For each m/z peak identified at MS1, the intensity is integrated against the timescale of the 
LC chromatogram to determine peptide intensity as a measure of ion area; accounting for 
physiochemical properties of peptides and different elution width windows. Each peptide 
identified for a protein has the intensity areas averaged to infer protein intensity, which is 
then compared between experimental conditions (Bondarenko et al., 2002, Old et al., 2005 





1.1.18.2. Label based quantification 
Label-based quantification approaches are generally considered more accurate because 
they allow the mixing of samples at an early stage in sample preparation so that each 
sample experiences identical experimental and analytical variation (Bantscheff et al., 2007 
& Bantscheff et al., 2012). Labelling approaches require the covalent incorporation of a 
known mass difference, either by in cellulo metabolic C13 labelling (SILAC, Ong et al., 2002) 
or post-digest isobaric tagging of peptides (TMT, Thompson et al., 2003 or iTRAQ, Ross et 
al., 2004). However, these experiments are expensive and complicated by the need to 
optimally achieve near 100% labelling efficiency. They also require samples to be prepared 
simultaneously, which was not feasible with the experiments performed here (Chapter 3). 
 
1.1.19. Software tools  
Various software packages are available to analyse LC-MS/MS data, which can be open 
source or commercial. Generally, the ideal software tool is dependent on the required 
analysis and is influenced by the experimental design and MS instrumentation used. In this 
thesis, Proteome Discoverer was used for protein identification and phosphorylation 
analysis, through the MASCOT and ptmRS pipeline described above. PEAKS PTM was used 
for searching of all known PTMs, both biological and artefactual, in an ‘open’ PTM search, 
and MaxQuant was used for label free, intensity-based quantification. 
 
1.1.19.1. PEAKS PTM 
PEAKS is a software package that allows identification of proteins without a database 
present, or has a poor quality database, through the de novo sequencing of PSMs to directly 
determine peptide primary sequence (Ma et al., 2003 & Zhang et al., 2012). PEAKS PTM 
then creates a smaller secondary database of all proteins identified from the initial de novo 
peptide primary sequence. The concatenated secondary database is then used in a 
database search fashion for all unidentified m/z ratios with variable modifications of all 
known PTMs in the Unimod database (>300, Han et al., 2011 & Creasy et al., 2004). PEAKS 
PTM uses a novel FDR calculation where the initial large database is used as reversed decoy 
database to search against in an open PTM fashion. The identifications from the larger 
reversed database are then compared against the identifications in the smaller correct 
orientation database to determine the FDR in a more strigent manner, reducing potential 
bias for underestimating FDR (Zhang et al., 2012 & Bern et al., 2009). As such PEAKS was 





MaxQuant is an open source software package with high flexibility for the quantification of 
both labelled and label free LC-MS/MS data by spectral matching and ion intensity 
methods, discussed above (Cox et al., 2014). MaxQuant uses its in-built search engine, 
Andromeda (Cox et al., 2011). As discussed, quantification approaches generally rely on the 
ability for large, global normalisation techniques against ‘housekeeping proteins’ assumed 
to be at identical levels independently of treatment (Välikangas et al., 2018). However, 
hypoxia is known to induce large effects on the level of expression for many housekeeping 
genes (Caradec et al., 2010), and thus potentially protein level, and may not be suitable for 
these type of normalisation strategies.  
 
Critically, MaxQuant utilises a process termed delayed normalisation, in which protein 
intensities are initially inferred from peptide area intensities (Cox et al., 2014). Identified 
proteins with minimal differences in protein intensity between experimental conditions are 
then used to normalise data, independently of being considered a housekeeping protein or 
not (Cox et al., 2011 & Cox et al., 2014). Thus, MaxQuant software is a more suitable 
package for the label free quantification of the LC-MS/MS analysis data obtained in this 
work. Perseus is a complementary, open source, software designed to aid in the extraction 
and interpretation of required information from MaxQuant, having various built in 
statistical and visualisation tools (Tyanova et al., 2016). 
 
1.12. Research Aims: 
The aim of this thesis was discover putative PTMs and binding partners that may regulate 
full length HIF-1α and HIF-2α proteins in cellulo, and in response to hypoxia. The results will 
aid to further understand the cellular mechanisms used to regulate HIF-1α and HIF-2α, and 
how their dysregulation may lead to pathologies. Using proteomics techniques, I identified 
a large number of novel PTMs and binding partners that occur in both O2-dependent and -








2.1. Chemicals and reagents 
Tissue culture reagents were purchased from Gibco. Powdered chemical reagents and 
custom DNA primers were purchased from Sigma-Aldrich, unless otherwise stated. Mass 
spectrometry (MS) solvents were purchased from Thermofisher, HPLC grade. All Eppendorf 
tubes used are Ultra-High recovery Eppendorf tubes (STARLAB). 
 
2.2. Cell culture, transfection and treatment 
2.2.1.  Cell passaging 
HeLa cells (ECACC catalogue #: 93021013) were grown in DMEM media supplemented with 
10% (v/v) Foetal calf serum, 1% (v/v) Non-Essential Amino Acids and 1% (v/v) 
Penicillin/streptomycin and incubated at 37 oC, 5% CO2 , 21% O2. Cells were passaged at 80-
90% confluency. Passaging involved removing the media, washing cells in PBS and 
incubating with 1X Trypsin/EDTA for 5 min. Detached cells were re-suspended in growth 
media, cell count obtained using a TC20- Automate cell Counter (BioRad) and seeded at a 
density of 1x105 cells/mL (~1.35x105 cells/cm2). 
 
2.2.2.  PEI 40K MAX linear stock solution 
PEI 40K MAX linear powder (Polysciences #24765) was resuspended to make a 1% (w/v) 
solution in sterile PBS by continual stirring for 18 hr at 4 oC. The stock solution was adjusted 
to pH 7.5 by addition of 5 M NaOH before sterile filtering through a 0.22 µm filter, 
aliquoting and storage at 4 oC. Referred to as PEI in this thesis. 
 
2.2.3.  Transient transfection 
Transient transfection was conducted 24 hr prior to experimental use. During transfection 
optimisation, various reagents were tested, following manufacturers guidelines (Table 2.1). 
Additionally, the recommended ratio for volume of transfection reagent (µL):quantity of 
DNA (µg), was changed 0.5 and 2 fold, in order to identify if a better ratio existed. The final 
transfection conditions used throughout were as follows:  unsupplemented DMEM media 
was used to dilute DNA to a final DNA concentration of 10 ng/µL. For MS experiments (High 
HIFα expression level), the total quantity of DNA was at a 1:1 ratio of HA-Clover-HIFα:empty 
vector (pcDNA3(-)). For biochemical and functional assays (low HIFα expression level), the 
DNA was at a 1:19 ratio of HA-Clover-HIFα:empty vector. To this, a ratio of 4 µL PEI:1 µg of 
DNA was added. Transfection mixes were vortexed and left to stand at room temperature 
for 30 min. The volume of transfection mix added to cultured cells is equivalent to 5% of 
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the total cell culture volume (example volumes in Table 2.2). Cells were incubated for 18 hr 
before media was replaced and cells treated. All plasmids used are listed in Table 2.3. 
 
Table 2.1: Transfection reagents tested during optimisation and recommended conditions.  
*Recommended to determine empirically for different plasmids. 
 
Table 2.2: Transfection conditions for a 10 cm (56.7 cm2) plate.  
Table includes required volumes (μl) of reagents and quantities (μg) of DNA for the High and low expression 
levels of HA-Clover-HIFα and empty vector. 
 
Table 2.3: Plasmids used and their availability. 
 
2.2.4.  Hypoxic incubation 
Hypoxic incubation was at 1% O2, performed in a Don Whitley H35 Hypoxystation. To 
ensure correct O2 tensions, the hypoxic chamber was tested monthly using a Microx 4 fibre 
Optic Oxygen Meter (PreSens). Cells, PBS and lysis buffer were incubated in hypoxia for 4 




2.3. Cell lysis and protein extraction 
2.3.1.  Cell lysis and protein extraction 
Post treatment, cells were washed in PBS before adding 11.4 µL/cm2 (equivalent to 600 µL / 
10 cm plate) lysis buffer (50 mM Tris pH 8.0, 120 mM NaCl, 5 mM EDTA, 0.5% (v/v) NP-40, 
1X EDTA-free cOmplete protease inhibitor (Roche) and 1X phosSTOP (Roche), unless 
otherwise specified). Cells were scraped and supernatant collected into Ultra-High recovery 
Eppendorf tubes (STARLAB) before removal from the hypoxic chamber, in case of hypoxic 
incubation. Normoxic treated cells were lysed identically. Lysates were rotated end-over-
end for 30 min at 4 oC, unless otherwise specified, before centrifugation at 10,000 g for 10 
min at 4 oC. Cleared supernatant was collected into fresh Ultra-High recovery Eppendorf 
tubes. 
 
2.3.2. Protein concentration determination 
Protein quantification was performed using the Pierce BCA Protein assay Kit (ThermoFisher) 
following the manufacturer’s recommended protocol, using a serial dilution of bovine 
serum albumin (BSA) of: 1.5, 1.0, 0.5, 0.25 mg/mL, as the reference standard. 
 
2.4. HaloTag visualisation 
2.4.1. In vivo labelling 
The required volume of HaloTag- Oregon Green (Promega, G2801), of 0.25 µL/cm2 of 
culture plate, was diluted 200 fold in unsupplemented DMEM media. An equivalent volume 
of media was removed from cells and replaced by the diluted HaloTag- Oregon Green 
solution. Cells were returned to incubation for 15 min and then washed 2 X with equal 
volumes of unsupplemented DMEM, before adding growth media. Cells were incubated for 
30 min and the growth media replaced before being taken for microscopy or lysed for SDS-
PAGE analysis. 
 
2.4.2. In vitro labelling 
Cells were lysed as described above. HaloTag- Oregon Green (Promega, G2801) was diluted 
200 fold by direct addition into cell lysate. This was rotated end-over-end for 30 min at 






2.5. Immunoprecipitation (IP) 
2.5.1. Endogenous protein IP 
Post hypoxic incubation, 5x106 cells (1x 10 cm plate) were lysed as previously described 
(600 µL lysis buffer) using the HA-Tag IP optimised lysis buffer (25 mM Tris pH 8.0, 350 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% (v/v) Triton X-100) or antibody manufacturer 
recommended lysis buffer (50 mM Tris pH 8.0, 120 mM NaCl, 1 mM EDTA, 0.2% (v/v) NP-
40), both supplemented with EDTA free cOmplete protease inhibitors (Roche) and 
phosSTOP phosphatase inhibitors (Roche). IP used the Pierce CrossLink Magnetic IP/CO-IP 
Kit (88805) following manufacturers recommended protocol, omitting the antibody-bead 
crosslinking stages. Briefly, using a magnetic stand for all bead collection steps, 25 µL of 
protein A/G beads were washed in the provided lysis buffer (25 mM Tris pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% (v/v) NP-40, 5% (v/v) glycerol) before 2 µg of antibody in 100 µL 1X 
coupling buffer (provided) was added and left to shake at 600 rpm for 15 min at room 
temperature, to pre-bind antibodies to beads. Antibody-bead complexes were washed in 
supplied lysis buffer and 1 mg of cleared protein lysate added and left to rotate end-over-
end for 18 hr at 4 oC. IPs were washed 3 X in lysis buffer and eluted in 25 µL of 2 X Laemmli 
buffer with boiling at 95 oC for 10 min. 
 
2.5.2. HaloTag IP 
All components required for IP are part of the HaloTag Mammalian Pull-Down System 
(G6504) kit, except the wash buffer (TBS + 0.05% (v/v) NP-40). The manufacturers 
recommended protocol for IP was followed, alongside 2 published protocols (Ohana et al., 
2011 & Daniels et al., 2014), all scaled to work with 5x106 cells (1 X 10 cm plate). All 
methods collect cells by scraping in PBS followed by centrifugation at 2,000 g for 10 min 
and lysed in 50 µL/mL of cell culture medium using the supplied mammalian lysis buffer (50 
mM Tris pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100, 0.1% (v/v) sodium deoxycholate & 1 X 
Protease inhibitor cocktail (G6521)). Physical perturbations to aid cell lysis were as follows: 
1) Manufacturer recommend: passing cell lysate through a 25- gauge needle, 2) Ohana et 
al., 2011: Sonication max power 10 s on, 10 s off (Cavitek 27 L professional ultrasonic 
cleaner, Allendale-ultrasonics) 3) Daniels et al., 2014: -80 oC for 1 hr freeze-thaw cycle with 
dounce glass homogenizer (2.0 mL size). Cell lysates were then cleared by centrifugation at 
10,000 g for 10 min at 4 oC and collected into fresh tubes before following the 
manufacturer recommend IP protocol. Briefly, all centrifugation steps were performed at 
2000 g for 3 min, 100 µL of HaloLink resin was washed 3 X in the supplied lysis buffer before 
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adding 1 mg of protein lysate and rotating end-over-end for 2 hr at room temperature. 
Bead-protein complexes were washed 3 X in the supplied lysis buffer and 2 X in wash 
buffer. Bound protein was eluted with 30 U of TEV protease (V6101) according to 
manufacturer’s recommended protocol. 
 
2.5.3. GFP-Traps IP for Mass spectrometry analysis 
A total of ~1.5x108 cells (30 X 10 cm plates) were lysed as previously described in section: 
2.3.1, but collected into a 50 mL falcon tube (~18 mL lysis buffer). Cell lysate (20 mg) was 
diluted in dilution buffer (lysis buffer without NP-40) to a final concentration of 0.2% NP-40, 
a 2.5 fold dilution. Preclearing was performed with bab-20 (CHROMOTEK) beads at a 
volume equivalent to 1:200 of bab-20 beads (µL):diluted lysate (µL) (~300 µL of bab-20 
bead suspension). Unless stated, all centrifugation steps were performed at 3,000 g for 2 
min. Before addition to diluted lysate, bab-20 beads were equilibrated by washing 3 X in 5 
volumes worth of dilution buffer, compared to volume of bead suspension. To preclear, the 
diluted lysate - bab-20 beads were rotated end-over-end for 1 hr at room temperature and 
centrifuged at 5,000 g for 5 min, supernatant was collected into fresh tubes. IP was 
performed with GFP-TRAP_A (CHROMOTEK) beads at a volume equivalent to 1:800 of GFP-
TRAP_A (µL):diluted lysate (µL) (~75 µL of GFP-TRAP_A bead suspension). Before addition 
to diluted lysate, GFP-TRAP_A beads were equilibrated as stated for bab-20 beads. To IP, 
the diluted lysate – GFP-TRAP_A beads were rotated end-over-end for 18 hr at 4 oC. IP 
complexes were collected and washed sequentially 3 X as described for bead equilibration 
and 2 X in 25 mM AmBic (ammonium bicarbonate in HPLC grade H2O). For all subsequent 
steps, HPLC grade solvents were used. An equal volume of 1% (w/v) Rapigest SF (WATERS) 
in 25 mM AmBic, to the initial volume of GFP-TRAP_A bead suspension, was added to 
washed beads and boiled at 95 oC for 15 min with 5 s vortexing every 2.5 min. Rapigest SF 
was diluted to a final concentration of 0.06% (v/v) in 25 mM AmBic and centrifuged 10000 g 










2.6. Gel based analysis 
2.6.1. SDS-PAGE sample preparation 
Cleared protein lysates (30 µg) were mixed with 5X Laemmli buffer (250 mM Tris-HCl pH 
6.8, 30% (v/v) glycerol, 10% (w/v) SDS, 500 mM DTT, 0.05% (w/v) bromophenol blue) and 




Gels were made to obtain 3 mL a 4% stacking gel (4% (v/v) acrylamide, 125 mM Tris-HCl pH 
6.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.1% (v/v) TEMED) and 5 mL of a 7.5% resolving gel 
(7.5% (v/v) acrylamide, 375 mM Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.1% (v/v) 
TEMED). For IP efficiency determination, an equal volume of protein sample was loaded per 
lane. For specific protein quantification, equal total protein (20 µg) of protein samples was 
loaded. For western blotting, all gels were loaded with 5 µL of Color prestained Protein 
Standard, Broad Range (10-250 kDa, New England Biolabs, P7719). For Coomassie staining, 
all gels were loaded with 5 µL of unstained SDS-PAGE standard, broad range (BIORAD, 161-
0317). Electrophoretic separation was performed at 200 V until the bromophenol blue dye 
front reached the end of the gel (~45 min) in electrophoresis running buffer (25 mM Tris pH 
~8.3, 192 mM Glycine, 1% (w/v) SDS). 
 
2.6.3. Coomassie staining 
Colloidal coomassie stain was prepared as described by Candiano et al., 2004. Briefly 
colloidal coomassie consists of: 0.12% (w/v) Coomassie G250 dye, 10% (w/v) ammonium 
sulphate, 10% (v/v) phosphoric acid and 20% (v/v) methanol. Gels were immersed in 
colloidal coomassie solution and allowed to stain for 18 hr at room temperature on an 
orbital shaker. Gels were destained in milliQ H2O on an orbital shaker at room temperature, 
changing the water frequently, until the gel was clear. Images were captured using an 
Epson Scanner. 
 
2.6.4. Western blotting 
Protein transfer onto nitrocellulose membrane (0.2 µm, BIORAD) was performed in transfer 
buffer (electrophoresis buffer + 10% (v/v) ethanol) for 2 hr at 300 mA, 4 oC. Membranes 
were blocked in a 5% (w/v) skimmed milk solution (Marvel) dissolved in TBST (20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.1% (v/v) Tween-20) for 1 hr at room temperature on an orbital 
shaker. Membranes were washed 3 X 10 min in TBST with shaking before addition of 
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primary antibody for overnight incubation at 4 oC with orbital shaking. After primary 
incubation, membranes were washed 3 X 10 min in TBST and incubated with the secondary 
antibody for 1 hr at room temperature with orbital shaking. All antibodies used are listed in 
Table 2.4, and were diluted in 5% (w/v) BSA in TBST. After secondary antibody incubation, 
membranes were washed 3 X 10 min in TBST and detected using ECL reagents: ECL clarity 
(BIORAD) or, the more sensitive, Amersham ECL select (GE Lifesciences). Images were 
captured using a Syngene gel imaging G-Box using the GeneSnap image acquisition 
software. Densitometry of western blots was performed using Fiji (Schindelin et al., 2012). 
 
Table 2.4: Summary of antibodies used for western blotting and IP.  
 
 
2.7. Bacterial expression 
2.7.1. LB (Luria-Bertani) broth 
A 2.5% (w/v) solution was made using LB broth powder (Miller, Merck Millipore) in MilliQ 
H2O, as per manufacturer’s recommendations. LB broth was autoclaved once dissolved and 
allowed to cool to room temperature before use. 
 
2.7.2. LB agar and antibiotic selection 
A 3.7% (w/v) solution was made using LB agar powder (Miller, Merck Millipore) in MilliQ 
H2O, as per manufacturer’s recommendations. LB agar was autoclaved once dissolved and 
allowed to cool to ‘touch hot’ temperature before adding required antibiotic selection and 
pouring plates under flame. Plates were allowed to cool and either used instantly or stored 




2.7.3. Generation of heat-shock competent cells 
Subcloning Efficiency DH5α competent cells (Thermofisher #18265017) were streaked onto 
agar plates without selection and grown for 18 hr at 37 oC. A single colony was picked and 
grown in 100 mL LB broth, without antibiotic selection, at 37 oC in an orbital shaker to an 
OD600 of 0.6. Bacterial suspension was centrifuged at 1500 g for 10 min at 4 oC and the 
supernatant discarded. Maintaining all steps and buffers on ice, the cell pellet was 
resuspended in 50 mL of 50 mM autoclaved CaCl2 (calcium chloride) and incubated on ice 
for 30 min. Centrifugation was repeated and cells resuspended in 1 mL of 100 mM 
autoclaved CaCl2 and incubated at 4 oC for 18 hr. 100% glycerol was added to a final 
concentration of 20% (v/v) (250 µL), and cells aliquoted and stored at -80 oC, minimum of 
48 hr before use. 
 
2.7.4. Heat shock transformation 
For cloning purposes STELLAR competent cells were used (TakaraBio), for plasmid 
propagation purposes DH5α heat shock competent cells were used (in-house generated, 
section: 2.7.3). Bacteria were defrosted from -80 oC on ice for 30 min. Unless otherwise 
stated, 5 ng plasmid DNA was added to 50 µL bacterial cells and left on ice for further 30 
min in polypropylene tubes (Fisher scientific #10384641). Using a water bath, tubes were 
heated to 42 oC for 45 s before returning to ice for 2 min. SOC media (450 µL, ThermoFisher 
#15544034) was added and cells incubated at 37 oC on an orbital shaker for 1 hr. Bacteria 
were plated, under flame, at 100 µL and 400 µL onto relevant antibiotic selection plates and 
grown at 37 oC for 18 hr. 
 
2.8. DNA based and cloning techniques 
2.8.1. Plasmid visualisation and cloning design 
SnapGene Viewer was used to visualise plasmids maps and sequences, identify restriction 
sites and aid in the design primers (SnapGene software (from GSL Biotech; available 
at snapgene.com)). 
 
2.8.2. Restriction digestion 
All restriction enzymes were purchased from New England Biolabs (NEB) in their HF (High 
Fidelity) format. Digestion was performed using the CutSmart buffer provided at 37 oC for 1 
hr. For testing purposes, 250 ng of DNA was digested with 0.25 µL of enzyme(s) in a total 
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volume of 25 µL. For DNA extraction and further cloning purposes, 1 µg of DNA was 
digested with 1 µL of enzyme(s), in a total volume of 25 µL. 
 
2.8.3. Primer design and generation 
The sequences of all primers used are available in Table 2.5 to Table 2.8. All primers were 
synthesised by Sigma-Aldrich as standard oligonucleotides in a desalted format. Primers 
were resuspended to 100 µM (information supplied by manufacturer) in MilliQ water and 
vigorously vortexed before use, stored at -20 oC. Primers were diluted to 5 µM stocks for 
use.  
 
Table 2.5: Sequencing primers.  
Includes a description of which primers were used for each construct. Sequencing of full length HIFα genes 
required multiple primers due to the length of the genes, only 1 primer used per sequencing reaction. The 
location of the primer binding within the respective gene, and the stop codons, respective to promoter and 5’ -> 
3’ sequence are included. 
 
Table 2.6: In-Fusion cloning primers. 
Includes a description of how the primer was used, 5’ -> 3’ sequence and predicted melting temperature (Tm) 
for the gene specific portion of primer. For sequence, uppercase letters are vector specific and bases inserted to 










Table 2.7: Site Directed mutagenesis primers. 
Includes plasmid for mutation, position of amino acid mutation site with from and to mutations, 5’-> 3’ 
sequence and predicted melting temperature. For sequence, uppercase letters match plasmid sequence, lower 
case letters are sites of mutation. 
 
Table 2.8: Quantitative Real Time PCR (qRT-PRC) primers. 
Includes the gene name that primers were against, direction of primer and 5’ -> 3’ sequence. 
  
2.8.4. Polymerase Chain Reaction (PCR) 
The KOD polymerase kit (Merck Millipore), a high fidelity, proof-reading polymerase, was 
used throughout to reduce mutation risk. PCR reactions were made using the supplied 
reagents and as described by manufacturer. For a 50 µL reaction mix: 5 µL 10X KOD 
polymerase buffer, 5 µL mixed dNTPs (2 mM each dNTP), 3 µL MgSO4 (25 mM), 3 µL of each 
diluted primer stock (5 µM), 20 ng plasmid and milliQ H2O to make the final volume. For 
new primers, a 50 µL reaction was split equally into 10 tubes to test a gradient of 
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temperatures at Stage 2 (b). Once the optimal temperature is determined a larger scale PCR 
reaction was set-up for extraction purposes. PCR reaction conditions in Table 2.9. 
 
Table 2.9 PCR reaction conditions.  
A gradient of 55-70 oC is used for new primers to determine optimal temperature. X = 1 min/kBp of amplified 
gene. 
 
2.8.5. Agarose gel electrophoresis 
A 1% (w/v) high melting temperature agarose gel (Bioline) was made by diluting agarose in 
TAE buffer (40 mM Tris-acetate pH ~8.5, 1 mM EDTA) and boiled until bubbling, ~2 
min/100mL, in a microwave. Molten agar was left to cool until ‘touch hot’ before a final 
concentration of 5% (v/v) Midori Green advanced DNA stain (Nippon Genetics) was added, 
mixed and poured into the gel casting tray (~75 mL). DNA samples were mixed with 
homemade DNA loading dye (5X stock) to a 1X concentration (10% (v/v) glycerol, 3.3 mM 
Tris pH 8.0, 10 mM EDTA, 0.01% (w/v) Bromophenol Blue). Samples ran alongside 10 µL of 
HyperLadder 1KB+ (Bioline). Samples were run at 100 V for 30 min. For extraction, gels 
were visualised using a UV box. For imaging, gels were visualised and imaged using a 
Syngene gel imaging G-Box using the GeneSnap image acquisition software. 
 
2.8.6. In-gel DNA extraction 
DNA fragments were excised from agarose gels using a scalpel and purified using the 
E.Z.N.A in gel extraction kit (Omega bio-tek) following adjusted manufacturers 
recommendations. Briefly, the agarose slice is melted, bound to a DNA binding membrane 
and washed before elution. Adjustments include: extending washing conditions to 4 X 5 
min, and, after the max speed drying spin step, a 10 min incubation at 70 oC with the lid 
open to further dry spin the column membrane before elution. Elution was done in TAE 
buffer, elution volume was dependent on downstream purposes: for In-Fusion Cloning: 20 




2.8.7. In-Fusion Cloning 
In-Fusion Cloning (Clontech) technology was used to create all HA-Clover based plasmids 
(HA-Clover only, HA-Clover-HIF-1α and HA-Clover-HIF-2α) following manufacturers 
recommended protocols. Briefly, destination vector was linearised with restriction 
enzymes, PCR was performed on the insert of interest using In-Fusion cloning compatible 
primers: Primers as described in Table 2.6 (with a 5’ 15 bp overhang complementary to the 
destination plasmid). Bases were inserted as necessary to correct the reading frame and 
recover restriction digest sites. Both linearised plasmid and amplified inserts were purified 
using in gel extraction (section 2.8.6). In-Fusion reaction mixes were performed in a total 
volume of 20 µL with a 3:1 molar ratio of insert:vector using the following equation: 
For transformation, 5 µL of the infusion reaction mix was used to with Stellar competent 
cells (Clontech), (conditions described in 2.10.4). 
 
2.8.8. Ligation 
All ligation reactions were performed using T4 DNA ligase and supplied buffer reaction (1X 
concentration: 50 mM Tris-HCl pH 7.5, 10 mM MgCl2 1 mM ATP, 10 mM DTT) following the 
manufacturer’s recommended protocol (New England Biolabs, #M0202S). Briefly, 50 ng of 
digested linearized vector backbone was mixed with digested insert a 1:3 molar ratio of 
vector:insert, calculated using the above equation, with 2 µL of T4 DNA ligase and made to 
total volume of 20 µL with milliQ H2O. Ligation was performed at 37 oC for 30 min, followed 
by heat inactivation at 65 oC for 15 min. For bacterial heat shock transformation, 5 µL of 
ligation reaction was transformed into STELLAR competent cells (Clontech). 
 
2.8.9. Plasmid amplification 
For cloned and mutagenic plasmids, 5 colonies were picked from antibiotic selection plates 
and added into separate 50 mL falcon tubes containing 5 mL LB broth, maintaining 
antibiotic selection, and grown at 37 oC shaking on an orbital shaker for 8 hr. 0.5 mL cell 
suspension was mixed with 0.5 mL 80% (v/v) sterile glycerol to create glycerol stocks and 
froze at -80 oC. The remaining cell suspension was used for DNA extraction using the 
GeneJET plasmid miniprep kit (ThermoFisher). Briefly, cells were pelleted, lysed, neutralised 
to precipitate protein and cleared by centrifugation (13,000 g for 5 min) before applying to 
a DNA binding membrane for washing and elution using centrifugation (13,000 g for 1 min). 
The same adaptions as described for in gel extraction (section 2.8.6) are used. Plasmids 
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were sequenced (see LightRun DNA sequencing section 2.8.10). For a plasmid containing 
the correct gene, 100 µL of the glycerol stock was added into 200 mL LB broth, with 
antibiotic selection, and grown for 18 hr at 37 oC in an orbital shaker. Plasmid was extracted 
from bacteria using the PureLink HiPure Plasmid Maxiprep Kit (Invitrogen), following the 
manufacturer’s protocol. Principles are identical to miniprep, but include an additional 
isopropanol-ethanol precipitation step to further purify the DNA. 
 
2.8.10. LightRun DNA sequencing 
All sequencing was performed with GATC Biotech (Eurofins genomics) using the LightRun 
sequencing option. Sequencing required, 100 ng of purified plasmid mixed with 5 µL of a 
single diluted sequencing stock (5 µM), made to a total of 10 µL in H2O. Sequencing primers 
listed in Table 2.5. 
 
2.9. Cloning HA-Clover plasmids 
A schematic view of cloning protocol is presented in Figure 3.10. 
 
2.9.1. HA-Clover-HIF-1α  
HA-HIF-1α plasmid (a gift from Prof Sonia Rocha) was linearised with BamHI. The Clover 
gene was PCR amplified using the stated primers (Table 2.6) from a Clover-only plasmid 
(Addgene #40259). The Clover stop codon was removed and both BamHI sites were 
restored (either end of sticky ends) during primer design, to maintain the reading frame 
and allow easy removal of the Clover gene should other tags be required in the future. The 
final plasmid map is depicted in (Figure 2.1). 
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Figure 2.1: Plasmid map of cloned HA-Clover-HIF-1α.  
Viewed and annotated in Snapgene viewer (SnapGene software (from GSL Biotech; available at snapgene.com)) 
 
2.9.2. HA-Clover only  
The HA-HIF-1α plasmid was digested with both BamHI and EcoRV to remove the HIF-1α 
gene. The clover gene was amplified with new stated primers (Table 2.6) from the Clover-
only plasmid. Primer design restored the N-terminal Clover BamHI and C-terminal EcoRV 
sites, and a stop codon C-terminally adjacent to the EcoRV site. This was done for future 
cloning with easy production of N-terminal and C-terminal clover constructs by linearization 







Figure 2.2: Plasmid map of cloned HA-Clover only.  
Viewed and annotated in Snapgene viewer (SnapGene software (from GSL Biotech; available at snapgene.com)). 
 
2.9.3. HA-Clover-HIF-2α  
The HA-Clover only plasmid was linearised with EcoRV and the HIF-2α gene PCR amplified 
with stated primers (Table 2.6) from a HaloTag-HIF-2α plasmid available in the Sée lab. The 










Figure 2.3: Plasmid map of cloned HA-Clover-HIF-2α.  
Viewed and annotated in Snapgene viewer (SnapGene software (from GSL Biotech; available at snapgene.com)) 
 
2.10. Site directed mutagenesis (SDM) - 
aaaMEGAprimer 
SDM was used to create point mutations within the HIFα gene. MEGAprimer protocol is 
depicted diagrammatically in Figure 2.4. The PCR protocol described (2.8.4) was used for 
SDM. Flanking primers were designed within the vector backbone to create a full-length 
mutant HIFα gene, irrespective of HIF-1α or HIF-2α gene, thus allowing the same flanking 
primers to be used for SDM of either the HIF-1α or HIF-2α genes. Mutagenic primers (7 bp 
either side of mutated codon) were designed so that their orientation would create the 
smallest PCR fragment in a first round of PCR (all primers listed in Table 2.7). First round 
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PCR used the mutagenic primer and a single flanking primer to create the MEGAprimer. 
MEGAprimer was extracted following the in-gel extraction protocol described (section 
2.8.6). Second round PCR followed an adapted version of the described PCR protocol 
(2.8.4), using: 250 ng MEGAprimer and 50 ng plasmid. The second flanking primer was used 
with the MEGAprimer to amplify the full length gene. The full length gene was in-gel 
extracted and digested with the restriction enzymes: BsrGI and NotI. HA-Clover was 
digested identically and both subjected to in-gel extraction (2.8.6). Vector backbone and 
insert were ligated together (see ligation section: 2.8.8) and transformed by heat shock 
(2.7.4) into STELLAR competent cells (Takarabio). 
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Figure 2.4: Schematic depiction of the MEGAprimer protocol used for SDM of S31 of HIF-1α.  
Includes a description of each step performed throughout the creation of SDM plasmid. F1 and F2 = flanking 
primer locations, M = mutagenic primer location, MP = MEGAprimer location, MFL = mutant full-length gene. B 
= BsrGI and N = NotI restriction enzyme sites. X = ligation site. Plasmid viewed and automatically annotated 




2.11. Sample preparation for mass 
aaaspectrometry (MS)  
HPLC grade solvents and highest purity powdered chemical reagents were used 
throughout. 
 
2.11.1. Reduction and alkylation 
A Nanodrop-2000 was used to determine protein concentration of eluted material at a 
wavelength of 205 nm. DTT (Dithiothreitol), dissolved in 25 mM AmBic, was added to a final 
concentration of 3.33 mM and heated at 60 oC for 10 min. The sample was cooled to room 
temperature and IAA (Iodoacetamide), dissolved in 25 mM AmBIC, was added to a final 
concentration of 9.5 mM and incubated at room temperature in dark for 30 min. Remaining 
IAA was quenched by the addition of DTT to a final concentration of 7 mM DTT. 
 
2.11.2. Proteolytic digestion 
Reduced and alkylated samples were split equally into three Ultra low bind tubes for 
digestion by either: 10:1 (w/w) Trypsin Gold (Promega), 7.5:1 (w/w) Chymotrypsin 
(Promega) or 5:1 (w/w) Elastase (Promega) (w/w: total eluted protein : enzyme). Total 
eluted protein determined from the nanodrop 2000 protein concentration reading in 
2.11.1. Samples were incubated at manufacturers recommended temperatures for 18 hr 
with 600 rpm shaking on a Thermomixer (Eppendorf). Post digestion, trifluoroacetic acid 
(TFA) and acetonitrile (ACN) was added to a final concentration of 1.5% (v/v) and 3% (v/v), 
respectively, and incubated at 37 oC with 600 rpm shaking for 2 hr before incubating on ice 
for 2 hr. The sample was centrifuged at 13000 g for 15 min at 4 oC and the clear supernatant 
collected. For mass spectrometry analysis of binding partners, 5% (20 µL) of the 
supernatant was removed, the remaining 95% was dried to completion under cooled 
vacuum centrifugation (Centrifuge: UNIVAPO – 150 ECH, Cooling unit: UNICRYO MC2L -60 
oC, Vacuum pump: UNIVAC DQ4). 
 
2.11.3. Strong Cation Exchange (SCX) 
Strong cation exchange (SCX) was used for removal of PEG contamination from peptide 
samples prior to TiO2 phospho-peptide enrichment. Dried peptides were dissolved in 200 µL 
of 1.5% (v/v) TFA in H2O and sonicated at maximum power for 10 min (Cavitek 27 L 
professional ultrasonic cleaner, Allendale-ultrasonics). SCX stage tips were prepared by 
packing 5 discs of SCX membrane (Empore™ Supelco 47 mm Cation Exchange disc #2251) 
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into a 200 µL pipette tip. Tips were equilibrated by the sequential washing of 2X 200 µL of 
each: acetone, methanol, H2O, 5% (v/v) ammonium hydroxide (in H2O) and H2O. All 
centrifugation steps were performed at 4000 g for 4 min, or until all liquid had passed 
through the stage tip. Peptide samples were passed through the equilibrated tip 2 X and 
washed 5 X in 50 µL 1.5% (v/v) TFA in H2O before eluting in 3 fractions of 100 µL of 5% (v/v) 
ammonium hydroxide (in H2O). Elutions were combined and dried to completion under 
cooled vacuum centrifugation (described in section: 2.11.2).  
 
2.11.4. Titanium dioxide (TiO2) phospho-peptide 
aaaaaaenrichment 
Dried peptides were dissolved in loading buffer (80% (v/v) ACN, 5% (v/v) TFA, 1 M glycolic 
acid in H2O) to a concentration of 25 ng/μl and sonicated as stated for SCX (section 2.11.3). 
Concentration was determined using the Nanodrop settings described in 2.11.1. A ratio of 
100:1 (w/w) TiO2 resin (GL Sciences) to peptide was added and mixed at 1400 rpm on a 
thermomixer (Eppendorf) at room temperature for 20 min with intermittent vortexing 
every 5 min for 5 s. Sequential wash steps equivalent to 1.2:1 (w/v) TiO2 resin to wash 
buffer were performed subsequently with loading buffer, wash buffer 1 (80% (v/v) ACN, 1% 
(v/v) TFA in H2O) and wash buffer 2 (10% (v/v) ACN, 0.2% (v/v) TFA in H2O) with 1400 rpm 
shaking for 10 min. All centrifugation steps were at 2000 g for 1 min and supernatant was 
removed between washes. Peptides were eluted by sequential 1% (v/v) and 5% (v/v) 
ammonium hydroxide elutions, equivalent to 1.5:1 (w/v) TiO2 resin to elution buffer, and 
combined before drying to completion by vacuum centrifugation (as described in 2.11.2). 
Dried peptides were resuspended in 20 μL of 3% (v/v) ACN, 1% (v/v) TFA (in H2O) and 
sonicated as stated in 2.11.2. Samples were centrifuged at 13000 g for 15 min at 4 oC and 
18 µL taken for LC-MS/MS analysis. 
 
2.12. Orbitrap Fusion Tribrid Mass 
aaaispectrometer 
2.12.1. Liquid chromatography peptide separation 
Peptides were separated by reverse-phase HPLC using an UltiMate 3000 nano system 
(Dionex) coupled in-line to an Orbitrap Fusion mass spectrometer (ThermoScientific). 
Peptides were loaded onto a trapping column (PepMap100, C18, 300 µm x 5 mm) in MS 
loading buffer (3% (v/v) ACN, 0.1% (v/v) TFA) at a flow rate of 9 µL/min for seven minutes. 
Peptides were then resolved at a flow rate of 0.3 µL/min on an analytical column (Easy-
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Spray C18 75 µm x 500 mm, 2 µm bead diameter column) over a 60 minute gradient of 3% 
buffer A (0.1% (v/v) Formic acid in H2O):97% buffer B (80% (v/v) ACN, 0.1% (v/v) Formic acid 
in H2O) to 20% buffer A:80% buffer B, with a final 5 min 100% B wash. 
 
2.12.2. High-Low MS/MS method, binding partner 
aaaaaaidentification 
For unenriched samples, MS1 spectra were acquired in the Orbitrap (60K resolution at a 
m/z 200) over a m/z range of 350-2000, AGC target = 2E5, maximum injection time = 100 
ms. MS2 data were acquired in a data dependent acquisition (DDA) mode, using a ‘top 
speed’ method with a cycle time of 3 s. HCD fragmentation was set to 32% normalised 
collision energy (NCE) in the Iontrap. Iontrap MS2 settings were as follows: rapid mode (15K 
resolution at m/z 200), maximum injection time = 50 ms, fragmentation intensity threshold 
= 5E4 for 2+ to 5+ charge states. A dynamic exclusion window of 60 s was applied at a 0.5 Da 
mass tolerance. 
 
2.12.3. HTP HCD and EThcD method development 
The High-High method by Ferries et al., 2017 was used as an initial starting point to 
optimise MS data acquisition for the IP and TiO2 enriched samples. Briefly, the Orbitrap was 
used for MS1 and MS2 scans (60K and 30K resolution at 200 m/z respectively) in a DDA 
mode, 32% NCE HCD only fragmentation, AGC target = 2E5, fragmentation intensity 
threshold = 5E4, maximum injection time = 100 ms. For EThcD methods, the instrument 
parameter settings were kept the same. ETD reaction time was calibrated relative to the ion 
charge state, using an angiotensin standard. The HCD NCE was changed between 22%-18% 
in sequential LC-MS/MS experiments. 
 
2.12.4. High-High MS/MS method, phospho-peptide 
aaaaaaidentification 
Final method for TiO2 enriched phospho-peptide samples, MS1 spectra were acquired in 
the Orbitrap (60K resolution at a m/z 200) over a m/z range of 350-2000, AGC target = 5E5 
ions, maximum injection time = 250 ms. MS2 data was acquired in a DDA mode, using a top 
speed method with a cycle time of 3 s. HCD fragmentation was set to 32% NCE in the 
Orbitrap. Orbitrap MS2 settings were: 30K resolution at m/z 200, maximum injection time = 
250 ms, fragmentation intensity threshold = 2E4 for 2+ to 5+ charge states and 2 µscans 




2.13. Mass spectrometry Data analysis 
2.13.1. Proteome Discoverer (PD) 
Proteome Discoverer v1.4 was used to process LC-MS/MS data from the Orbitrap Fusion 
Tribrid for binding partner identification and phospho-peptide identification and site 
localisation. All database searches were performed using the MASCOT search engine 
against the UniProt Human reviewed database (updated August 2018); instrument type = 
ESI-FTICR, fixed modifications = cysteine carbamidomethylation; variable modifications = 
methionine oxidation. For TiO2 enriched samples, phosphorylation of S/T/Y was also 
included as a variable modification. For samples digested with trypsin (K/R -not P) a 
maximum of 2 miscleaves allowed. For samples digested with chymotrypsin (F/Y/L/W/M) a 
maximum of 4 miscleaves allowed. For samples digested with elastase (A/V/S/G/L/I) a 
maximum of 8 miscleaves allowed. For the High-Low MS/MS methods (binding partner 
identification), mass tolerances were MS1 = 10 ppm and MS2 = 0.5 Da. For High-High 
MS/MS methods (phospho-peptide detection and PTM localisation), mass tolerances were 
MS1 = 10 ppm and MS2 = 0.01 Da. The ptmRS mode, in PD, was used to localise the site of 
phosphorylation on the peptides. All identified peptides were filtered to a 1% False 
Discovery Rate (FDR) at the Peptide Spectral Match (PSM) level. 
 
2.13.2. MaxQuant and Perseus 
MaxQuant (1.6.7.0, Cox et al., 2011 & Cox et al., 2014) was used for label free 
quantification (LFQ) of high-low data for binding partner analysis. Perseus (1.6.7.0, Tyanova 
et al., 2016) was used to extract and visualise data from the MaxQuant output. All data 
were searched against the UniProt Human Reviewed database (August 2019) and the in-
built contaminants database using the Andromeda search engine. Miscleaves for the 
different enzymes were set as described previously for Proteome Discoverer (section 
2.13.1). For intensity calculations, split peaks was disabled and peptides were selected if 
they were 7 amino acids or longer. Constant modification of cysteine 
carbamidomethylation and variable modifications of methionine oxidation and N-term 
acetylation were used. Default instrument parameter settings were used for an Orbitrap - 
Iontrap system. The match between runs option was enabled with a time window of 10 
min. MS1 and MS2 scans were set to a 10 ppm and 0.5 Da tolerances respectively, peptides 
were filtered to a 1% FDR at the PSM level. Perseus was used to group identified peptides 
by unique protein identifier and average peptide intensity to estimate protein abundance. 
Missing values were imputed with a normalised distribution below the lowest intensity 
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peptides identified. A 2-sample t-test was performed between the two O2 conditions, s0 = 
0.1. Data was imported into R for use with a custom R script (provided by Dr Amy Campbell, 
part of the Eyers group) that colours significant identifications (P value <0.05) red, labels 
points with Gene name (from UniProt) if P value <0.01, and scales point size depending on 































2.14. Final method for HA-Clover 
aaaiimmunoprecipitation and mass 
aaaispectrometry analysis 
Figure 2.5: Flow diagram of the final methodology applied for the immunoprecipitation of HA-Clover tagged 
HIFα proteins 
Figure includes: Day each step was performed, which protocol was used (indented bullet points) and 




2.15. Bioinformatics analysis 
2.15.1. Phylogeny 
Phylogenetic analysis was performed using the human HIF-1α (Q16665) and HIF-2α 
(Q99814) sequences following instructions from Hall, 2013. Briefly, protein sequences were 
BLAST searched for all homologous sequences and a manual filter of 50% sequence 
homology applied. All partial and ‘unknown protein’ labelled sequences were removed. If 
multiple isoforms existed for a single species, reciprocal blast searches were performed to 
identify those sequences with most similarity to the human equivalent, and the others 
removed. Genus-species names were converted into common names using the Taxize 
plugin for R (using the Global Names Resolver (GNR)). Phylogeny analysis was performed in 
MEGA7 using 500 bootstrap replicates. 
 
2.15.2. DAVID 
Gene ontology functional annotation was performed using DAVID (Database for 
Annotation, Visualisation and Integrated Discovery, version 6.8, Dennis et al., 2003). 
Molecular function and Biological process annotations were kept, filtering out all other 
annotations, and P-values adjusted using the Benjamini-Hochberg method; a stringent P-
value correction that multiplies the initial P-value by the total number of annotations 
divided by the rank of a given annotation. Data visualisation was performed using a custom 
R script (provided by Dr Amy Campbell). 
 
2.16. Biochemical assays 
2.16.1. Real Time Quantitative PCR (RT-qPCR) 
Per sample, 4x105 cells (1 X 6 cm plate) were plated, transfected as stated (Section 2.2.3) 
and incubated for a further 24 hr at 21% or 1% O2. Cells were washed in PBS, lysed (400 µL 
of the supplied lysis buffer (Roche)) and RNA extracted using the HiPure RNA isolation kit 
(Roche), following the manufacturer’s recommended protocol. RNA (1 µg), determined 
from a Nanodrop 2000 reading, was converted into cDNA using the SuperScript Vilo reverse 
transcription master mix (Invitrogen), following the manufacturer’s recommended 
protocol. Briefly, all components were mixed and incubated at 25 oC for 10 min, followed by 
1 hr at 42 oC and terminated at 85 oC for 5 min. cDNA was diluted 20 fold in RNAse/DNAse 
free H2O before use. RT-qPCR was performed using a LightCycler480 using white bottom, 96 
-well plates (Roche). Master mixes were prepared so that a single well contained a total of 
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20 µL, consisting of: 10 µL SYBR Green PCR mix (Roche), 2 µL cDNA (or H2O for negative 
controls), 1 µL of each forward and reverse diluted stock primers (5 µM) for VEGF/GLUT-1 
in H2O. For EGLN1/EGLN3 4 µL cDNA and 3 µL of each forward and reverse diluted stock 
primers (5 µM) were used. All primers are listed in Table 2.8. Three technical replicates 
were performed per sample, per run. Three biological repeats were performed. Real Time 
qPCR cycling parameters are detailed in Table 2.10. Data analysis was performed using the 
LightCycler480 SW1.8 software, using the relative quantification method against the house 
keeping gene CYCLOA. 
 
Table 2.10: Cycling parameters used for RT-qPCR. 
 
2.16.2. Luciferase assay 
Per sample, a total of 2x105 cells per dish/well (1 X 35 mm dish / 6 well plate) were grown 
and transfected as described (2.2.3), using 50% of the total DNA quantity for transfection as 
a HRE-Luciferase plasmid (Addgene # 26731). Cells were washed in PBS and lysed in 35 
µL/cm2 of plate surface area (200 µL/ well) using luciferase lysis buffer (25 mM Tris-
phosphate pH 7.5, 15% (v/v) glycerol, 1% (w/v) BSA, 8 mM MgCl2, 0.1 mM EDTA, 2 mM DTT, 
1% (v/v) Triton-X 100) and shaken for 10 min on an orbital shaker. Cell lysate was split into 
three separate wells of 80 µL in a white walled and bottomed 96 well plate (Greiner), for 
triplicate technical replicates. A 2.5 fold excess (200 µL) of luciferase working solution was 
added to each well (500 µM Luciferin (Abcam, #ab145164), 5 µM ATP (Sigma-Aldrich, 
#FLAAS-1VL) in lysis buffer). A BMG Labtech FLUOstar Omega plate reader was used to 
shake the plate at 200 rpm for 5s before standing in the dark for 5 min and an endpoint 
luminometry readings taken. Readings were taken twice to ensure that the luciferase 





Cells (~5x106, 1x 15 cm dish) were transfected following the high expression level 
transfection (as described in section 2.2.3). CHIP protocol was followed from Batie et al., 
2019. Cells were subjected to incubation at normoxia or 1% O2 for 4 hr, before washing in 
PBS and crosslinking in 1% formaldehyde for 10 min, while maintaining O2 incubation 
conditions. Excess formaldehyde was quenched using 125 mM glycine for 5 min before 
taking cells to the bench. Cells were washed 2 X in PBS before lysing in 400 µL CHIP lysis 
buffer (50 mM Tris pH 8.1, 1% (w/v) SDS, 10 mM EDTA and 1X EDTA free cOmplete 
protease inhibitors (Roche)) per 15 cm dish (2.75 µL/cm2). Cells were scraped for collection 
and left on ice for 10 min before sonication, 8 cycles of 15 s on 30s off at 50% amplification 
on ice (Sonics Vibra-Cell # VCX130). Samples were cleared by centrifugation at 13000 g, 4 oC 
for 10 min and supernatant collected. Lysate (100 µL) was diluted 10 fold in dilution buffer 
(20 mM Tris pH 8.1, 1% (v/v) Triton-X100, 2 mM EDTA, 150 mM NaCl) and precleared using 
2 µg sheered salmon sperm DNA, 20 µL G-Sepharose 50% bead slurry (Generon) and end-
over-end rotation for 2 hr at room temperature. IP was performed by addition of a final 
concentration of 0.1% (v/v) Brij-35, 2 µg of the anti-GFP antibody (Roche, #11814460001) 
and end-over-end rotation at 4 oC for 18 hr. Anti-Mouse IgG was used as a negative control 
for IP (I5381, Sigma). Antibody complexes were captured using 30 µL G-Sepharose 50% 
bead slurry (Generon) in 2 µg sheered salmon sperm DNA with end-over-end rotation at 4 
oC for 1 hr. Captured complexes were sequentially washed for 5 min each at 4 oC with end-
over-end rotation in wash buffer 1 (20 mM Tri pH 8.1, 0.1% (w/v) SDS, 1% (v/v) Triton X-
100, 2 mM EDTA and 150 mM NaCl), wash Buffer 2 (wash buffer 1 + 500 mM NaCl), and 
Wash Buffer 3 (10 mM Tris pH 8.1, 250 mM Lithium Chloride, 1% (v/v) NP-40, 1% (w/v) 
sodium deoxycholate, 1 mM EDTA), 2 X TE buffer (10 mM Tris pH 8.0, 1 mM EDTA) before 
elution with 120 µL elution buffer (1% (w/v) SDS, 100 mM sodium-bicarbonate). Crosslinks 
were reversed by addition of NaCl to a final concentration of 200 mM and incubated at 65 
oC for 18 hr with 300 rpm shaking on a Thermomixer. For proteolytic digestion, Tris-HCl pH 
6.5 and EDTA were added to a final concentration of 40 mM and 10 mM respectively. 
Proteinase K (20 µg) was added and incubated at 45 oC for 1 hr. DNA was purified using the 
PCR product purification kit (NBS biologicals) following the manufacturer’s recommended 






2.16.4. Microscopy  
Samples were grown and transfected, as stated, using 35 mm glass bottom dishes (Greiner). 
Imaging was performed on a LSM780 Zeiss Microscope equipped with GFP (488 nm) and 
RFP (561 nm) filters, 20X and 63X objectives (numerical apertures of 0.75 and 1.4 
respectively) and a temperature (37 oC), O2 (21%) and CO2 (5%) tension control unit. 
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3. Chapter 3: Development 
of a mass spectrometry 
compatible 
immunoprecipitation 





As discussed in the introduction, HIF-1α and HIF-2α have a high sequence homology of 
~50% but, despite this homology, have different characteristics, including: sub-nuclear 
localisation, oxygen sensitivity and target genes. Regulatory mechanisms of the HIFα 
subunits have been investigated through targeted approaches, yet lack a discovery style 
experiment to identify all PTMs in an unbiased manner. Current published data 
investigating PTM regulation of HIFα subunits have used recombinant fragment-based 
approaches coupled with in vitro assays to identify and characterise PTMs. However, 
there are intrinsic issues with using these types of approaches to define PTMs and their 
roles, including incorrect folding of recombinant proteins, particularly for fragments, and 
thus there is a high possibility that the target proteins may not interact with endogenous 
modifying proteins. Hence, the false discovery (and false negative) rate of these 
techniques can be quite high. It is essential to investigate the regulatory roles of PTMs and 
of interactions with binding partners on full length HIFα expressed in cells, in order to 
understand the isoform specific characteristics observed in cells. 
 
To achieve this, we aimed to adopt a high throughput (HTP) mass spectrometry (MS) 
analysis strategy for the in-depth characterisation of HIF-1α and HIF-2α PTMs and their 
binding partners in cells cultured at different O2 levels. The initial objective was to design 
an immunoprecipitation (IP) protocol for full length HIF-1α and HIF-2α proteins from 
human HeLa cell lines that is compatible with such MS approaches. 
 
3.2. Aims: 
The aim of this chapter was to optimise a strategy for the specific IP of full-length HIF-1α 
and HIF-2α proteins from the widely used human HeLa cell line model.  Due to the low 
expression levels of endogenous HIFα and the relatively high amount of protein required 
for discovery proteomics and comprehensive PTM analysis, this ultimately required 







3.3. Endogenous HIF-1α and HIF-2α 
aaaiimmunoprecipitation: 
3.3.1.  Antibody selection 
For greatest biological relevance (minimal artefactual data) in identified PTMs and binding 
partners, the direct IP of endogenous cellular HIF-1α and HIF-2α proteins is required to 
ensure that the physiological signalling pathways are maintained. However, this relies on 
the availability of antibodies that are isoform specific and that recognise proteins in a 
folded state. HIF-1α and HIF-2α have a high sequence homology and their secondary 
structures are unknown; thus, specific antibody selection can be problematic. For IP, 
monoclonal and polyclonal antibodies have intrinsic advantages and disadvantages. For 
example, monoclonal antibodies have little batch-to-batch variation due to their robust 
production techniques, however, although a single antibody may increase the isoform 
specificity, it simultaneously increases the chance of epitope masking due to altered protein 
folding or differential protein binding and/or PTMs within the epitope. These could 
potentially result in IP variability/bias or even failure (Wardle et al., 2015). On the other 
hand, polyclonal antibodies detect multiple epitopes, limiting the risk of epitope masking 
but also may lack isoform specificity, and have a larger risk of batch-to-batch variation 
(Wardle et al., 2015). The most important consideration for IP-based PTM mapping is the 
risk of enrichment of proteins in an unmodified state, or conversely in a particular modified 
state, associated with monoclonal antibody-based IPs. Thus, monoclonal antibody-based IP 
can potentially introduce a bias in identified PTMs and binding partners, if the pathways are 
mutually exclusive, a problem circumvented by polyclonal antibodies and detection of 
multiple epitopes. 
 
A review of the literature identified 4 commonly used antibodies suitable for IP for each 
isoform, which were purchased and tested. A summary of the antibodies evaluated is 
provided in Table 2.4. Interestingly, there is a lack of evidence by manufacturers, or in 
publications, that unequivocally show isoform specificity of antibodies. Considering that 
HIF-1α and HIF-2α have near identical masses from western blotting (~120 kDa) it is 
impossible to distinguish between them without tagged-overexpression (resulting in a 
molecular weight shift) or silencing/knockdown controls.  
 
Specificity testing was conducted using the exogenous expression of a GFP tagged- HIF-1α 
or HIF-2α protein, using O2 stable GFP-HIF-1α-DM and GFP-HIF-2α-DM constructs, available 
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in the Sée lab. The DM constructs have been mutated to remove the O2 sensitive proline 
residues (P402A/P564A and P405A/P531A for HIF-1α and HIF-2α respectively), thus 
eliminating their O2 dependent regulation for maximal stability, and abundance, regardless 
of environmental O2 levels. These GFP-tagged HIFα proteins have an increased apparent 
molecular weight to ~150 kDa by western blot, thus independent exogenous expression can 
be used for cross reactivity testing by western blot (Figure 3.1).   
 
Figure 3.1: Sensitivity and specificity testing of 8 different commercially available HIF-1α and HIF-2α 
antibodies. 
Untransfected HeLa cells were incubated for 4 hr at 21% or 1% O2 as indicated. Transiently transfected GFP-
HIFα-DM isoforms were left at 21% O2 for 24 hr post transfection, before lysing all conditions simultaneously. 
Western blotting antibody dilutions are stated in Table 2.4. β-actin was used as a loading control. 
 
Except for BD610959 and 26422-1-AP, every antibody tested could specifically and 
adequately detect the exogenously expressed GFP-HIF-1α-DM or GFP-HIF-2α-DM proteins. 
However, only 20960-1-AP (Proteintech) and a700-003 (Bethyl laboratories) could detect 
the endogenous HIF-1α and HIF-2α proteins respectively, thus these antibodies were used 
for IP optimisation. These antibodies are used throughout this thesis for western blotting 
and referred to as HIF-1α or HIF-2α primary antibodies. 
 
3.3.2. Antibody IP optimisation 
When using IP of bait proteins to identify binding partners it is important to consider and 
minimise the co-purification of non-specific ‘background’ proteins. These contaminants are 
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generally environmentally introduced, inadvertent from sample preparation, or of high 
cellular abundance proteins, such as serum albumin or myosin, and are predicted to 
account for up to 95% of all IP coupled mass spectrometry identified proteins (Trinkle-
Mulcahy, 2012). Hence it is essential to optimise IP conditions to limit non-specific 
interactions, while maintaining weak or transiently interacting proteins of interest.  
 
A protocol for the IP of HA-tagged proteins using a commercially available anti-HA antibody 
cross-linked to magnetic beads (Pierce) had previously been optimised in the Eyers lab. 
Therefore, this protocol was used as a starting point for the IP of endogenous HIFα 
proteins, substituting the anti-HA antibody for the anti-HIF-1α or anti-HIF-2α antibodies. 
Although this protocol uses a cross-linking strategy, for initial optimisations this step was 
not included. This protocol uses a relatively stringent lysis and wash buffer to minimise non-
specific interactions, however is above the manufacturers recommended concentrations, 
therefore a second lysis buffer recommended by the antibody manufacturers was also 
tested (Figure 3.2). 
 
Figure 3.2: IP optimisation for endogenous HIF-1α and HIF-2α proteins.  
Western blot analysis using either the HIF-1α or the HIF-2α antibodies of total lysate (10% volume), unbound 
protein material (10% volume) and eluted fraction (100% volume) following IP using either the Eyers lab 
protocol, or manufacturer recommended conditions. HeLa cells were incubated at 1% O2 for 4 hr before lysis in 
the relevant lysis buffers. Arrows indicate bands of the correct molecular mass for HIF-1α and HIF-2α. Lysis 
buffer 1 composition: 25 mM Tris pH 8.0, 350 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% Triton X-100. Lysis 
buffer 2 composition: 50 mM Tris pH 8.0, 120 mM NaCl, 1 mM EDTA, 0.2% NP-40. Both lysis buffers were 
supplemented with EDTA-free cOmplete protease inhibitors and phosSTOP phosphatase inhibitors (Roche). 
 
The initial immunoprecipitation protocol from the Eyers lab was successful in purifying 
~40% of total endogenous HIF-1α protein. IP efficiency was increased by ~2 fold when using 
the manufacturer recommended lysis/wash buffer (Figure 3.2), determined by 
densitometry (data not shown). However, neither method tested was successful for IP of 
HIF-2α, shown primarily by a lack of a band at the correct molecular weight in the elution 
lane, and secondarily by equally intense bands between the lysate and unbound lanes. 
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Combined, these data suggest a potential problem with antibody-epitope recognition or 
antibody-bead association, rather than loss caused by wash steps or failure to elute. An 
intense band of ~55 kDa is seen in the elution lane of all conditions; presumably the 
antibody heavy chain given that the same antibody is used for IP and western blotting. This 
suggests that the anti HIF-2α antibody can efficiently bind to the magnetic beads, thus the 
problem rather lies in epitope recognition. To confirm this, the antibody-bead binding 
efficiency was tested by following the IP protocol for both anti-HIF-1α and anti-HIF-2α 
antibodies without cellular lysate. ‘Mock’ IPs were then analysed by SDS-PAGE and stained 
with Colloidal Coomassie stain to highlight all proteins in the sample (Figure 3.3). 
Figure 3.3: Antibody bead binding efficiency.  
Colloidal coomassie stained SDS-PAGE gel of lysate free, mock IPs using the anti-HIF-1α and anti-HIF-2α 
antibodies. IPs were performed following the optimised protocol from the Eyers lab without cross-linking and 
using the manufacturer recommended lysis/wash buffer. Lysis performed in 5X Laemmli’s buffer. 10% of input, 
unbound and elution samples were loaded and stained with Colloidal Coomassie stain. 
 
For the anti-HIF-1α antibody, where IP was successful (Figure 3.2), there was a single band 
of ~55 kDa in the input material. As expected for successful IP, without cross-linking, this 
band is significantly reduced and then recovered by bead binding and elution stages 
respectively (Figure 3.3). A faint band in the unbound lane can be explained by the high 
quantity of antibody used potentially being above the maximum binding capacity of the 
beads. For the anti-HIF-2α antibody, 3 bands were detected in the input lane; a prominent 
~66 kDa band and two equally intense bands of ~55 kDa. The manufacturer (Bethyl 
Laboratories) states this antibody is supplied in a 0.1% BSA solution (~66 kDa), which aligns 
to the 66 kDa BSA standard of the molecular weight ladder (BIORAD Broad MW range 
marker unstained, catalogue #: 1610317), thus confirming the identity of the heavier band. 
This suggests that the ~55 kDa bands are the antibody chains. The ~55 kDa bands have an 
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identical band pattern to the anti-HIF-1α antibody positive control (Figure 3.3), thus this 
suggests that the anti-HIF-2α antibody successfully binds to, and elutes from, the magnetic 
beads. Hence, the likely explanation for IP failure is that the HIF-2α antibody cannot identify 
the epitope; either by protein folding or protein-complex formation that masks the epitope, 
as hypothesised previously, but works for western blotting because of protein 
denaturation. 
 
Overall, endogenous HIF-1α could be successfully and efficiently pulled-down using the 
manufacturer recommended buffers with the method developed in the Eyers lab. However, 
due to the high amount of protein necessary for discovery PTM analysis (see Figure 3.15 
(A)) and without a successful method to IP endogenous HIF-2α, it was decided to explore 
tag-based exogenous expression strategies.  
 
3.4. Exogenous expression of tagged- HIF-1α 
aaaiand HIF-2α for immunoprecipitation: 
3.4.1.  Exogenous expression optimisation: 
There are many options for the expression of tagged fusion proteins in cell lines including 
genomic knock-in technology (CRISPR/Cas9), bacterial artificial chromosomes (BACs) and 
plasmids, each with inherent advantages and disadvantages. Although technically 
challenging and costly, the development of CRISPR/Cas9 has revolutionised human cell 
genetic manipulation. This technology can insert genes/tags within the genome at specific 
sites, thereby maintaining endogenous protein levels and improving biological reliability for 
pathway interrogation (Cong et al., 2013 & Hsu et al., 2014). BACs are large supercoiled 
segments of DNA that allow expression of a target gene of interest under its endogenous 
promoter, following expression into relevant cells. BACs are typically ~200 kbp in size and 
contain large segments of upstream and downstream neighbouring DNA to the endogenous 
gene of interest. Putting the gene into its natural context increases the likelihood that 
endogenous gene expression regulation may be maintained, but is not 100% successful. As 
an added complication, BACs require extensive genetic manipulation for tag insertion and 
screening of clones to evaluate copy number, and thus BAC-mediated protein expression 
levels, in comparison with endogenous protein (Shizuya et al., 2001). In contrast, plasmids 
are small (usually <10 kbp) circular pieces of DNA which contain all the essential signalling 
motifs to promote self-replication and transcription of the tagged-gene of interest 
independently to the host genome (reviewed by del Solar et al., 1998). Consequently, 
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plasmids do not contain endogenous transcriptional promoters or regulatory pathways and 
typically result in high expression of the desired protein, either continuously or following 
induction. Their easy genetic manipulation, ability for large scale fusion-protein production 
and ease for transient transfection/stable cell line selection have popularised the use of 
plasmids exponentially.  
 
Without prior knowledge of which tags will work for successful HIFα IP, combined with the 
difficulty of creating knock-in/BACs systems and the requirement for large quantities of 
protein post IP (which would not be available with endogenous expression levels (Figure 
3.15 (A)), a transient plasmid based exogenous expression system was selected for 
optimisation for the pull-down and PTM analysis experiments. 
 
Plasmid DNA introduction into cells involves getting the hydrophilic DNA through the 
hydrophobic phospholipid bilayer. Three main strategies have been developed for DNA 
transfection into cells: virus-mediated, chemical reagents and physical perturbations, each 
having different degrees of cytotoxicity, efficiency and reproducibility (reviewed by Kim et 
al., 2010). The most common, and simplest, technique for DNA transfection is the use of 
commercially available chemical reagents, known as transfection reagents. These are 
designed to facilitate DNA endocytosis and subsequent ejection inside the cytoplasm. As 
high quantities of tagged-HIFα proteins are required for IP and subsequent comprehensive 
PTM analysis by MS, it was important to optimise transfection efficiency. Several available 
transfection reagents were tested (Table 2.1). Optimisation studies aimed to obtain the 
greatest number of transfected cells, with a reasonable level of expression, while 
maintaining nuclear localisation, cell viability and avoiding cellular stress (membrane 
blebbing). 
 
For initial optimisations, a luciferase reporter construct under the control of a strong viral 
CMV promoter (CMV-Luc) was transfected into HeLa cells, following the manufacturers 
recommended protocols for each reagent. Thus, luciferase signal reflects the total 
transfection rate of cells. Additionally, the volume of each transfection reagent was altered 
0.5X and 2X, maintaining the quantity of plasmid DNA, to identify the best DNA:reagent 
ratio for transfection efficiency (Figure 3.4 (A)).  
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Figure 3.4: Transfection efficiency optimisation by luciferase assay and fluorescence imaging.  
A) Comparison of transfection efficiencies between 7 different transfection reagents, measured as a luciferase 
response from a CMV-Luciferase plasmid in HeLa cells. B) Microscopy analysis of FuGENE HD, PEI and JetPrime 
using the optimised DNA:reagent ratios from (A). Overexpression of GFP-HIF-2α-DM was used for fluorescence 
imaging at 20X magnification, with a 2x2 grid of images at brightfield and 488 nm fluorescence excitation, and 




These studies showed that PEI 40K MAX linear (referred to as PEI from now) and JetPrime 
had the greatest transfection efficiencies according to CMV-luciferase response, 
considerably outperforming the more common transfection reagents by 2-5 fold 
respectively (Figure 3.4 (A)). Although luciferase assays provide a high throughput method 
for determining transfection efficiency, they cannot distinguish between an increased 
number of transfected cells or dramatic luciferase overexpression in fewer cells. Therefore 
the two best transfection reagents (PEI and JetPrime) and FuGENE HD, used as a 
benchmark as it was previously optimised within the Sée lab, were further assessed for 
exogenous protein expression by confocal fluorescence microscopy (Figure 3.4 (B)).  
 
GFP-HIF-2α-DM expression was used because of the highly distinct, nuclear only, fine 
punctate localisation of the HIF-2α protein (Hara et al., 1999 & Taylor et al., 2016). Strong 
overexpression of GFP-HIF-2α-DM has been shown to lead to aggregation and cytoplasmic 
expression; thereby allowing an assessment of aberrant expression. The 20X magnification 
images (Figure 3.4 (B)) clearly confirm the better transfection efficiency of PEI and JetPrime 
compared to FuGENE HD, measured by the number of fluorescent cells. Brightfield images 
of the same region shows considerably more cell death (rounded cells) with JetPrime and 
FuGENE HD transfections compared to PEI transfection. At 63X magnification, which 
permits visualisation of nuclear localisation, it is apparent that JetPrime causes significant 
cellular stress with membrane blebbing and cytoplasmic expression of GFP-HIF-2α-DM. 
Conversely, FuGENE HD and PEI transfections have the expected specific nuclear punctate 
localisation (Hara et al., 1999 & Taylor et al., 2016). Thus, PEI was selected as the 
transfection reagent for optimising tagged-HIFα IPs, at a 4 µL:1 µg transfection 
reagent:DNA ratio per 200,000 cells in a 35 mm dish (8.8 cm2). 
 
3.4.2.  Tag selection 
Exogenous expression of an IP tagged- fusion protein can have many advantages over 
target-antibody based IP approaches, including the circumnavigation of problems 
associated with the use of polyclonal and monoclonal antibodies discussed previously 
(section 3.3.1). A multitude of tags have been developed for IP, each with intrinsic 
advantages such as enhancing solubility or fluorescence for ease of visualisation (reviewed 
by Terpe, 2003). Within the Sée lab, there has been some success in using the HaloTag and 
GFP-Traps technology for purification of non-HIFα proteins. N-terminal tagged HaloTag-HIF-
2α and GFP-HIFα-DM constructs (N-terminal and C-terminal tagged), were readily available 
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in the Sée lab and were therefore used as initial starting points for optimisation. IP kits 
against these tags are commercially available, HaloLink resin (Promega) and GFP-Traps 
(CHROMOTEK), and have been successfully used by many groups for IP and MS analysis 
(Daniels et al., 2014, Ohana et al., 2011, Trinkle-Mulcahy et al., 2008, Lipinszki et al., 2014 & 
Smits et al., 2013). 
 
3.4.3.  HaloTag IP optimisation 
A problem associated with all antibody-based IP protocols is that the IP efficiency reaches a 
saturation equilibration, thus resulting in efficiencies of 60-90%. This is dependent on 
factors such as antibody strength/dissociation constant (Kd) and steric hindrance of 
neighbouring antibodies by target protein binding (Encell et al., 2012). This effect can be 
overcome by using an excess of antibody and capturing beads, but simultaneously results in 
the increased risk of contaminant binding partner identification. Thus, for low expression 
level proteins, such as transcription factors, large numbers of cells may be required. 
HaloTag was developed to bypass this equilibrium effect by covalent capture of 
HaloTagged- fusion proteins (Los et al., 2008). HaloTag is a haloalkane dehalogenase 
protein that contains a mutated aspartate catalytic triad. This allows the activation and 
nucleophilic attack of haloalkanes to form a covalently bound intermediate but lacks the 
ability to hydrolyse the bond to release free enzyme (shown schematically in Figure 3.5). 
Thus HaloLink resin, coated with haloalkanes, covalently captures HaloTag- fusion proteins. 
For elution, a highly specific protease sequence can be incorporated into a linker sequence 
between the HaloTag and protein of interest to recover the protein and binding partners, 
away from the HaloTag and non-specific contaminants (Los et al., 2008, Encell et al., 2012 & 
Daniels et al., 2014). 
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Figure 3.5: Schematic view of the catalytic mechanism of the Haloalkane dehalogenase protein versus the 
HaloTag technology. 
Critical residues required for function are shown with hydrogen bonding (dotted lines) and movement of 
electrons (arrows). Red is the haloalkane molecule that is coupled to R, for example beads. A) Endogenous 
haloalkane dehalogenase, Asp106 acts as a nucleophile to attack haloalkanes to form the covalently bonded 
alkane-enzyme intermediate. Glu130 promotes the general base nature of His272 resulting in the hydrolysis of 
the alkane-enzyme bond, releasing free enzyme. B) HaloTag technology, mutation of His272 to Phe results in 
the inability to hydrolyse the covalently bound intermediate; thus covalently trapping HaloTag (Taken from 
Encell et al., 2012). Asp = aspartic acid, His = histidine, Glu = glutamic acid, Trp = tryptophan, Phe = 
phenylalanine 
 
Initially we needed to determine whether the exogenous expression of HaloTag-HIF-2α 
maintained the physiological properties of HIF, such as nuclear localisation. A benefit of the 
HaloTag is the ability for specific labelling and direct visualisation, using a cell permeable 
fluorescent dye (Los et al., 2008), such as HaloTag- Oregon Green (Promega). HaloTag-HIF-
2α was transfected into HeLa cells and visualised by fluorescent confocal microscopy 
(Figure 3.6). Inclusion of an untransfected control highlights that the labelling was specific 
to HaloTag expressing cells. At 10X magnification a poor transfection efficiency was 
observed at ~20% (Figure 3.6), however this could be artificially under-represented due to a 
potentially inefficient labelling step. Importantly, at 100X magnification nuclear localisation 
is punctate, as expected (Figure 3.6). Thus, IP optimisation was conducted. 
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Figure 3.6: Transfection efficiency and nuclear localisation of HaloTag-HIF-2α. 
Untransfected or HaloTag-HIF-2α transfected HeLa cells, using the PEI protocol as described and imaged 
following HaloTag- Oregon Green labelling, following the manufacturer’s protocol. Single images were acquired 
using brightfield and at 488 nm fluorescence excitation at 10X and 100X magnification with a Zeiss LSM 780 
microscope. 
 
To obtain enough HaloTag-HIFα protein for LC-MS/MS analysis it was essential to ensure 
that transfection efficiency scaled proportionally with plate size. Due to the covalent nature 
of the HaloTag, either fluorescent labelling or IP can be performed per experiment. Hence, 
cells were grown in small dishes (as optimised) or large 10 cm dishes and transfected, 
scaling for plate surface area (~6 fold). Cells from both plate sizes were lysed, as for IP, and 
an aliquot of lysate was fluorescently labelled in vitro. Subsequent SDS-PAGE and 
fluorescent gel scanning allowed me to assess the protein expression levels of HaloTag-HIF-
2α in comparison to a standard that was fluorescently labelled in live cells (Figure 3.7). 
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Figure 3.7: Transfection efficiency & scalability of HaloTag-HIF-2α exogenous expression. 
A composite image of HaloTag- Oregon Green labelled untransfected or HaloTag-HIF-2α expressing HeLa cell 
lysates, grown as stated. Labelling was performed as indicated and lysis performed following manufacturer’s IP 
protocol. Labelled lysates were analysed by SDS-PAGE and fluorescently imaged on an ImageQuant LAS4000 
system, using the Cy2 filter, and then stained colloidal coomassie. 
 
Similar to in culture labelling, in vitro labelling is specific to HaloTag expressing cells (Figure 
3.7). Comparing identical plate sizes of the in culture labelled standard to the in vitro 
labelled lysate shows an ~1.5 fold increase in fluorescent intensity, thus ~50% transfection 
efficiency (determined by densitometry, data not shown). This apparent increase is likely 
the result of a more efficient labelling technique in vitro than in culture, confirming the 
potential under-estimation of transfection efficiency when live cell imaging, as discussed 
earlier. Similar band intensities were observed between small (35 mm) and large (10 cm) 
cell culture plates, showing that the transfection efficiency was unaffected by plate size. 
Therefore, large plates were prepared for initial IP optimisations. Protocols selected as an 
initial basis included the manufacturer’s recommended protocol and two published 
protocols from Ohana et al., 2011 and Daniels et al., 2014. These protocols are referred to 
as Method 1, Method 2 and Method 3 respectively from now on. 
 
All methods evaluated used the manufacturer recommended lysis buffer, short bead 
binding times and TEV based elution. However, physical perturbations to aid cell lysis 
differed: method 1 uses a 25-gauge needle, method 2 uses sonication and method 3 uses -
80 oC freeze-thaw cycles. All cell lysis methods are followed by centrifugation to remove 
cellular debris. Post lysis, all samples were analysed through In vitro lysate labelling and 
SDS-PAGE analysis. A lack of a fluorescent band was observed for each tested method, 
suggesting a failure in transfection. However, an identically prepared plate labelled in 
culture and analysed by fluorescence confocal microscopy showed adequate levels of 
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transfection (data not shown). Combined, these data suggest a potential loss of the 
HaloTag-HIF-2α protein during lysate preparation, which was not observed previously. 
Differences between the previously used in vitro labelling protocol and the IP protocol is 
the inclusion of a centrifugation step to remove insoluble cellular debris in the latter. Thus, 
to check the effects of centrifugation, lysate and pellets were analysed by western blot 
(Figure 3.8). 
 
Figure 3.8: Analysis of HaloTag-HIF-2α solubility when lysed under different conditions. 
Western blot analysis of untransfected and HaloTag-HIF-2α transfected HeLa cells, probed with an anti-HIF-2α 
primary antibody. Each method uses a lysis buffer of: 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM DTT, 0.5 mM 
EDTA and 0.005% NP-40. Method 1: manufacturer recommended, lysis by passing through a 25-gauge needle. 
Method 2: Ohana et al., 2011, lysis by sonication, maximum power for 10 s on 10 s off for 2 min. Method 3: 
Daniels et al., 2014, lysis by a 1 hr -80 oC Freeze-Thaw cycle. Post lysis, lysates were centrifuged 10 min at 
13,000 g and cleared supernatant collected. Cellular debris pellets were resuspended in Laemmli’s buffer. 
Method 1 was used for the untransfected and uncleared lysates, but without the centrifugation step for the 
latter. 
 
Using an anti-HIF2α antibody provides the advantage of simultaneous investigation of the 
endogenous and exogenously expressed HIF-2α proteins. An untransfected control shows 
that lysis is efficient and the endogenous HIF-2α protein is soluble, with a single band of 
~120 kDa in the cleared lysate lane only (Figure 3.8). For the transfected samples, the 
uncleared lysate shows a doublet band pattern equating to endogenous HIF-2α and the 
HaloTag-HIF-2α protein, at ~150 kDa. All three tested lysis methods result in the removal of 
the HaloTag-HIF-2α protein, shown by a single 150 kDa band in the resuspended cellular 
debris lanes only. The solubility of endogenous HIF-2α protein was unaffected by the 
exogenous expression of HaloTag-HIF-2α protein, yet the HaloTag-HIF-2α protein was 
clearly lost from the lysate fraction post centrifugation. Without centrifugal clearing, or the 
ability to pre-clear samples, the ratio of non-specific interactors will inevitably increase 
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dramatically, which may mask the signal of true binding partners. Thus, HaloTag based IP 
was abandoned and GFP tagged IP approaches were explored. 
 
3.4.4.  GFP-Trap IP optimisation 
GFP-Traps (CHROMOTEK) are commercially available, pre-conjugated antibody-beads 
designed for the IP of GFP-tagged proteins. Unlike traditional antibody IP approaches, GFP-
Traps utilise the development of nanobodies, which are comparable to a single heavy chain 
of antibodies but retain epitope recognition. Due to their more simplistic nature, 
nanobodies can be created with much greater affinities; usually with dissociation constants 
(Kd) in the pM range (reviewed by Muyldermans, 2013). GFP-Traps are claimed to have a Kd 
of <1 pM and are available conjugated to different matrices; agarose coupled are used 
throughout these studies. 
 
GFP-HIF-2α-DM was previously used during transfection optimisation (Figure 3.4 (B)), as 
such localisation studies were not repeated. Previous data from the Sée lab, and 
manufacturer’s statements, suggests orientation of the GFP-tag in relation to the protein of 
interest can be essential for successful IP. Thus, both GFP-HIFα-DM and HIFα-DM-GFP were 
tested for IP efficiency (Figure 3.9 (A)). By comparing elution efficiency it was clear that N-
terminally tagged GFP-HIFα-DM constructs are required for IP; with ~90% efficiency 
compared to an undetectable band for C-terminal HIFα-DM-GFP constructs (Figure 3.9 (A)). 
C-terminal HIFα-DM-GFP constructs appear to bind GFP-Traps, because of the lack of a 
band in unbound lanes, but lack an elution band. This result is unlikely to be due to failure 
to elute, because of the use of 5X Laemmli’s buffer (10% (w/v) SDS). Alternatively, a more 
likely scenario is that weak binding interactions between GFP traps and C-terminal HIFα-






Figure 3.9: The development of a mass spectrometry compatible GFP-Trap IP protocol. 
HeLa cells were grown in 21% O2 and transfected with the indicated plasmid. Cells were lysed 24 hr post 
transfection in 50 mM Tris pH 8.0, 120 mM NaCl, 1 mM EDTA, 0.5% NP-40 supplemented with EDTA free 
cOmplete protease inhibitors (Roche) and phosSTOP (Roche). Lysate was diluted to 0.2% NP-40 in an identical 
lysis buffer lacking NP-40. IP was performed according to the manufacturer’s protocol. Western blots were 
performed with a primary anti-GFP antibody. A) Efficiency of IP using N-terminal and C-terminal GFP tagged 
HIFα-DM constructs, elution with 5X Laemmli’s buffer. B) Development of a GFP-Trap IP protocol compatible 
with high throughput mass spectrometry analysis. Changes include a preclearing step with bab-20 beads, HPLC 
grade buffers, addition of 2 X 25 mM Ambic washes, and elution with 1% RapiGest SF in 25 mM Ambic pH 8.0. A 
secondary elution in 5X Laemmli’s was performed subsequently.  
 
N-terminal GFP-HIFα-DM was efficiently immunoprecipitated for both HIFα proteins, 
therefore further optimisations focused on modifications to create a MS compatible 
protocol and limit non-specific binding partners (Figure 3.9 (B)). To this end, all buffers were 
made with HPLC grade components, a preclearing step and elution in a MS-compatible 
buffer were all employed. bab-20 beads (CHROMOTEK) have an identical composition of 
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matrix compared to the GFP-Traps, but lack the nanobody conjugation. Thus, incubation of 
bab-20 beads with cleared lysate, prior to IP, can remove non-specific binding partners 
resulting from matrix association (pre-clear). RapiGest SF (Waters) is an acid labile, mild 
detergent that can be degraded into an insoluble product (and a volatile soluble 
component) for removal by centrifugation (Yu et al., 2003). Thus, RapiGest SF elution allows 
the recovery of proteins and HTP MS analysis without the need for sample clean-up steps. 
 
Western blot analysis of the modified protocol (Figure 3.9 (B)) shows that pre-clearing does 
not affect the levels of available GFP-HIFα-DM protein, shown by near identical band 
intensities of lysates pre- and post- preclearing lanes. Importantly, RapiGest SF elution is 
highly efficient, resulting in ~80% IP efficiency of both GFP-HIF-1α-DM and GFP-HIF-2α-DM 
proteins (Figure 3.9 (B)). Although a prominent band exists with the secondary elution, it is 
crucial to note that 100% of this elution was loaded for analysis, 10 fold greater than the 
RapiGest SF elution. Hence, the secondary elution is artificially abundant for direct 
comparisons. Once the IP protocol was developed, WildType (WT) GFP-HIFα constructs 
were required for biological relevance of IP experiments. Previous WT HIFα plasmids 
obtained by the Sée lab were found to have multiple point mutations that result in amino 
acid substitutions, therefore new WT HIFα constructs were obtained and cloned to contain 
the GFP tag. 
 
3.5. WildType HA-Clover-HIFα Cloning: 
A WT HA-HIF-1α plasmid was obtained (a gift from the Prof Rocha lab) and a GFP isoform 
(Clover) was cloned into the plasmid for GFP-Trap IP, and allow further downstream 
microscopy analysis. Although a HA-tag is present in this construct there is no guarantee 
that the previously optimised HA IP protocol within the Eyers lab would be successful. 
Clover is a GFP isoform with greater dynamic range and photostability, thus is preferable 
for advanced microscopy techniques (Lam et al., 2012). GFP-Traps are stated to be as 
efficient for IP when using Clover. To evaluate this, a Clover- only plasmid was 
immunoprecipitated prior to cloning. Western blot analysis showed an efficiency of ~80% 
for Clover IP (data not shown). Thus, insertion of the clover gene into the HA-HIF-1α 
plasmid was conducted (HA-Clover-HIF-1α), and subsequent cloning of HA-Clover-HIF-2α 
and HA-Clover only plasmids performed, using the In-Fusion cloning (TakaraBio) 




Figure 3.10: Schematic view of the In-Fusion cloning strategy used for the creation of HA-Clover-HIFα and HA-
Clover plasmids. 
Green = Clover sequence, Grey = HIFα sequences, yellow/pale green = regulatory domains of plasmid. 
Restriction enzyme sites (B=BamHI, E=EcoRV) and primer designs for each plasmid are included A) HA-Clover-
HIF-1α from HA-HIF-1α. B) HA-Clover from HA-HIF-1α. C) HA-Clover-HIF-2α from HA-Clover. Plasmid maps 




Initially it was presumed that the HA-tag would have minimal effect on IP efficiency of HA-
Clover-HIFα, due to its short length of 9 amino acids. Therefore, once cloned, HA-Clover-
HIF-1α was tested for IP efficiency with GFP-Traps; confirming this assumption with an 
efficiency of ~85% (Figure 3.11). Thus, cloning of HA-Clover and HA-Clover-HIF-2α was 
performed (Figure 3.10 (B) and (C) respectively). The HA-Clover only construct was used as 
a negative control to allow contaminant binding partner identification and background 
subtraction of non-specific binding partners associated with the HA-Clover tag. 
 
Figure 3.11: Determination of the suitability of the HA-Clover tag for IP. 
Western blot analysis of HeLa cells transfected with the indicated plasmid 24 hr prior to 4 hr incubation at 1% 
O2. The mass spectrometry compatible GFP-Trap IP protocol was followed and probed with an anti-GFP primary 
antibody. 
 
All plasmids were validated by DNA sequencing using GATC Biotech, sequencing primers 
listed in Table 2.5. As before for HA-Clover-HIF-1α, HA-Clover-HIF-2α was 
immunoprecipitated and western blotting performed to ensure successful IP with the HA-
Clover tagged construct (Figure 3.11). This shows a similar IP efficiency of ~85% is obtained. 
To obtain more biologically relevant data, I undertook final optimisation steps to test the 
feasibility of low level exogenous expression systems for in-depth PTM analysis. 
 
 
3.6. Final optimisations: 
3.6.1.  Exogenous expression levels 
The newly cloned HA-Clover-HIFα plasmids are under the control of different regulatory 
elements (in the plasmid backbone) compared to the previously used, and optimised, GFP-
HIFα-DM plasmids. Thus, identical transfection conditions may result in different expression 
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levels. In order to optimise the exogenous expression levels of HIFα, maintaining 
physiological O2 dependent protein stability and transcriptional activity, a reporter assay 
using a luciferase plasmid under the control of the Hypoxia Responsive Element (HRE) was 
used (HRE-Luciferase). Hence, luciferase signal is representative of the level of active HIF 
transcription. The optimised PEI transfection protocol was used and the amount of HA-
Clover-HIF-1α was sequentially altered (Figure 3.12). HA-Clover-HIF-1α exogenous 
expression was selected for optimisations due to the endogenous protein being completely 
O2 dependently degraded, thus aberrant exogenous expression at 21% O2 is easy to 
identify. To maintain the overall quantity of DNA in transfection mixes, the addition of a 







































































































































































































































































































































The optimised expression levels of GFP-HIF-1α-DM result in <2 fold greater transcriptional 
activity compared to endogenous HIF-1α (Figure 3.12). An O2 dependent induction of 
transcription of fully stable HIF-1α is unsurprising considering the second O2 dependent 
regulatory mechanism involving FIH-1 (Lando et al., 2002), see introduction (1.6). A 
dramatic increase in transcriptional output was observed (~35 fold) for identical 
transfection conditions using the HA-Clover-HIF-1α plasmid. By using decreased amounts of 
the HA-Clover-HIF-1α plasmid (as low as 10 ng (0.01 μg)) an O2 dependent transcriptional 
activity could be observed, at a reasonable level compared to endogenous conditions. To 
highlight the transcriptional output of the cloned HA-Clover-HIF-1α, at 10 ng of plasmid 
there was an observable ~2 fold increase in HRE-luciferase signal compared to the 
optimised (0.5 µg (50 X more DNA)) GFP-HIF-1α-DM conditions. 
 
There are two possible explanations for these observations: 1) induction of expression from 
the HA-Clover-HIF-1α plasmid is orders of magnitudes higher than the GFP-HIF-1α-DM 
plasmid, therefore although HA-Clover-HIF-1α is O2 dependently degraded, the quantity of 
HA-Clover-HIF-1α protein outweighs the system flux, and thus accumulates in normoxia. 2) 
The GFP-HIF-1α-DM protein is highly inefficient at initiating transciption. Possible 
explanations for the latter include: a short linker sequence resulting in steric hindrance with 
the GFP-tag, or the known point mutations result in amino acid substitutions that effect 
HIF-1α transactivation, although being fully stable. Sequencing the full length HIF-1α gene, 
from the GFP-HIF-1α-DM plasmid, identified six amino acid substitution mutations, besides 
the known proline hydroxylation sites: 13N insertion, K14R, V87M, D544G, K548R and 
T627I. Although removing the prospect of direct comparisons between constructs, the 
identification of these mutations may be helpful in the future when identifying PTMs to 
characterise. 
 
Considering in-depth discovery PTM analysis requires a large quantity of protein, we 
decided to benchmark a low expression level (fully O2 dependently degraded) against a high 
expression level (maximal expression without observable effects on nuclear localisation, 
cell stress and cell viability) to determine the scale required for MS analysis, and feasibility 
of using a low expression model. Therefore, similar to Figure 3.12, sequentially decreasing 
levels of HA-Clover-HIF-1α plasmid was transfected into cells and investigated using 








Complementary to luciferase data, transfection of 1 µg HA-Clover-HIF-1α resulted in vast 
protein expression at 21% O2. Additionally microscopy analysis identified that 1 µg of HA-
Clover-HIF-1α resulted in significant cell death rates of  ~70% (Figure 3.13 (A)). This result 
was mimicked with the HA-Clover only plasmid, however no significant cell death was 
observed with the empty vector control. Therefore, combined, these data suggest that the 
HA-Clover tagged plasmids are causing lethality, likely due to their high expression levels. 
To reduce expression levels, we tried lowering the length of timings that transfection mixes 
were incubated with cells and/or reducing the quantity of HA-Clover-HIF-1α plasmid DNA in 
the transfection mix (Figure 3.13 (A)). 
 
Reduction of the transfection time to 6 hr resulted in poor transfection efficiencies (<10%) 
at any DNA quantity, however maintained a high cell death rate in fluorescent cells (Figure 
3.13 (A)). Reduction of HA-Clover-HIF-1α plasmid maintained high transfection efficiences 
whilst reducing the rate of cell death. At 0.5 μg HA-Clover-HIF-1α (per 200,000 cells in a 35 
mm plate), cell death rates were comparable to the empty vector controls (<10%) and 
maintained nuclear only expression. Thus 0.5 µg equivalents for transfection were selected 
as the high expression level (Figure 3.13 (A)). 
 
To create the low expression level system, which is fully O2 dependently degraded, clover 
fluorescence was to be visualised in an O2 dependent manner. Thus, fluorescence imaging 
was performed pre- and post- 1% O2 incubation. Thus, an absence of fluorescence at 21% 
O2 could be explained by a failure to transfect, or an expression level too low for detection. 
Therefore, a different wavelength fluorescent protein encoding plasmid (pcDNA3-mRUBY2) 
was included as an internal transfection control, in order to monitor transfection efficiency 
(Figure 3.13 (B)).  
 
A time point of 8 hr of 1% O2 incubation was used for microscopy analysis, as this is when 
maximal endogenous HIF-1α protein accumulation occurs (Bagnall et al., 2014). At 50 ng 
(0.05 μg) DNA (per 200,000 cells in a 35 mm plate) clover fluroescence was found to be O2 
sensitive, and maintaining a transfection efficiency of ~50% (Figure 3.13 (B)). Greater or 
reduced DNA concentrations resulted in either abnormal expression at 21% O2 or 
undetectable expression levels respectively (Figure 3.13 (B)). Thus 50 ng equivalents were 




To validate microscopy data, the same transfection condtions were analysed by western 
blotting (Figure 3.13 (C)). Probing with anti-HIF-1α shows that the HA-Clover-HIF-1α protein 
(~150 kDa) at the low expression level had an identical banding pattern to endogenous HIF-
1α protein (~120 kDa); having complete O2 dependent degradation (Figure 3.13 (C)). 
Supporting microscopy data, the high expression level of HA-Clover-HIF-1α was not O2 
sensitive, shown by equally intense bands at both O2 tensions (Figure 3.13 (C)). 
Comparisons between low and high expression models finds an ~20 fold increase in 
exogenous expression in the latter (determined by densitometry analysis, data not shown). 
 
Interestingly, the large overexpression of HA-Clover-HIF-1α does not result in the 
dysregulation of the O2 dependent degradation pathways for endogenous HIF-1α, which 
maintained 21% O2 degradation (Figure 3.13 (C)). It could be argued that the large 
overexpression of HA-Clover-HIF-1α in 21% O2 may be the result of overloading the 
endogenous system flux, thus maintaining endogenous HIF-1α regulation is surprising.  
 
3.6.2. Mass spectrometry optimisations 
As mentioned, discovery proteomics requires a considerable quantity of protein to be 
purified for analysis. Therefore, with the development of high expression and low 
expression models, we decided to benchmark both expression levels for LC-MS/MS 
analysis, post Titanium Dioxide (TiO2) phospho-peptide enrichment (TitanSphere, GL 
Sciences). This will aid in the determination of whether scaling the low expression (more 
biologically relevent) model is feasible (Figure 3.14). Figure 3.14 (A) shows western blot 
analysis of 600 μg lysate (1x 10 cm plate) IPs from both the high and low expression levels. 
For IP, lysate requires a 2.5 fold dilution; likely explaining the lack of a band for endogenous 
HIF-1α or HA-Clover-HIF-1α in the low expression model whole cell lysate. Importantly, 
Figure 3.14 (C) shows that the high expression level model obtains ~20 fold more HA-
Clover-HIF-1α protein post IP than compared to the low expression model (in agreement 
with Figure 3.13 (C)). Hence, 20 X 10 cm plates would be required for similar levels of HA-






Figure 3.14: IP model comparison and assessment of the variability introduced by SCX based removal of PEG.  
A) Western blot analysis of 600 μg IPs of high and low HA-Clover-HIF-1α expression models in HeLa cells 
incubated with 4 hr 1% O2. B) BPC’s of trypsin digested IPs pre- (white) and post-SCX (grey). C) Enlarged boxed 
region of pre-SCX BPC of (B), highlighting the +44 Da repeating unit (red arrows). D) Venn diagram of proteins 
identified at 1% FDR confidence from identical injections pre-SCX at time point 0 (1), 24 hr later (2) and post 
SCX. Includes the number of proteins and equivalent percentage for each overlap. 
 
Trypsin digested IPs were split 5% for LC-MS/MS analysis (to analyse sequence coverage 
and binding partners, Figure 3.14 (B)) and 95% for TiO2 enrichment (for phospho-peptide 
identification and site localisation), following the HCD Orbitrap only method from Ferries et 
al., 2017. Digest injections found a repeating unit contamination of +44 Da at ~5% relative 
intensity, likely to be Polyethylene Glycol (PEG) (Figure 3.14 (B) and Figure 3.14 (C)). TiO2 






to much greater levels than any phospho-peptides (data not shown). A ‘mock’ control IP, 
using identical buffers without cellular lysate, lacked this PEG contamination (data not 
shown). Thus, the likely source of contamination is during lysate preparatory stages in cell 
culture plates. 
 
With the requirement of using a hypoxic chamber to generate hypoxic samples, there is not 
an easy and reliable method to incorporate a trypsinisation protocol during cellular lysis. 
Therefore, a strategy to remove PEG post IP and digestion was adopted, using a Strong 
Cation Exchange (SCX) stage-tip protocol. LC-MS/MS analysis of digests post SCX shows the 
PEG contaminant was successfully removed, however the Base Peak Chromatogram (BPC) 
was simultaneously affected (Figure 3.14 (B)). It is likely that SCX may cause the loss of 
peptides in a stoichiometric fashion. However, SCX incorporation results in the addition of 
24 hr of sample preparation time prior to LC-MS/MS analysis, hence BPC variations could be 
the result of analytical variance. To investigate the variability induced by SCX, a large IP was 
performed and split equally for analysis in a pre-SCX state, at the time points of 0 hr and 24 
hr, whilst SCX was performed and analysed alongside the 24 hr time point. 
 
Data was analysed through a Proteome Discoverer coupled MASCOT pipeline and filtered to 
a 1% False Discovery rate (FDR), matching protein identifications were determined using 
the BioVenn tool (Hulsen et al., 2008) (Figure 3.14 (D)). Figure 3.14 (D) found that the 2 pre-
SCX samples had ~65% of all identified proteins matched, hence a baseline of ~35% 
variability. The majority of this variance is accounted for by substantially more protein 
identifications at the initial 0 hr time point analysis, likely reflecting peptide instability and 
precipitation over time. Figure 3.14 (D) also shows that post-SCX identifications matched 
~80% of the identified proteins that were identified in the 24 hr pre-SCX time point control. 
Additionally, ~70% of all proteins identified in both pre-SCX time points were also identified 
post-SCX, thus SCX inclusion does not appear to introduce any further variation into LC-
MS/MS based protein identification Figure 3.14 (D). 
 
IPs (600 μg) of high and low expression level lysates were repeated, with the incorporation 
of the SCX PEG removal and TiO2 enrichment protocols. BPC’s of TiO2 enriched IPs show 
very small peaks in the high expression level samples only (Figure 3.15 (A)). This intensity is 
far below the fragmentation intensity threshold required for discovery analysis, hence no 
peptide identifications were obtained. Considering that a ~20 fold increase in HA-Clover-
HIF-1α is obtained by high expression level IP (Figure 3.14 (A)), the low expression model 
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would be insufficient for discovery PTM analysis without very large experiments, therefore 





Figure 3.15: TiO2 enrichment phospho-peptide detection and scaling. 
A) BPC’s of HA-Clover-HIF-1α IPs post TiO2 enrichment. IPs of model and quantity of protein as stated from HeLa 
cells incubated with 4 hr 1% O2. B) Table of identified HIF-1α peptides at a 1% FDR confidence. Data from 6 mg 
High expression model IP. Analysis through Proteome Discoverer 1.4 using the MASCOT search engine. Fixed 
modifications = Carbamidomethlation of Cysteine. Variable modifications = phosphorylation of Serine, 
Threonine or Tyrosine and oxidation of methionine. Table includes peptide sequence (lower case letter 




A 10 fold increase of initial high expression lysate (10 X 10 cm plates, 6 mg lysate) was 
tested for phospho-peptide detection post TiO2 enrichment. The BPC showed numerous 
intense peaks (Figure 3.15 (A)). Using the described Proteome Discoverer data analysis 
pipeline, with variable modifications of phospho- Serine, Threonine and Tyrosine, 17 
peptides were confidently identified at a 1% FDR, 13 of which were phosphorylated (Figure 
3.15 (B)).  
 
3.6.3.  Bead ratio and elution optimisations 
Currently, the manufacturer recommend bead:lysate ratio was used (25 μl bead slurry:1 X 
10 cm plate (600 μg lysate)). However, because a 10 fold increase to the recommended 
amount of lysate was required for LC-MS/MS analysis, this would result in a large quantity 
of GFP-Traps used per experiment. Besides the associated cost, an excess of GFP-Traps 
provides an increased opportunity for ‘noise’ proteins to bind the bead resin. Therefore, 
identical lysate was split for multiple IPs using varying densities of GFP-Traps (Figure 3.16 
(A)). It has to be noted that the band intensity in the unbound lane is ~2 fold greater when 
using 10 fold less GFP-Traps (2.5 μl / 600 μg lysate). However, RapiGest SF elution resulted 
in equal quantities of HA-Clover-HIF-2α obtained. Therefore this bead:lysate ratio was 




Figure 3.16: Bead density and non-canonical phosphorylation compatibility optimisations. 
High expression model HA-Clover-HIFα (as stated) HeLa cell lysate (600 µg) incubated at 1% O2 for 4 hr prior to 
IP. A) GFP-Trap bead density optimisation, stated fold change of GFP-Traps (and buffer volumes) used to 
manufacturer’s recommendation, probed with a primary anti-HIF-2α antibody. B) Non-canonical 
phosphorylation compatibility, identical IPs eluted as stated, probed with a primary anti-HIF-1α antibody. Boxed 
regions are to highlight that a lane from a single gel has been moved post-processing. 
 
 
Within the Eyers lab there is particular interest in non-canonical phosphorylation. Histidine, 
Lysine, Arginine, Aspartic acid, Glutamic acid and Cyesteine can all be phosphorylated, as 
well as the traditional Serine, Threonine and Tyrosine residues (Besant et al., 2009, 
Attwood et al., 2011 & Hardman et al., 2017). However, non-canonical phosphorylation is 
heat and acid labile, therefore nor the GFP-Trap IP protocol, SCX clean-up, TiO2 phospho-
peptide enrichment or traditional mass spectrometry methodolgy is applicable for such 
investigations. A non-canonical phosphorylation pipeline has been developed in the Eyers 
lab, using HeLa cells and 8 M urea (Hardman et al., 2017). Therefore, identical IPs were 
performed and eluted by RapiGest SF (optimised here) or an equal volume of 8 M urea, in 
order to determine the feasibility of adopting the non-canonical phosphorylation pipeline 
(Figure 3.16 (B)). Western blot analysis found that the urea elution resulted in the lack of a 
band, whereas a secondary elution in 5X Laemmli’s buffer resulted in a very significant band 
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(Figure 3.16 (B)). Combined, this suggests that 8 M urea is not a strong enough elution 
condition to dissociate HA-Clover-HIF-1α from GFP-Traps. Thus, the non-canonical 




At the time of writing, this chapter describes the first protocol able to IP full length HIF-1α 
and HIF-2α from mammalian cell lines with sufficient abundance for in-depth discovery 
PTM analysis. Initially, target antibody-based IPs were investigated for the analysis of 
endogenous HIFα protein regulation. Although several antibodies were tested for 
sensitivity, selectivity and IP ability, they all failed the requirements. Combined with the 
apparent level of expression required for discovery PTM analysis, exogenous 
overexpression of IP-tag based HIFα was investigated. The HaloTag tag was found to make 
the HIF-2α protein insoluble, whereas GFP tagging was successfully used for IP with ~85% 
efficiency. The use of HA-Clover-HIFα proteins not only provides a means of IP but also 
allows for live-cell microscopy techniques, hence having the advantage of not requiring 
immunostaining protocols for visualisation. 
 
Although a large exogenous overexpression is required for the initial identification of PTMs, 
future experiments could adopt a Selective Reaction Monitoring (SRM) MS approach to 
specifically search for m/z ratios of interest. SRM can provide in excess of 100 fold increases 
to sensitivity, feasibly allowing endogenous protein investigations, however requires pre-
knowledge of known modified peptides and respective m/z ratios for selective MS filtering 
and fragmentation (reviewed by Lange et al., 2008). Therefore, this approach is not possible 
currently. Thus, future experiments could use SRM to validate PTMs identified here using 
the low expression model or endogenous HIFα proteins in the future. 
 
An interesting observation is that the large exogenous overexpression of WT HA-Clover-HIF-
1α (>20 fold greater than endogenous HIF-1α) resulted in the exogenous protein expression 
at 21% O2 without affecting endogenous HIF-1α O2 dependent stability, which maintained 
complete O2 dependent degradation. Several possibilities could explain this, including: 1) 
The HA-Clover tag interferes with the PHD-VHL targeting for degradation, possibly by steric 
hindrance and blocking modifying proteins from binding as efficiently. 2) A different, and 
prominent, unknown degradation pathway exists for HIF-1α, which is disrupted by N-
terminal tagging. A potential example could be the N-end rule; endogenous HIF-1α protein 
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has a glutamic acid residue at its secondary position, known to be destabilising in mammals, 
while HA-Clover-HIF-1α protein has an alanine residue, known to be stabilising in mammals 
(Varshavsky, 2011 & Tasaki et al., 2007). Therefore, the O2 dependent stability observed for 
endogenous HIF-1α, although there is a large excess of HA-Clover-HIF-1α that accumulates 
in 21 O2, may not be due to the PHD-VHL pathway but rather the result of the N-end rule 
pathway, which is more efficient in degrading the endogenous protein. 
 
Another interesting observation is the comparison of WT HA-Clover-HIF-1α transcriptional 
output versus GFP-HIF-1α-DM, with 50 fold less DNA of HA-Clover-HIF-1α resulting in a 
greater HIF dependent luciferase signal than GFP-HIF-1α-DM. We never investigated 
protein expression levels, thus the WT HA-Clover-HIF-1α protein expression level could be 
several fold higher than GFP-HIF-1α-DM, although maintains the ability for O2 dependent 
degradation at low expression levels. Further investigations should determine the protein 
expression level differences between plasmids, western blotting of samples will provide an 
answer to this. However, assuming similar protein expression levels, then the difference in 
transcriptional activity is due to a biochemical reason. The identification of 6 separate 
mutations within the GFP-HIF-1α-DM protein is of potential interest as these may block the 
efficient transactivation of the exogenous protein. These identified mutations may guide 
functional characterisation studies, if PTMs are identified in close proximity. 
 
We attempted to adopt a non-canonical phospho-proteomics pipeline to investigate the 
complete phosphorylation status of HIF-1α and HIF-2α, however the GFP-Traps technology 
bound the HA-Clover tag too strongly to elute in current compatible methods. Future 
studies could use different strategies to investigate non-canonical phosphorylation, such as: 
anti-GFP antibody-based IPs, which are weaker than GFP-Traps and therefore may elute in 
8 M urea. Or eluting in a detergent based buffer and performing a buffer exchange into MS 
compatible buffers for digestion. 
 
We have been able to show that TiO2 based phospho-peptide is possible for in-depth LC-
MS/MS analysis, however this does not reflect the full PTM status of HIFα proteins; with 
many other PTMs known to regulate HIF-1α and HIF-2α (see introduction section 1.7). 
Additionally, TiO2 enrichment is known to be inefficient for tyrosine phosphorylation 
identification (Lombardi et al., 2015). Therefore, future studies could look to adopt the 
protocol described here for IP followed by secondary IP enrichment using antibodies 
against specific PTMs, for example anti- lysine acetylation antibodies. 
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4. Chapter 4: HIFα PTMs 




4.1. Introduction  
As discussed in the introduction, cell signalling strategies have been vital in the 
development and wide evolutionary variation of multi-cellular organisms. However, for a 
cell to elicit a response, a ligand needs to transduce a signal through the cell membrane to 
induce its downstream effect, such as gene transcription. The evolution of reversible 
modifications of proteins, known as post translational modifications (PTMs) has allowed for 
rapid activation and termination of effector proteins to finely regulate a response. Many 
PTMs exist and regulate each protein differently, however phosphorylation is considerably 
one of the largest mechanism utilised by cells with >500 known kinases in humans 
(Manning et al., 2002). It is also predicted that a third of all proteins expressed at any time 
are phosphorylated (Olsen et al., 2006).  
 
To further complicate PTM regulation, the same type of PTM within a given protein can 
have functionally distinct effects depending on the residue that is modified. For example, 
HIF-1α phosphorylation at S692 results in protein stabilisation (Bullen et al., 2016), whilst 
phosphorylation on S657 results in protein degradation (Xu et al., 2010) and 
phosphorylation on S641/S643 promotes nuclear localisation (Mylonis et al., 2006 & 
Mylonis et al., 2008). PTMs are generally sub-stoichiometric, thus allowing diverse and 
independent regulatory mechanisms and pathways to co-exist by functionally altering 
subsets of the protein (Mann et al., 2002). Thus, the involvement of PTMs results in the 
proteome being exponentially more complex and dynamic than a collection of expressed 
gene products. 
 
There has not yet been a study that defines the PTM status of full length HIFα proteins 
occurring within cells or in response to hypoxia. As a consequence the effects of hypoxia on 
the HIF-1α and HIF-2α PTM network have not been elucidated either. This is particularly 
relevant for HIF-2α, where O2 dependent protein stability appears to play a lesser role in 
functional regulation, compared to HIF-1α (see introduction 1.1.3). 
 
The lack of in cellulo data for HIFα PTMs can be explained by several technical challenges, 
including: 
1) Endogenous HIFα proteins are of extremely low abundances within cells, 0.123 
ppm and 1.53 ppm for HIF-1α and HIF-2α respectively (data obtained from PAXdb, 
Wang et al., 2012). For comparison  the p53 protein (gene: TP53), an essential 
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transcription factor where dysregulation of PTM status is well-known for cancer 
progression (reviewed by: Meek et al., 2009), has an abundance of 22.2 ppm; ~200-
20 fold greater than the HIFα isoforms respectively (data obtained from PAXdb, 
Wang et al., 2012). Combined with poor HIFα antibodies that are not suitable for IP 
(discussed in chapter 3, section 3.3), the ability to purify endogenous HIFα in 
sufficient quantities for discovery mass spectrometry analysis is difficult. Given the 
stoichiometric ratio of PTMs, this reduces the abundance of the different PTM 
states (proteoforms) further, to levels potentially below the limit of detection for 
discovery MS experiments. Thus PTM identification and correct site localisation are 
challenging (Mann et al., 2002). I solved these challenges in Chapter 3, by using HA-
Clover-HIFα constructs overexpression and IP against the Clover tag. 
2) The selection of PTMs to investigate. From previous studies (Table 1.2 & Table 1.3), 
HIF-1α has been shown to be modified by multiple different types of PTMs, 
including: hydroxylation (Jaakkola et al., 2001) phosphorylation (Kalousi et al., 
2010), acetylation (Jeong et al., 2002), methylation (Lee et al., 2017), ubiquitination 
(Tanimoto et al., 2000), SUMOylation (Bae et al., 2004) and S- nitrosylation 
(Yasinska et al., 2003). Because the stoichiometric ratio of PTMs is undetermined, it 
is possible that PTM containing peptides may be below the limit of detection of the 
analytical system and/or masked by unmodified peptides. Thus, in a paradoxical 
fashion, discovery analysis attempting to identify all PTMs can lead to the lack of 
confident data. Strategies exist to enrich a specific PTM, in the background of 
unmodified/different PTM peptides, allowing the in-depth analysis of a specific 
PTM per LC-MS/MS experiment. Enrichment strategies can be antibody IP based or 
affinity based. The former is useful for specific modifications such as ubiquitination 
(Udeshi et al., 2013). However, phospho- serine and threonine antibodies are 
generally poor and highly dependent on the sequence environment of the PTM 
(Fíla et al., 2012). Therefore, it is preferential to investigate phosphorylation 
through Immobilised Metal ion Affinity Chromatography (IMAC). As discussed in 
the introduction, IMAC exploits the charge specific properties of phosphorylation to 
bind and purify phospho-peptides from the background of unmodified peptides 
(Mann et al., 2002 & Rainer et al., 2015). In chapter 3, we demonstrated that it was 
possible to use TiO2, the most commonly used IMAC resin, for phosphorylation 
enrichment of HIF-1α peptides. Thus, phosphorylation will be the main focus for 
PTM identification in this work. 
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3) The poor sequence coverage observed by LC-MS/MS analysis of HIFα digestion. A 
traditional proteomics workflow utilises trypsin as a proteolytic enzyme to create 
analysable peptides from proteins. Trypsin is preferentially used due to its specific 
cleavage pattern at the C-terminus of Lysine (K) and Arginine (R) residues, thus 
resulting in 2+ ion peptides (on average) which aid in peptide flyability and 
fragmentation (Paizs et al., 2005, Zhang et al., 2013 & Michalski et al., 2012). 
However, the peptides analysed are thus dependent on the distribution of K and R 
residues throughout a protein of interest. Hence tryptic digestion can be 
disadvantageous because it can result in peptides too large or too small for LC-
MS/MS analysis, determined by sequence (Tsiatsiani et al., 2015 & Mallick et al., 
2006). As a consequence, trypsin digestion alone can result in large sections of 
proteins that are unanalysed, resulting in poor protein sequence coverage and 
concomitant loss of PTMs being identified. By utilising a combination of proteolytic 
strategies, each generating their own identifiable peptides, it is possible to increase 
protein coverage detected by mass spectrometry analysis; providing a more in 
depth view of the PTM status of proteins (reviewed by Meyer et al., 2011). 
4) The labile nature of the phosphate moiety and difficulty in PTM localisation. 
Although phosphorylation is a covalent modification, the phospho-bond is much 
more susceptible to collisional induced fragmentation techniques (CID), which are 
required for amide bond fragmentation to obtain the peptide primary sequence 
and to localise the PTM. Thus, CID and, more pertinently, higher energy collision 
dissociation (HCD) can result in the neutral loss of the phosphate moiety and 
reduced ability to localise the PTM (Lehmann et al., 2007). Software has been 
developed to statistically infer phosphorylation localisation post neutral loss (Taus 
et al., 2011). Alternatively, additional fragmentation methods are available such as 
Electron Transfer Dissociation (ETD). ETD induces fragmentation specifically at the 
N-Cα bond in a non-vibrational fragmentation method, bypassing the neutral loss 
effect of phosphorylation (Syka et al., 2004). However, ETD fragmentation is highly 
inefficient for low charge state peptide ions (<3+) and the prominent tryptic ions 
are 2+. Hence a combinatorial method utilising both ETD and HCD fragmentations 
(EThcD) was developed (Frese et al., 2012 & Frese et al., 2013). In theory, by 
creating mixed ETD/HCD fragmentation spectra it maximises fragmentation for 
determining peptide primary sequence (HCD) while increasing the likelihood that 
localisation data may be maintained (ETD) (Frese et al., 2012 & Frese et al., 2013). 
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5) Biological interpretation. The development of large datasets can make it difficult to 
identify interesting aspects to initially focus on for further characterisation. Beyond 
defining presence and absence of PTMs between biological conditions, MS can be 
used quantitatively to investigate how the level of a PTM changes depending on a 
specific treatment (Thompson et al., 2003). The more accurate labelling strategies 
require the different samples to be prepared simultaneously to remove LC-MS/MS 
variation, a prospect not possible here due to the experimental size (Chapter 3, 
section 3.6.2). However, label free quantification can be performed, which 
experiences greater experimental error but allows the theoretical comparison of an 
unlimited number of samples. Additionally, investigating the evolutionary history of 
a PTM site can be insightful as highly conserved sites are likely to have essential 
functional importance (Bui et al., 2016, Beltrao et al., 2013 & Capra et al., 2007). 
Label free quantification and evolutionary analysis strategies were used here. 
 
An additional aspect of IP-coupled MS analysis is the Co-IP of binding partners. Although 
impossible to determine whether a Co-IP’d protein is a direct or an indirect interactor of 
the target protein, binding partners can be essential for function, for example the HIFα – 
HIF-1β interaction (Wang et al., 1995). Additionally, for a PTM to occur the modifying 
enzyme must come into contact with the protein of interest, although may not be stably 
bound. Thus, using a High Throughput (HTP) mass spectrometry approach to discover the 
binding partners that are Co-IP’d with HIF-1α and HIF-2α may not only unlock the signalling 
mechanisms differentiating the two isoforms but also potentially identify any modifying 
enzymes which may cause a given PTM. The latter can be fed back into pathway analysis to 
understand the global regulatory pathways acting on the HIFα proteins. 
 
4.2. Aims: 
The aim of this chapter was to use the developed GFP-Traps IP protocol for HA-Clover-HIFα 
proteins in order to identify: 1) The PTMs that occur in response to hypoxia for full length 
HIF-1α and HIF-2α in cellulo. A specific focus on phosphorylation will be applied, for the 
technical reasons mentioned above, however all PTMs were investigated. 2) The binding 
partners of HIFα isoforms in response to hypoxia. As mentioned above, several technical 




1) Improving sequence coverage identified by LC-MS/MS analysis. Traditional 
tryptic digests resulted in <35% HIFα protein coverage, thus digestion with multiple 
proteases was investigated.  
2) The attainment of maximal and confidently localised PTM data, by benchmarking 
different MS/MS fragmentation methods.  
3) Biological Interpretation of identified PTMs. Upon PTM data acquisition, a 
quintuple approach to biological interpretation was applied. Domain, treatment, 
isoform sequence comparison, phylogenetic/evolutionary and cancer database 
screening analyses were performed to aid in the identification of potentially more 
important sites of regulation. Where applicable, PTM sites were analysed using 
crystal structure modelling to predict the impact of a modification through close 
proximity intra- and inter- molecular interactions.  
 
Additionally, using the binding partner information obtained, gene ontology analysis and 
label free quantification approaches were performed to identify how binding partners 
acting on HIFα change between O2 tensions. I used these data to determine specifically 
enriched pathways, and identify the upstream enzymes potentially responsible of the PTMs 
identified, which may have a regulatory role in the HIF signalling network. 
 
4.3. Improving sequence coverage: 
In order to define an in-depth PTM map it is important that most of the protein sequence of 
interest can be analysed, at the peptide level, using MS methods. Therefore, the developed 
GFP-Trap IP coupled MS protocol was followed and the digested eluent analysed using a 
high scan frequency Orbitrap-Iontrap method. Trypsin digestion resulted in <35% of the 
HIF-1α protein sequence being identified at a 1% FDR (Figure 4.1), hence two-thirds of the 
protein, and potentially PTMs occurring, were not detectable. To improve the depth of PTM 
map obtainable, the IP process was repeated multiple times and digested with different 
proteases and analysed identically to trypsin. Proteases tested included: Chymotrypsin, 
Elastase, Asp-N, Glu-C and Lys-C (Figure 4.1, not all data shown). 
 
Chymotrypsin (cleaves at tyrosine (Y), phenylalanine (F), tryptophan (W), leucine (L) and 
methionine (M)) and particularly Elastase (cleaves at alanine (A), glycine (G), valine (V), 
serine (S), leucine (L) and isoleucine (I)) are prone to not cleaving at every possible site, 
known as miscleaves. Miscleave frequency needs to be accounted for at the time of data 
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interrogation because increasing the number of permitted miscleaves allows for more 
peptide identifications, however simultaneously increasing the chance that a given 
fragmentation spectrum (PSM) can match the reversed sequence database, used to 
determine FDR, by chance. Thus a balance exists when filtering to a 1% FDR, allowing too 
few potential miscleaves results in not all fragmented peptides being identified, and 
allowing too many increases the false positive rate and subsequent removal of correctly 
matched data by FDR filtering. To calculate the optimal parameters for data analysis, the 
same data file was analysed repeatedly, sequentially changing the permitted number of 
miscleaves per peptide, and recording the number of peptides and total number of PSMs 
identified at 1% FDR filtering (Table 4.1). This allowed me to evaluate the miscleave 
propensity for each protease and determine optimal parameters to assess obtainable 
protein coverage. 
 
Table 4.1: Determination of the best miscleave parameters for maximal confidently identified peptides for 
Elastase and Chymotrypsin.  
Table includes stated number of miscleaves post 1% FDR filtering, Protein confidence as determined by MASCOT 
score, number of unique peptides and the total number of PSMs identified for HIF-1α. LC-MS/MS was acquired 
following digestion at pre- (using a High-Low high scan frequency Orbitrap-Iontrap MS/MS method) and post- 
TiO2 enrichment (using a High-High low scan frequency Orbitrap-Orbitrap method), digest peptides and TiO2 





Table 4.1 shows that, as expected, as the number of miscleaves decreases, the number of 
PSMs and peptides identified generally do as well. At a 1% FDR cut-off, elastase with 9 
miscleaves identified 15 PSMs, however, successive decreases to 8 and 7 miscleaves found 
that 90 and 73 PSMs were maintained respectively. Hence 8 miscleaves was selected for 
elastase digestion samples, equating to ~65% protein sequence coverage (Figure 4.1). At a 
1% cut-off, chymotrypsin identified equal numbers of PSMs for both 5 and 4 miscleaves 
(174). Thus, to reduce the potential for increased false positive rates, 4 miscleaves was used 
to analyse chymotrypsin digest samples; equating to ~45% protein sequence coverage 







Figure 4.1: Identified sequence map of HIF-1α. 
HA-Clover-HIF-1α protein sequence, with peptide identifications at a 1% FDR highlighted. Data from the digest 
stage LC-MS/MS analysis using a High-Low MS/MS method. Bold and underlined = HA-Clover tag sequence, Pink 
= Trypsin digested (2 miscleaves), Green = Chymotrypsin digested (4 miscleaves), Grey = Elastase digested (8 
miscleaves). An overall coverage map is displayed to determine complete protein coverage, where a hierarchy 
for highlighting was applied of Trypsin, Chymotrypsin, and Elastase. 
 
As Figure 4.1 shows, combining data obtained from trypsin, chymotrypsin and elastase 
digestions equates to >90% of the HIF-1α protein sequence confidently identified at a 1% 
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FDR. The majority of the missing sequence is located at the HIF-1α N-terminus which is K/R 
rich, thus producing small peptides that are difficult to multiply charge, hence having poor 
fragmentation efficiency. Significantly, for phosphorylation analysis, >95% of the total S/T/Y 
residues were identified, allowing the creation of an in-depth phosphorylation map. 
Although additional proteases were investigated (Asp-N & Glu-C), no further protein 
coverage was obtained by their addition into the protocol, as such were not used. This 
experiment was repeated with HA-Clover-HIF-2α, using the same digest miscleave 
parameters, similarly obtaining >90% sequence coverage (data not shown). 
 
4.4. MS/MS method development: 
As discussed in the introduction, different methods for peptide fragmentation exist, namely 
HCD, ETD & EThcD. Many benchmark studies comparing these fragmentation methods have 
been performed for HTP phosphorylation analysis of trypsin digested human proteome, yet 
leading to different conclusions. Frese et al., 2012 showed that EThcD resulted in an 
improved peptide confidence score in 72% of all peptides when compared to HCD alone, 
translating to a marginal increase in correct phosphorylation localisation to 97%, from 95%. 
However, due to the increased time required for a dual fragmentation approach, EThcD 
resulted in 11% less total number of PSMs, thus a trade-off exists in HTP ability versus 
peptide confidence. This study was performed on the human proteome, thus is much more 
complex than my samples that are post IP (of a low copy number protein) and TiO2 
enrichment. As a result, the reduced PSM count of EThcD may be inconsequential for my 
study, if providing more confidently localised PTMs. However, a more recent study from the 
Eyers lab found that an Orbitrap only, HCD only fragmentation strategy combined with 
ptmRS analysis outcompeted EThcD in the total number of PSMs and correct 
phosphorylation site localisation (Ferries et al., 2017). Therefore, it was necessary to 
determine whether an HCD only or EThcD strategy provided the most confident data for my 
samples. 
 
The MS/MS methods from Ferries et al., 2017 (Orbitrap only, HCD collision energy (NCE) at 
32% and Orbitrap only EThcD, ETD calibrated time and HCD collision energy at 25%) were 
tested. Alongside these, a series of successive changes to the HCD collision energy of EThcD 
methods (25%-18%) were tested to potentially increase PTM localisation confidence, by 
providing less collisional energy. Additionally, it was theorised that a second HCD only 
method, designed to increase sensitivity and fragmentation time, could be beneficial within 
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this study (due to the vastly reduced complexity of samples post –IP and –TiO2 phospho-
peptide enrichment, compared to the human proteome). Changes to the Ferries et al., 2017 
method included: intensity required for peptide fragmentation (lowered to 2E4 ions, from 
2E5), targeted peptide ion count before fragmentation (AGC target, increased to 5E5, from 
2E5), maximum injection time (time spent collecting ions before fragmentation, if AGC 
target is not reached, increased to 250 ms from 100 ms) and the inclusion of 2 µ-scans (a 
technique that fragments a particular m/z ion twice and additively combines spectra to 
improve the signal to noise ratio). Each method was tested on the identical, post TiO2 
enrichment, HA-Clover-HIF-2α IP sample. The number of peptides identified, ptmRS score, 








As reported by Ferries et al., 2017, we found that the HCD-Orbitrap only method 
outperformed any of the tested EThcD methods in terms of the number of confidently 
localised phospho-peptides. We observed that many of the peptides identified in HCD 
methods are of 2+ charge state, thus explaining their lack of identification in EThcD 
methods (Sobott et al., 2009). The newly created high sensitivity, HCD only, Orbitrap only 
method resulted in the most phospho-peptides identified at a 1% FDR. Peptides identified 
were also at a greater confidence using MASCOT Score and E-value statistics and, 
significantly, resulted in greater ptmRS scores for identical peptides identified by different 
MS/MS methods. For example the LLSsVcSENEsEAEADQQmDNLYLK doubly phosphorylated 
peptide had both sites of phosphorylation identified to a confidence of  >99.0, while the 
Ferries et al., 2017 method could not distinguish between S7 or S11 as a phosphorylation 
site, both at a 50/50 chance. Thus, for this study, all phosphorylation analysis was 
performed using the newly developed HCD only MS/MS method. 
 
4.5. Biological interpretation of MS data- 
aaaiPhylogeny analysis: 
With the identification of potentially many PTM sites, attempting to prioritise sites for 
further investigation is a non-trivial task. Using a combined approach of MS data analysis 
and evolutionary history analysis of a particular site, it can potentially provide insight into 
the functional importance of a modification. Evolutionary conserved sites have more 
chance to be associated with essential functionality, while a highly mutated site could 
reflect poor functional importance (Beltrao et al., 2013 & Capra et al., 2007). However, the 
mutations that arise during evolution can also provide insight. For example, if a 
phosphorylated serine residue is mutated to a negatively charged aspartic acid residue it 
may reflect a state of permanent phosphorylation, conversely mutation to an uncharged, 
unmodifiable residue, such as alanine, could reflect a state of permanent 
unphosphorylation (Pham et al., 2008, diagrammatically depicted in Figure 5.1). Therefore, 
combining the evolution of a PTM site with species knowledge, of where a mutation 
occurred (for example Carp species known for extreme hypoxia tolerance (Nilsson et al., 
2004)), may lead to the identification of potential sites of importance. 
 
Following the guidelines from Hall, 2013, all protein matches to either HIF-1α or HIF-2α 
were obtained by BLAST searching. This was reduced to a non-redundant database by 
134 
 
reciprocal BLAST searching and a phylogenetic tree created for both HIF-1α (data not 
shown) and HIF-2α (Figure 4.2). The multiple sequence alignments were reoriented to 
match the order of the evolutionary tree, thus allowing the evolution of a specific site to be 
followed with ease. For this analysis, only vertebrate species were used for two reasons: 1) 
HIF-2α has only evolved in species with extensive oxygen delivery systems (Graham et al., 
2017). 2) Invertebrate HIF-1α homologs are vastly different to vertebrate homologs. For 
example, Drosophila melanogaster HIF-1α homolog, sima, is >1500 residues long 
(approximately twice the size), contains only one proline (P) hydroxylation site, lacks a 
definable CTAD and has primary functions in tracheal proliferation (Gorr et al., 2004). 








Figure 4.2: Molecular Phylogenetic analysis of HIF-2α protein sequences by Maximum Likelihood method.  
Evolutionary history was inferred by use of maximum Likelihood based on the JTT matrix model (Jones et al., 
1992). The highest log likelihood (-47644.35) tree is shown. Initial tree(s) for the heuristic search were obtained 
using Neighbour-Join and BioNJ algorithms to a matrix of pairwise distances estimated using a JTT model, and 
selecting the superior log likelihood topology. A discrete Gamma distribution was used to model evolutionary 
rate among sites (5 categories (+G, parameter = 0.9749)). The rate variation model allowed for some sites to be 
evolutionarily invariable ([+I], 8.63% sites). The tree is drawn to scale, with branch lengths measured in the 
number of substitutions per site. The analysis involved 227 amino acid sequences. All positions with less than 
95% site coverage were eliminated. That is, fewer than 5% alignment gaps, missing data, and ambiguous bases 
were allowed at any position. There were a total of 730 positions in the final dataset. Evolutionary analyses 
were conducted in MEGA7 (Kumar et al., 2016). 500 bootstrap replicates were used and values represent the 




4.6. Mass spectrometry sample preparation: 
Following the optimised GFP-Trap IP protocol on exogenously expressed HA-Clover-HIFα, 
IPs were performed in duplicate at both 21% and 1% O2 concentrations. After SCX clean-up, 
5% of the sample was analysed on a 1 hr LC gradient using a High-Low MS/MS method for 
maximal protein identifications, facilitating binding partner identification. The remaining 
95% was TiO2 enriched and 100% analysed using the optimised HCD only High-High 
Orbitrap only MS/MS method (section 4.4). All data were analysed using Proteome 
Discover, searching against the human non-redundant database and filtered to 1% FDR, 
equating to ~90% and ~60% sequence coverage post IP and TiO2 enrichment respectively. 
The next sections discuss the PTMs and binding partners identified. 
 
4.7. Phosphorylation data: 
Overall, ~25 phosphorylation sites were identified for both of HIF-1α and HIF-2α at a 
confidence of 1% FDR and ptmRS >99.0 (Figure 4.3, supporting peptide data in appendix 1), 
showing these proteins undergo extensive PTM. Comparing the phosphorylation sites 
identified to previously published data (Table 1.2 & Table 1.3) and HTP data recorded in 
PhosphoSitePlus (Hornbeck et al., 2015 & Hornbeck et al., 2012), showed  that the vast 
majority of the identified sites here are novel, with only 7 sites for HIF-1α and 2 sites for 
HIF-2α previously characterised. Considering the wealth of data published for HIF-1α 
phosphorylation, ~40 sites when including HTP identified sites, it is surprising that so few 
were identified in our data. However it is important to consider that the majority of 
proteomics studies will not be under hypoxic conditions, as well as the inefficiencies with 
trypsin digestion (Figure 4.1), therefore will artificially select against HIFα phospho-peptide 
detection. It can also be argued that the lack of previously identified phospho-sites (with 
functional characterisation) could be a reflection of the cell type specific regulation or a 
combination of previous studies not using true O2 deprivation hypoxia or the potentially 
high false positive rates of in vitro assays.  
 
For discussion, phosphorylation sites have been grouped together below based on their 
previous discovery, O2 dependence and domain localisation. The groups have been selected 
by observed characteristics and discussed in an order based on their potential interest, with 
a grouping order of:  1) previously characterised, 2) localisation in the ODDD, 3) localisation 
in the NTAD, 4) O2 dependency, 5) proline hydroxylation site proximity 6) localisation in the 
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bHLH and PAS-A/B domains, 7) clustering and 8) localisation in the inhibitory domain. If a 
particular PTM is applicable to multiple groups it is discussed in the primary group only, 
unless otherwise stated. However the site is present in the respective table containing their 





















































































































































































































































































































































































































































4.7.1. Previously characterised: 
In total 7 phosphorylation sites, out of 22, have been previously characterised for HIF-1α 
(S31, S465, S641, S643, S657, S687 and S696) and 3, out of 5, have been previously 
characterised for HIF-2α (S383, T528 and S830), listed in Table 4.3. 
 
Table 4.3: Characteristics of HIF-1α and HIF-2α phosphorylation sites identified.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variations are highlighted by single letter amino acid code, the O2 tension 
a PTM was identified in and comparisons to HIF-2α sequence. NA = not applicable, X = residue was not 
phosphorylated. 
 
4.7.1.1. Serine 31, a potential DNA binding role 
Utilising a recombinant fragment of HIF-1α in an in vitro PKA assay, Bullen et al., 2016 
identified multiple sites of phosphorylation (see introduction, 1.7); including S31 and S465. 
Based on the lack of observable effects on protein stability, when expressing the HIF-1α 
fragments in cells which contained a phospho-null mutation (serine to alanine), both sites 
were deemed not to have a biological function and not investigated further. Importantly, 
only investigating a phospho-null mutation removes the effect that phosphorylation may 
have through the introduction of charge. Similarly, it is possible that phosphorylation may 
not have a resultant effect on protein stability but rather transactivation. Thus the 
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evolutionary history of both S31 and S465 poses a potentially interesting view, particularly 
for S31 which resides in the bHLH domain, an almost 100% conserved domain in all species 
of HIF-1α (Figure 4.4 (A)) and HIF-2α. Interestingly, the residue at position 31 is a non-
phosphorylatable glycine residue in all bony fish species (Osteichthyes). To investigate this 
site further, I performed Pymol modelling on the partial HIF-1α-HIF-1β-DNA crystal 
structure (PDB: 4ZPR, Wu et al., 2015), using the PyTMs plugin to in silico phosphorylate 
S31 (Warnecke et al., 2014, Figure 4.4 (B)). 
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Figure 4.4: Serine 31 Evolutionary and structural analysis.  
A) Multiple sequence alignment comparisons of residues 29-34, arrow identifies S31. Selection of model 
organisms from a variety of phylogenetic families within the full dataset are shown, boxed region shows the 
Bony fish species (Osteichthyes), which is expanded to include all Bony fish species within the dataset. B) Crystal 
structure of phosphorylated S31. PyTMs plugin (Warnecke et al., 2014) was used to in silico phosphorylate S31 




Figure 4.4 (B) shows that S31 phosphorylation is in close proximity to the DNA backbone. It 
could be hypothesised that the negatively charged phosphate group may repel the 
negatively charged DNA backbone, thus resulting in transcriptional inhibition induced by 
phosphorylation, due to decreased ability to bind DNA. Hence, Bullen et al., 2016 would not 
have discovered the role of S31 phosphorylation, based only on protein stability 
measurements and phospho-null mutations. Interestingly, in our dataset and published 
data, there are no reports of phosphorylation at the respective HIF-2α serine residue (S28), 
thus identifying a potential HIF-1α specific pathway. Sequence alignment comparisons 
between isoforms finds the only amino acid different in the surrounding region is HIF-1α 
S28 to HIF-2α C25, identifying a potentially important site for motif analysis. 
 
4.7.1.2. Nuclear localisation 
HIF-1α phosphorylation at S641 and/or S643, by ERK1/2, have been shown to be 
responsible for nuclear accumulation, by preventing its nuclear export (Mylonis et al., 2006 
& Mylonis et al., 2008). In their study, MS analysis was inconclusive to determine which 
serine residue, if not both, were phosphorylated. However phospho –mimetic (nuclear 
accumulation) and –null (nuclear exclusion) mutations of either site resulted in the same 
phenotypic effect. Data presented here provide strong evidence that both phosphorylation 
sites co-exist as a doubly phosphorylated peptide (appendix 1). Interestingly, S643 
phosphorylation was detected as a singly phosphorylated peptide while S641 was only 
identified in the presence of S643, as a doubly phosphorylated peptide. This suggests a 
possible priming, or synergistic, mechanism where S643 phosphorylation is essential for the 
secondary phosphorylation at S641 (as seen with GSK3β signalling (Beurel et al., 2015)). In 
agreement with this hypothesis, S643 is highly evolutionarily conserved while S641 is poorly 
conserved, with variation primarily to non-phosphorylatable residues. Hence, these sites 
may work synergistically or have slightly different roles not yet discovered. 
 
HIF-2α phosphorylation at S383 and T528, by CK1δ, have previously been shown to be 
responsible for nuclear accumulation, in an identical mechanism to HIF-1α S641/643 
(Pangou et al., 2016). Interestingly, both S383 and T528 are highly conserved across 
vertebrate species, with 100% conservation of T528, suggesting an important role. 
Sequence comparisons identifies that HIF-2α S383 aligns with the novel S380 
phosphorylation site of HIF-1α. The surrounding sequences of these phosphorylation sites 
are poorly conserved between isoforms. Interestingly, HIF-2α T528 phosphorylation is O2 
dependent, only present at 21% O2, and is within very close proximity to the proline 
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hydroxylation site P531. Thus, T528 may have underlying roles not identified by Pangou et 
al., 2016, discussed further in the Proline hydroxylation proximity section (4.7.5). 
 
4.7.1.3. Protein stability 
The remaining HIF-1α phosphorylation sites (S657, S687 and S696) have all been shown to 
regulate protein stability. S657, phosphorylated by Plk3, has been shown to promote HIF-
1α degradation (Xu et al., 2010), while both S687, phosphorylated by CDK5 (Herzog et al., 
2016) and S696, phosphorylated by ATM (Cam et al., 2010) stabilise HIF-1α.  S657 is a 100% 
conserved site and sequence alignment comparisons finds that it aligns to the, novel T626 
phosphorylated residue of HIF-2α, which too is highly conserved. However, sequences 
surrounding S657 of HIF-1α and T626 of HIF-2α are poorly conserved between isoforms. 
 
HIF-1α S687 phosphorylation by CDK5 suggests a role in cell cycle progression, thus 
evolutionary analysis identifying that a serine residue only exists in primate species is 
intriguing. The ability for phosphorylation is maintained in other mammals by variaton to a 
threonine residue, except for Ungulate species which instead have a non-phosphorylatable 
alanine residue. All other vertebrate species contain a non-phosphorylatable residue, with 
no distinct residue selection.  Interestingly, HIF-1α S687 aligns to the novel phosphorylation 
site S672 of HIF-2α, which has an identical evolutionary pattern to the former. However, 
the surrounding sequence is poorly conserved, this may provide an explanation to how HIF-
1α S687 phosphorylation only occurs in 21% O2 while HIF-2α S672 is O2 independent. S696 
of HIF-1α is evolutionarily poorly conserved, and although aligns to a threonine residue of 
HIF-2α the latter is not phosphorylated. 
 
4.7.1.4. Transcriptional effects 
Of all phosphorylation sites that have previously been characterised and identified in this 
study, only HIF-2α S830 has been shown to effect transcription. S830 phosphorylation 
resulted in an increase of transcriptional output by ~2 fold, without affecting protein 
stability, although this was not investigated further (Gradin et al., 2002). S830 resides in the 
CTAD, involved with p300/CBP binding interactions, which is a 100% conserved domain 
among all vertebrate species analysed. Sequence comparisons between isoforms shows 
that HIF-2α aligns to the novel phosphorylation site of HIF-1α: S786, which too is 100% 
conserved. The surrounding regions of respective sites are also highly conserved, both 
between isoforms and evolutionarily, thus suggesting a potentially essential function 
shared between isoforms, such as regulating p300/CBP association. Interestingly, HIF-2α 
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S830 phosphorylation was only detected in 1% O2 while HIF-1α S786 phosphorylation was 
detected O2 independently.  
 
All phosphorylation sites discussed below are novel and therefore have no functional 
assessment in the narrative. 
 
4.7.2. ODDD hyperphosphorylation 
The ODDD was named due to containing the oxygen sensitive proline resides, which upon 
hydroxylation leads to degradation (see introduction 1.6). However, a striking feature in our 
data is the hyperphosphorylation of the HIF-1α ODDD, especially compared to the HIF-2α 
ODDD. Indeed, there was 15 and 5 phosphorylation sites identified respectively (Figure 4.5), 
listed in Table 4.4 and Table 4.5 respectively. 
 
Figure 4.5: Schematic view of the ODDD and NTAD phosphorylation map of HIF-1α and HIF-2α.  
Stated domains of HIFα proteins are highlighted, with canonical domain numbering. Confidently identified 
phosphorylation sites (1% FDR, ptmRS score >99.0) are mapped to the protein and coloured dependent on 
whether they are novel (red), have been seen by previous HTP mass spectrometry studies (blue) or have 
previously undergone functional characterisation (green). The sequence coverage seen from mass spectrometry 
analysis (from Figure 4.1, bold line) and the sequence homology between isoform domains (fine line and score) 
is depicted below the protein schematic. A) Phosphorylation sites identified in 1% O2, B) Phosphorylation sites 








Table 4.4: Characteristics of HIF-1α phosphorylation sites identified within the ODDD.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variations are highlighted by single letter amino acid code, the O2 tension 
a PTM was identified in and comparisons to HIF-2α sequence. NA = not applicable, X = residue was not 
phosphorylated. 
 
Interestingly, 7 (out of 15) of the HIF-1α phosphorylation sites within the ODDD are O2 
dependent, being observed in my investigations only in 21% O2: S415, T418, T490, S510, 
S525, S581 and T605. Surprisingly, no phosphorylation sites within the ODDD were 
identified in 1% O2 only. Thus, it is likely that the O2 dependent regulation of HIF-1α protein 
stability, through the ODDD, is more complex than initially thought and may be influenced 
by phosphorylation status. It could be hypothesised that the hyperphosphorylation status 
of the ODDD in 21% O2 may enhance the efficiency of HIF-1α degradation, potentially by 
promoting PHD interactions and subsequent degradation. Interestingly none of these 
phosphorylation sites are highly conserved, with approximately half of these residues 
present in mammalian species only. Furthermore, the majority of residue variation at these 
phosphorylation sites were to non-phosphorylatable residues, or to regions of the protein 
that are missing, suggesting a potentially important regulatory mechanism that has evolved 
specifically in mammals. Similarly, since HIF-1α and HIF-2α share ~40% sequence homology 
in the ODDD, it is surprising that none of the phosphorylation sites identified in HIF-1α 
mapped to phosphorylation sites of HIF-2α. If these HIF-1α phosphorylation sites have a 
role in protein degradation, it may partially explain why HIF-2α regulation is less dependent 
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on O2 dependent degradation compared to HIF-1α. Intriguingly, HIF-1α phosphorylation 
sites S510 and S581 both align to Cysteine (C) residues of HIF-2α, which can experience 
redox sensitive PTMs and may have unique roles (reviewed by: Chung et al., 2013). 
Although there is currently no evidence for redox-mediated modification of these C 
residues. 
 
We observed that the O2 dependent phosphorylation sites: T490, S510 and S525 are 
interspersed with O2 independent phosphorylation sites: S484, S500 and S515. This region 
is the most densely phosphorylated portion of either HIF-1α or HIF-2α, and has an 
approximate repeating unit of a multiple of four, potentitally suggesting this region could 
be α-helical in structure (Pauling et al., 1951). Theoretically, this could allow an O2 
independent phosphorylation face of the α-helix to be used in essential functions, such as 
correct protein folding, while allowing an O2 dependent phosphorylation face to have 
secondary functions, such as protein degradation. Without a crystal structure it is 
impossible to validate this theory. Therefore we adopted an ab initio (sequence inferred) 
modelling approach of a 60 residue fragment encompassing these 6 phosphorylation sites 
(A475-L535), using the Robetta online server (Song et al., 2013 & Raman et al., 2009). The 
most likely model is shown in Figure 4.6 and has been phosphorylated in silico at all 6 
identified sites. Importantly, the homology aspect of modelling was very poor, at a score of 
0.05 (between 0 (no crystal structures for modelling) – 1 (complete crystal structure)), 
hence the model is highly reliant on sequence based protein structure prediction, which 
















Figure 4.6: Combined homology and ab initio model of the high density, O2 dependent phosphorylation region 




Figure 4.6 shows that although there are α-helical regions present, the initial hypothesis of 
a large α-helix is incorrect. However, it is clear that the O2 independent phosphorylation 
sites are in very close proximity to negatively charged glutamic acid residues: S484-E479 is 
<2 Á and S515-E518 is <5 Á, thus are likely to experience strong repulsive interactions 
(Barlow et al., 1983). We notice that the last O2 dependent site (S500) is ~7 Á in distance 
from Leucine (L) 535, the last residue that was used in this model. Investigating the next 
amino acids identifies E537, therefore it is possible this glutamic acid residue is within 
closer proximity to the S500 phosphorylation site than the modelled leucine residue; 
resulting in charge repulsion. Therefore, although not α-helical as initially hypothesised, the 
O2 independent phosphorylation sites are likely to have a dramatic role on protein folding. 
Additionally, all O2 dependent phosphorylation sites (T490, S510 and S25) are modelled to 
face externally, thus potentially acting as docking sites for binding partners. However, 
without knowing the stoichiometry of how these phosphorylation sites occur, it is possible 
that all occur simultaneously. Thus, the O2 independent phosphorylation sites, facing 
negatively charge glutamic acid residues, may result in large structural rearrangements, 
hence the O2 dependent sites will likely be in different positions to as modelled here.  
 
Evolutionary analysis of the modelled region shows that it is well conserved in the majority 
of vertebrate species analysed, except for Bony fish which show high rates of variation 
within this region; interesting considering they experience temporal hypoxia much more 
frequently than most species. Interestingly, sequence comparison to HIF-2α shows that this 
region is poorly conserved between isoforms, but is rich in serine/threonine residues; 
containing a total of 13 sites. Unfortunately, large parts of this region were not detectable 
by the MS/MS methods used, thus we were unable to evaluate the phosphorylation status 
of this region. 
 
Remaining HIF-1α phosphorylation sites within the ODDD (S438, S451, T458 and S589) are 
all O2 independent. Although all novel in terms of LTP studies, S451 phosphorylation has 
been observed in 5 separate HTP MS studies, thus supporting its existence. Interestingly, 
S451 is a 100% conserved site among species and lies within a highly conserved region 
between species, suggesting a functionally important role. Sequence comparisons with HIF-
2α show that this region is missing and therefore could be hypothesised to have a role in 
differentiating HIF-1α from HIF-2α. S438 and T458 are both highly conserved, with the 
former 100% conserved in all species analysed. S589 is much less conserved with non-
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phosphorylatable residues of glycine and lysine identified in bird species and bony fish 
species respectively. The identification that a negatively charged phosphorylation site aligns 
to a positively charged lysine residue is particularly interesting, and may suggest a potential 
charge importance role. For example, phosphorylation may inhibit a binding partner 
through charge repulsion, while a lysine residue can promote it by strengthening 
electrostatic interactions. Sequence comparisons to HIF-2α identifies that a negatively 
charged glutamic acid residue aligns to this phosphorylation site, thus could support this 
hypothesis and suggest a permanent role for HIF-2α in signal transduction and temporal 
role for HIF-1α. 
 
Table 4.5: Characteristics of HIF-2α phosphorylation sites identified within the ODDD.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variation are highlighted by single letter amino acid code, the O2 tension 
a PTM was identified in and comparisons to HIF-1α sequence. NA = not applicable, X = residue was not 
phosphorylated.  
 
Comparison of Table 4.4 and Table 4.5 highlights how different the phosphorylation status 
of the ODDD is between HIF-1α and HIF-2α. Interestingly, T406 and S413 are virtually 
conserved in all vertebrate species analysed and are in close proximity to the proline 
hydroxylation site P405, discussed further in the proline hydroxylation proximity section 
(4.7.5). 
 
The remaining phospho-sites T447, S449 and S453 form a tight cluster, however 
phosphorylated T477 is identified as an exclusive site while phosphorylated S449 and S453 
are identified as singly and doubly phosphorylated peptides (Table 4.6). It may be 
hypothesised that the T447 and S449/S453 phosphorylation sites could have different roles, 
with the latter two phosphorylation sites potentially having synergistic effects. However, 
this would require further investigation to support such statements. Evolutionary analysis 
reveals that all three sites are poorly conserved, with no species other than mammals 




Table 4.6: Identifying peptides and confidence of T447, S449 and S453 phospho-sites.  
Includes the peptide sequence, Uppercase letter = unmodified, Lowercase letter = phosphorylation site, the 
number of PSMs that identified a particular peptide, the ptmRS score, peptide confidence score and E-value 
from the best PSM. 
  
Overall, the functional characterisation of the identified phosphorylation status of the HIFα 
isoforms ODDD will be an interesting avenue to explore in the future, potentially providing 
an insight for better understanding of the fine tuning of HIFα protein stability at 21% O2. 
 
4.7.3. N-Terminal Transactivation Domain (NTAD) 
aaaaaahypophosphorylation:  
The NTAD is the fundamental region involved with determining gene specificity of the HIFα 
isoforms, and has the least sequence similarity of the canonical domains (Hu et al., 2007 & 
Tian et al., 1997). We therefore hypothesised that the NTAD may experience heavy PTM 
regulation in order to alter binding partners and gene specificity. Thus the complete 
absence of identified phosphorylation sites within the HIF-1α NTAD is surprising (Figure 
4.7). This observation is supported by published data too, where a distinct lack of 
phosphorylation is identified within the NTAD of HIF-1α (data from PhosphoSitePlus). In 
fact, only one publication has identified phosphorylation within the HIF-1α NTAD at S551 
and T555, both resulting in protein degradation; thus may explain why we were unable to 
identify these sites (Flügel et al., 2007 & Flügel et al., 2012). 
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Figure 4.7: Schematic view of the NTAD phosphorylation map of HIF-1α and HIF-2α.  
Confidently identified phosphorylation sites (1% FDR, ptmRS score >99.0) are mapped to the protein and 
coloured dependent on whether they are novel (red), have been seen by previous HTP mass spectrometry 
studies (blue) or whether they have undergone previous characterisation (green). The sequence coverage seen 
from mass spectrometry analysis (from Figure 4.1) is depicted below the protein schematic (bold line) along 
with the sequence homology between isoform domains (fine line and score). A) Phosphorylation sites identified 
in 1% O2, B) Phosphorylation sites identified in 21% O2. 
 
 
Table 4.7: Characteristics of HIF-2α phosphorylation sites identified within the NTAD.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variation are highlighted by single letter amino acid code, the O2 tension 
at which the PTM was identified in and comparisons to HIF-1α sequence. NA = not applicable, X = residue was 
not phosphorylated. 
 
Figure 4.7 and Table 4.7 show that HIF-2α is phosphorylated at 4 positions within the NTAD: 
T517, S543, T559 and T528, the latter discussed in the proline hydroxylation proximity 
section (4.7.5). All 4 sites are highly conserved across vertebrate species, although the 
NTAD itself is poorly conserved. Despite the poor sequence homology between HIF-1α and 
HIF-2α, it is interesting that the HIF-2α S543 and T559 phospho-sites both align to 




Overall, it will be interesting to investigate whether the HIFα isoforms undergo novel PTMs 
of different types in the NTAD domain, such as acetylation or ubiquitination which have 
previously been published (Jeong et al., 2002 & Paltoglou et al., 2007). Alternatively, it will 
be interesting to investigate whether the NTAD undergoes PTM regulation in different cell 
lines, which may explain differences seen (Bracken et al., 2006), or whether the sequence 
differences alone are responsible for the specificity of HIFα gene targeting. 
 
4.7.4. O2 dependent phosphorylation: 
Although the process of phosphorylation does not directly require O2 as a cofactor, wit is 
known that O2 tension can regulate kinase (or phosphatase) function by PTM (Shao et al., 
2014), therefore it can also be hypothesised that signalling pathways in response to hypoxia 
may change. Therefore the identification of O2 dependent phosphorylation sites is not 
surprising, with a total of 12 and 8 phosphorylation sites only identified in an O2 dependent 
manner for HIF-1α (Table 4.8) and HIF-2α (Table 4.9) respectively. 
 
Table 4.8: Characteristics of HIF-1α phosphorylation sites identified that are O2 dependent.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variation are highlighted by single letter amino acid code, the O2 tension 





Interestingly, only two phosphorylation sites on HIF-1α were identified in 1% O2 only: S31 
and S384, the former discussed previously in previously characterised section (4.7.1.1) and 
the latter in the negatively charged cluster section (4.7.7). The remaining ten phospho-sites 
that were differentially regulated by O2 tension were only identified in 21% O2: S415, T418, 
T490, S510, S525, S581, T605, S641, T652 and S687. Of these, only T652 has not been 
discussed above, phospho-sites S415-T605 were discussed in the ODDD section (4.7.2) and 
S641 & S687 were discussed in the previously characterised section (4.7.1.2 and 4.7.1.3 
respectively). T652 has been identified previously in a single HTP study and was only 
detected as a doubly phosphorylated peptide in this study with S657. As we identify S657 as 
a singly phosphorylated peptide it suggests that a possible priming mechanism may exist, in 
which S657 is initially phosphorylated and can result in secondary phosphorylation at S652, 
possibly affecting the functional degradation role of S657 (Xu et al., 2010). 
 
Table 4.9: Characteristics of HIF-2α phosphorylation sites identified that are O2 dependent.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variations are highlighted by single letter amino acid code, the O2 tension 
a PTM was identified in and comparisons to HIF-1α sequence. NA = not applicable, X = residue was not 
phosphorylated. 
 
HIF-2α phosphorylation status appears to be more O2 dependent, with 4 sites specifically 
identified in 21% O2 (S453, T528, S581 and S683) and in 1% O2 (S345, T597, S606 and S830), 
3 of these sites are discussed elsewhere: S453 in the ODDD section (4.7.2), T528 in the 
proline hydroxylation proximity section (4.7.5), and S830 in the previously characterised 
section (4.7.1.4). Both remaining 21% O2 only phospho-sites (S581 and S683) lie within an 
154 
 
undefined domain of HIF-2α that is poorly conserved among all species investigated. 
Similarly, there is poor sequence homology between HIFα isoforms within this region, thus 
it is difficult to determine their importance or their potential role beyond differentiateing 
HIFα isoforms. Of the remaining 1% O2 only phospho-sites, T597 and S606 are both within 
the same undefined domain of HIF-2α, as S581 and S683, and are equally poorly conserved. 
Based on my observations of numerous O2 dependent phosphorylation sites, it is possible 
that this undefined domain could have an important role in HIF-2α O2 dependent 
regulation. 
 
The last HIF-2α 1% O2 only phosphorylation site (S345) is within the PAS-A/B domains and is 
highly conserved among all vertebrate species analysed. S345 has been crystallised in the 
HIF-2α-HIF-1β crystal structure complex (PDB: 4ZP4, Wu et al., 2015), therefore I could 
model the S345 phospho-site (Figure 4.8). Figure 4.8 (A) shows that S345 phosphorylation 
introduces the negative charge within 2 Å from a negatively charged glutamic acid residue 
(E348, cyan), thus likely resulting in structural rearrangements through charge repulsion. 
Figure 4.8 (B) shows that this region of HIF-2α (green) is encapsulated by HIF-1β (blue). 
Although the amino acids 347-359 of HIF-1β failed to crystallise, it is clear that to connect 
the two fragments of HIF-1β that did crystallise then the unstructured region would have to 
pass over the HIF-2α S345 containing domain. Therefore, it is plausible that if 
phosphorylation at S345 results in a structural rearrangement, then the HIF-1β binding 
domain would be disrupted too; potentially regulating HIF-2α dependent transcription by 






Figure 4.8: Phosphorylated S345 of HIF-2α and potential resultant affects.  
Crystal structure (PDB: 4ZP4, Wu et al., 2015), modelled in Pymol and phosphorylated using the PyTMs plugin 
(Warnecke et al., 2014). Green: HIF-2α, Blue: HIF-1β, Red: phospho-S345, Cyan: possible S345 interacting 
residues; W318 & E348. Distances measured using Pymol Distance wizard. A) Close proximity of phospho-S345 
to W318 & E348. B) Zoomed out image to highlight possible role in HIF-1β binding. Residues between T346-
P360 did not crystallise (marked on the structure to highlight the start and end points of the missing region). 
 
 
4.7.5. Proline hydroxylation proximity 
The canonical proline hydroxylation sites are P402/P564 for HIF-1α and P405/P531 for HIF-
2α. These proline hydroxylation sites reside in highly conserved regions between isoforms 
(Figure 4.9). From domain analysis, the LAP (leucine, alanine, proline-hydroxylated) motif is 
essential for proline hydroxylation, observed at all sites for both isoforms. We found that a 
third site of the LAP motif exists within HIF-2α specifically (P576), which resides in a region 
of very poor sequence homology to HIF-1α (Figure 4.9). Evolutionary analysis shows that 
this third LAP motif only exists in mammalian species and thus may suggest an important, 











Figure 4.9: Hydroxylated Proline residues and close proximity phosphorylation sites observed with HIF-2α. 
Shows the aligned HIFα sequences from MUSCLE multiple sequence alignment and viewed in clustal X. * 
indicate identical residues at a position, : identifies a strong conservation mutation, . identifies a weak 
conservation mutation and blank spaces indicate no conservation mutation (determined by clustal matrix). Red 
boxes highlight the LAP motif for Proline hydroxylation and arrows identify sites of HIF-2α specific 
phosphorylation. 
 
Interestingly, as Figure 4.9 shows, although the canonical proline hydroxylation sites are 
highly conserved between HIFα isoforms, HIF-2α is specifically phosphorylated within close 
proximity to all hydroxylated Proline residues (arrowed): P405/T406, P531/T528 and the 
novel P576/S581. Additionally, HIF-1α has non-phosphorylatable residues at each 
respective site. Considering the increased O2 dependent stability of HIF-2α compared to 
HIF-1α, it is possible that these phosphorylation sites (T406, T528 and S581) could block, or 
reduce the affinity of, PHD binding; thereby preventing the O2 dependent degradation. 
Supporting this hypothesis, all three phosphorylation sites are identified at 21% O2 and, for 
the canonical proline hydroxylation sites, are highly conserved in all species (Table 4.10).  
 
Table 4.10: Characteristics of HIF-2α phosphorylation sites identified that are within close proximity to Proline 
hydroxylation sites.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variation are highlighted by single letter amino acid code, the O2 tension 
a PTM was identified in and comparisons to HIF-1α sequence. NA = not applicable, X = residue was not 
phosphorylated. 
 
Evolutionary analysis of all species identifies that S581 is less conserved, however, since this 
LAP motif only exists in mammalian species then the conservation of S581 in these species 
could support this theory. Overall, HIF-2α phosphorylation in close proximity to proline 
hydroxylation sites may stabilise the protein in an O2 independent manner, a mechanism 
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that is not present in HIF-1α; potentially explaining the 21% O2 HIF-2α protein stability 
observed. 
 
4.7.6. DNA binding and HIF-1β interaction domains: 
The βHLH and PAS-A/B domains are the most highly conserved domains between HIF-1α 
and HIF-2α, with 85% and 75% sequence homology respectively. Therefore, it was 
surprising to find that 5 of the 6 phosphorylation sites identified in this region align to non-
phosphorylatable residues between isoforms, and that the remaining HIF-1α S31 phospho-
site aligns to the non-phosphorylated HIF-2α S28, in this study (Figure 4.10). 
Phosphorylation sites are: HIF-1α S31, discussed in the previously characterised section 
(4.7.1.1), and HIF-2α sites S46, S72, S79, S163 and S345, the latter discussed in the O2 
dependent phosphorylation section (4.7.4, Table 4.11). 
 
Figure 4.10: Phosphorylated residues within the βHLH domain of HIF-1α and HIF-2α.  
Shows the aligned HIFα sequences from MUSCLE multiple sequence alignment and viewed in clustal X. * 
indicate identical residues at a position, : identifies a strong conservation mutation, . identifies a weak 
conservation mutation and blank spaces indicate no conservation mutation (determined by clustal matrix). Red 
boxes highlight the phosphorylation site and arrows identify sites position of phosphorylation, number based 
from isoform that is modified. 
 
Table 4.11: Characteristics of HIF-2α phosphorylation sites identified within the bHLH and PAS-A/B domains.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variation are highlighted by single letter amino acid code, the O2 tension 
at which a PTM was identified in and comparisons to HIF-2α sequence. NA = not applicable, X = residue was not 
phosphorylated. 
 
Evolutionary analysis shows that the HIF-2α bHLH domain is virtually 100% conserved 
among all species. However, S46 only exists in mammals and bony fish, with remaining 
species having the non-phosphorylatable residue asparagine. Sequence alignments to HIF-
1α also identifies an asparagine residue at this position. Since asparagine is present in all 
HIF-1α species and non-mammalian species of HIF-2α, it could highlight a HIF-2α specific 
function that has evolved in mammalian species only. HIF-2α S163 is better evolutionarily 
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conserved than S46, however is similarly a non-phosphorylatable residue in some species 
and in HIF-1α. 
 
Interestingly, HIF-2α S72 and S79 are located within a 16 residue region of the bHLH 
domain which is the only part of this domain that is not highly conserved between HIFα 
isoforms (Figure 4.10). HIFα isoform sequence alignment shows that HIF-2α phospho-sites 
S72 and S79 both align to non-phosphorylatable residues of alanine and isoleucine in HIF-
1α, respectively. HIF-2α S72 and S79 were both identified as singly phosphorylated peptides 
and as a doubly phosphorylated peptide (data in appendix 1) and are O2 independent. 
Therefore, it may be hypothesised that these sites may have roles in differentiating HIFα 
isoform functions through DNA or HIF-1β binding mechanisms. 
 
Interestingly, S72 is evolutionarily conserved, while S79 is only present in mammalian 
species, with non-phosphorylatable residues identified in all other species (Table 4.11). 
Hence, a previous HTP study providing supportive evidence for S79 phosphorylation makes 
this site of potential interest. The crystal structure of the bHLH and PAS-A/B domains (PDB 
4ZP4, Wu et al., 2015), did not crystallise efficiently within this region, with multiple large 




Figure 4.11: Phosphorylated S72 of HIF-2α and potential resultant effects.  
Crystal structure (PDB: 4ZP4, Wu et al., 2015), modelled in Pymol and phosphorylated using the PyTMs plugin 
(Warnecke et al., 2014). Green: HIF-2α, Blue: HIF-1β, Red: phospho-S72. Residues that failed to crystallise are 
highlight by white text identifying the positions of last crystallised residues. 
 
As Figure 4.11 shows, HIF-2α (green) regions between S75-M87, L149-M162 and V211-
L219, and HIF-1β (blue) region between L141-L158, are all missing. It is clear that this region 
is important for HIF-2α - HIF-1β binding interactions. For HIF-2α S75-M87 to connect, the 
missing sequence must directly pass over, or under, the HIF-1β α-helix. Interestingly, the 
lower face of the HIF-1β α-helix contains negatively charged glutamic acid residues while 
the upper face contains positively charged lysine residues. Thus, depending on how the 
missing sequence between S75-M87 folds, it is possible that phosphorylation at S79 could 
result in repulsive or attractive forces respectively. S72 appears to face into a missing 
region of HIF-2α (V211-L219), which contains both negatively charged glutamic acid 
residues and positively charged lysine residues. Thus, similar to S79, S72 phosphorylation 
may result in repulsive or attractive forces respectively. Hence it is possible that S72 and 
S79 phosphorylation could either result in structural rearrangements, by charge repulsion, 
and result in the loss of HIF-1β binding, or alternatively stabilise the HIF-2α - HIF-1β dimer, 





4.7.7. HIF-1α Negatively charged cluster: 
From our data we have identified a highly phosphorylated domain of HIF-1α, between 
residues 380-385: S380, T383, S384 and S385. Sequence analysis identifies that this 
phosphorylation cluster contains multiple negatively charged residues as well, possibly 
creating a negatively charged pocket (378 V-E-Sp-E-D-Tp-Sp-Sp-L 387). However, the 
available crystal structure (4ZPR) does not cover these regions to further validate this. Mass 
spectrometry analysis confidently identifies each phospho-site with >10 PSMs and ptmRS 
scores of >99.5 for each, thus I have confidence in their identifications (Table 4.12). 
Interestingly, these phosphorylation sites show a degree of mutual exclusivity, both S380 
and S384 only appear as singly phosphorylated peptides (mutually exclusive), while T383 
and S385 appear as singly- and doubly- phospho-peptides (Table 4.12). 
 
Table 4.12: Identifying peptides and confidence of S380, T383, S384 and S385 HIF-1α phospho-sites.  
Includes the peptide sequence, Uppercase letter = unmodified, Lowercase letter = phosphorylation site, the 
number of PSMs that identified a particular peptide, the ptmRS score, peptide confidence score and E-value 
from the best PSM. 
 
Table 4.13: Characteristics of HIF-1α phosphorylation sites identified within the negatively charged cluster.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variation are highlighted by single letter amino acid code, the O2 tension 
a PTM was identified in and comparisons to HIF-2α sequence. NA = not applicable, X = residue was not 
phosphorylated. 
 
All singly phosphorylated sites within this cluster are O2 independent, except for S384 
which was only identified in 1% O2 (Table 4.12). The doubly phosphorylated (T383 and 
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S385) peptide only identified in 21% O2 (Table 4.12). Overall, this could suggest two 
possibilities: 1) the different phosphorylation sites may have different roles, or 2) the 
introduction of a negative charge by phosphorylation is required for functional outcomes, 
irrespective of location. Evolutionary analysis finds this region to be conserved within 
phylogenetic vertebrate families, but poorly between families; especially for Bony fish 
which have large insertions. However, it is interesting that both mutually exclusive 
phosphorylation sites (S380 and S384) are exclusive to mammalian species, with non-
phosphorylatable residues in all other species (Table 4.13). Hence, evolutionary analysis 
could suggest that possibility (1) is more likely and that S380/S384 may allow for different 
regulatory pathways that have evolved specifically in mammalian species. Sequence 
alignment to HIF-2α shows this HIF-1α cluster and surrounding regions are poorly 
conserved. 
 
4.7.8. Inhibitory domain: 
The inhibitory domain was originally termed through deletion construct analysis attempting 
to identify the main functional domains of HIF-1α (Jiang et al., 1997). Jiang et al., 1997 
found that the HIF-1α CTAD was of residues 786-826, while a construct from residues 576-
826 had no function; hence the term “inhibitory domain” was coined for residues 576-785. 
From previously published data (PhosphoSitePlus), the inhibitory domain is the most PTM 
dense containing domain of HIF-1α; with 27 separate modifications identified from LTP and 
HTP studies. Here, we show that the inhibitory domain is a heavily phosphorylated domain 
















Table 4.14: Characteristics of HIF-1α phosphorylation sites identified within the inhibitory domain.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variation are highlighted by single letter amino acid code, the O2 tension 
at which a PTM was identified in and comparisons to HIF-2α sequence. NA = not applicable, X = residue was not 
phosphorylated. 
 
Table 4.15: Characteristics of HIF-2α phosphorylation sites identified within the inhibitory domain.  
Table includes position of PTM, how many studies have identified the respective site with function and 
reference, evolutionary history where variation are highlighted by single letter amino acid code, the O2 tension 
at which a PTM was identified in and comparisons to HIF-1α sequence. NA = not applicable, X = residue was not 
phosphorylated. 
 
Interestingly, sequence alignments between HIFα isoforms shows that the HIF-2α inhibitory 
domain has a large (~60 residue) insertion within the inhibitory domain, and in aligned 
regions, has very poor sequence homology between HIFα isoforms (Figure 4.12). However, 
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as Figure 4.12 shows, two sites of phosphorylation between HIFα isoforms do align (green), 
HIF-1α/HIF-2α numbering: S657/T625 and S687/S672, which could reflect an important 
shared function. The fact that many of the identified phosphorylation sites within the 
inhibitory domain are O2 dependent, for both HIFα isoforms, suggests that this domain 
could be an important domain for O2 dependent functions and differentiating HIFα isoform 
functions.  
 
Figure 4.12: Phosphorylated residues within the inhibitory domains of HIF-1α and HIF-2α.  
Shows the aligned HIFα sequences from MUSCLE multiple sequence alignment and viewed in clustal X. * 
indicate identical residues at a position, : identifies a strong conservation mutation, . identifies a weak 
conservation mutation and blank spaces indicate no conservation mutation (determined by clustal matrix). Red 
boxes highlight HIF-1α specific phosphorylation, Blue boxes highlight HIF-2α specific phosphorylation and Green 
boxes highlight phosphorylation of the same aligned residue between HIFα isoforms. 
 
Because many of the identified phosphorylation sites within the inhibitory domain have 
previously been characterised or are O2 dependent, they have been discussed in relevant 
sections (4.7.1 and 4.7.4). Therefore only HIF-2α S696 and S790 are discussed here. HIFα 
isoform sequence alignments show that HIF-2α S696 is within the poorly conserved region 
between both isoforms, aligning to a non-phosphorylatable asparagine residue, while S790 
is within the large insertion of HIF-2α (Figure 4.12). Interestingly, this entire region is poorly 
evolutionarily conserved among species and could reflect an evolutionary ‘hot-pocket’ for 
evolving novel regulatory mechanisms for HIFα isoforms. 
 
4.8. Search for other PTMs 
Since a dual mass spectrometry approach was used, for identifying binding partners and 
phosphorylation sites (post TiO2 enrichment), the former will contain every HIFα peptide 
present and thus all PTMs that have a role in regulating HIFα proteins. As discussed, un-
enriched, PTMs are likely to be at a very low level in comparison to unmodified peptides 
and therefore it is very likely that not every PTM peptide will be detected by our MS 
analysis. However, some PTMs may be at a high enough level to be detected. Additionally, 
it is possible that, TiO2 enriched phospho-peptides may contain additional types of PTM 
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that would not have been identified previously because they were not considered in the 
data analysis parameters.   
 
PEAKS is a software tool that can be used to perform an ‘open PTM’ search for over 300 
different PTMs (that are both biological and artefactual in nature), and is known to 
outperform similar software when filtering to a 1% FDR (Zhang et al., 2012, Han et al., 2011, 
Ma et al., 2003 & Creasy et al., 2004). Therefore all digested and TiO2 enriched LC-MS/MS 
data were additionally analysed using PEAKS, employing the optimised miscleave 
parameters (described in section 4.3). Searches were performed twice, where cysteine 
carbamidomethylation was set as a fixed and variable modification, in order to identify 
potential redox based cysteine PTMs; potentially interesting considering the O2 sensitive 
nature of HIFα proteins. Modifications confidently identified at 1% FDR and 5% minimal ion 
intensity (a measure of localisation score) are depicted in Figure 4.13 and labelled in Table 
4.16 to Table 4.19. Interestingly, the open PTM search clearly identifies considerably more 
PTMs in 21% O2 than 1% O2, in agreement with my phosphorylation data. Each PTM type is 
discussed as a separate modification below. No phosphorylation data is mentioned here as 




Figure 4.13: Schematic view of the PTM status of HIF-1α and HIF-2α, without phosphorylation.  
 
4.8.1. Oxidative modifications 
Redox sensitive PTMs are well known regulators of both HIFα protein stability, through 
proline hydroxylation (Jaakkola et al., 2001, Ivan et al., 2001 & Bruick et al., 2001), and 



































































































































































































































































































































2002 & Mahon et al., 2001). Considering that proline hydroxylation results in the rapid 
degradation of HIFα, it is not surprising that the canonical sites of proline hydroxylation 
were not identified (HIF-1α: P405 and P531 and HIF-2α: P405 and P531 (Jaakkola et al., 
2001, Ivan et al., 2001 & Masson et al., 2001). Therefore it was incredibly interesting to 
identify novel HIF-2α proline hydroxylation sites (P137 and P206) at a 5% FDR (removed at 
1% (data not shown)), that are specific to 1% O2 conditions. Therefore it is possible these 
sites are real but poorly fragment or, equally valid, they are matching by chance; hence 
should be validated before investigating further. These novel hydroxylation sites do not 
contain the LAP motifs required for the EGLN PHD function, either suggesting the action of 
different proline hydroxylases, discussed further in the known binding partners section 
(4.13.1.4), or that these sites may be false positive by the reduced stringency filter. 
 
It is known that FIH-1 maintains enzymatic activity in O2 tensions as low as 0.5% O2 (Lando 
et al., 2002), thus it was not surprising to identify N803 and N847 hydroxylation (HIF-1α and 
HIF-2α respectively) in 1% O2. It is likely that protein molecules that have been proline 
hydroxylated in 21% O2 are also aspargine hydroxylated, thus explaining the lack of 
identification for aspargine hydroxylation at 21% (due to it being rapidly degraded). 
 
Oxidation is also possible on the following amino acids: methionine, phenylalanine, 
tryptophan, histidine and cysteine, by either enzymatic reactions or interaction with 
Reactive oxygen species (ROS) (Sharma et al., 2010). Although methionine oxidation can 
have biological roles in disease and ageing (Mohsenin et al., 1989 & Hoshi et al., 2001), it is 
generally accepted that standard MS sample preparation techniques can artefactually 
increase methionine oxidation rates (Ghesquière et al., 2014), thus it was disregarded as a 
PTM here due to the lack of adequate controls. Neither phenylalanine or histidine oxidation 
was identified here. 
 
Although tryptophan oxidation is also potentially artifactual, it requires much stronger 
oxidising conditions and is seldom seen due to proteomics based sample preparation. 
During cellular lysis, tryptophan oxidation can occur artifactually but is generally identified 
in a very specific manner that is enriched to mitochondrial proteins, and is at a much 
reduced frequency than methionine oxidiation (Perdivara et al., 2010 & Taylor et al., 2003). 
Additionally, there are various pathologies associated with the dysregulation of these 




Similarly, cysteine residues can undergo multiple, reversible oxidation states by reaction 
with both reactive oxygen and nitrogen Species (ROS/RNS) at the free thiol group, if in a 
non-disulfide bonded state (reviewed by Chung et al., 2013). Under severe oxidative stress, 
cysteine residues can be irreversibly oxidised into 2+ and 3+ oxidative states: sulfinic acid 
and sulfonic acid respectively. Published studies have found an important regulatory role 
for irreversibly oxidised cysteine residues (Vivancos et al., 2005, Blackinton et al., 2009 & 
Fujiwara et al., 2007). Considering ROS/RNS accumulate in hypoxia (Chandel et al., 1998 & 
Bell et al., 2007), it is likely that hypoxia could ellict an oxidative based PTM response in HIF 
signalling. Thus both tryptophan and cysteine oxidative PTMs were considered as true 
PTMs rather than artefactual, and are discussed below. All oxidiative PTMs discussed are 

































































































































































































































































































































































4.8.1.1. Tryptophan oxidation 
HIF-1α has a single site of tryptophan oxidation (W752), specific to 21% O2. W752 is within a 
highly conserved region and is also a highly conserved site, with only a single clade of Bony 
Fish having a glycine residue. The functional importance of this variation is hard to predict; 
although glycine can not undergo an oxidative modification, the size and hydrophobicity 
differences between tryptophan and glycine are likely to have a larger structural effect.  
 
HIF-2α has 3 tryptophan oxidation sites (W318, W438 and W652) that are identified in both 
mono-oxidised and di-oxidised states. All 3 tryptophan sites are highly conserved from 
evolutionary analysis. Interestingly, the oxygenation state of both W318 and W438 are O2 
dependent; W318 is mono-oxidised in both O2 tensions but only di-oxidised in 21% O2, 
whilst W438 is mono-oxidised only in 1% O2 and di-oxidised only in 21% O2. Similarly, W652 
is both mono- and di- oxidised only in 21% O2, suggesting that the sites are all 
independently regulated. Of particular interest, W438 resides within the ODDD, which is a 
highly conserved domain between isoforms. Therefore it is surprising to identify HIF-2α 
W438 aligns to the phosphorylated HIF-1α T458 residue, with a single HTP study providing 
supportive evidence of its existence. These residues and PTMs have highly differing 
characteristics, suggesting possible functional differences. 
 
4.8.1.2. Cysteine oxidation 
Considering the accumilation of ROS/RNS in hypoxia (Chandel et al., 1998 & Bell et al., 
2007), it is not surprising to identify that the number of both sulfinic acid and sulfonic acid 
irreversible cysteine oxidative PTMs increases by hypoxic incubation, with 7 cysteines 
modified in 1% O2 compared to 4 in 21% O2. As the majority of cysteine oxidation sites 
identified here are found in both sulfinic and sulfonic acid forms, it is unknown whether 
they may have separate functions or function interchangably. All oxidised cysteine residues 
detected at 21% O2 were also detected at 1% O2, except for C780 in HIF-1α, suggesting that 
some sites are more readily oxidized than others. Besides C780, all oxidised cysteines are 
localised in the DNA binding (bHLH) and HIF-1β binding (PAS-A/B) domains. Interestingly, 
although the bHLH and PAS-A/B domains share the most sequence homology between HIFα 
isoforms, HIF-2α is much more extensively oxidised than HIF-1α and in a 1% O2 only 
dependent manner. Considering the near 100% conservation of all cysteine residues within 






Ubiquitination is a 8.5 kDa protein tag which is typically covalently attached to lysine 
residues, through a 3-stage activation process. Mono-ubiquitination and poly-ubiquitination 
chains can occur through multiple linkage strategies of monomers. Different linkage 
strategies have been shown to have different cellular outcomes. However, poly-
ubiquitination generally results in tagged-protein degradation through the proteasome 
(reviewed by Komander et al., 2012). Traditional shotgun- based proteomics (protein 
digestion) result in the concomitant digestion of ubiquitin, thus consequently it is 
impossible to distinguish between mono- or poly- ubiquitination. However, ubiqutination at 
a specific site is detectable by a ‘GG-tag’ that remains attached to the lysine residue post 
digestion (reviewed by Kirkpatrick et al., 2005).  
 
Ubiquitination is an important HIFα PTM, having roles in regulating protein stability, and 
potentially switching to a HIF-2α dependent signalling state in prolonged hypoxic conditions  
(Koh et al., 2008, Koh et al., 2011, Koh et al., 2014, Paltoglou et al., 2007, Tanimoto et al., 
2000 & Maxwell et al., 1999, reviewed by Schober et al., 2016). Recently, ubiquitination has 
been shown to be involved in a non-canonical activation pathway that results in the 
ubiquitination of cysteine, serine, threonine and tyrosine residues through thiol-ester and 
hydroxy-ester bonding respectively. These non-canonical ubiquitination generally result in 
protein degradation (Reviewed by: McDowell et al., 2013). All ubiquitination sites identified 

















Table 4.17: Characteristics Ubiquitination PTMs of HIF-1α and HIF-2α.  




































































































































































































































































































































Two sites of lysine ubiquitination were detected in total, both in HIF-1α at K214 and K477. 
Considering the rapid degradatory nature of ubiquitination, it is possible that this PTM is 
not easily identifiable without proteasomal inhibition. Interestingly, K214 is highly 
evolutionarily conserved, except in Bony fish where a negatively charged glutamic acid 
residue aligns. Not only does a glutamic acid residue remove the ability for ubiquitination, 
lysine and glutamic acid are oppositely charged residues, thus may reflect a dual role of 
K214 where there is a charge importance. K477 ubiquitination has a HTP study for 
supportive evidence, and was also identified as a site of methylation in this study. K477 has 
also been identified in multiple LTP as a site of SUMOylation, with conflicting results in 
terms of protein stability and transactivation roles (Cheng et al., 2007, Bae et al., 2004 & 
Berta et al., 2007).  
 
Taking into account the degradatory nature of non-canonical ubiquitination sites, it was not 
surprising to detect non-canonical ubiquitination predominantly in 21% O2, with only a 
single site identified in 1% O2 (HIF-2α at S747). We identified two hydroxy-ester 
ubiquitination sites: HIF-1α at T736 and HIF-2α at S747, these do not align between HIFα 
isoforms and have fairly poor evolutionary conservation.  
 
The remaining ubiquitination sites are all cysteine linked. Commonly used reduction 
strategies for mass spectrometry sample preparation have been shown to result in the 
removal of cysteine ubiquitination (Williams et al., 2007), which could explain the lack of 
previous identification within the proteome. It is observed that every cysteine 
ubiquitination site is neighboured by a serine/threonine residue, which could have resulted 
in mis-annotation of PTM localisation if the peptide was poorly fragmentated. However, 
setting the data analysis for fixed cysteine carbamidomethylation (chemically induced by 
sample preparation), in an attempt to force localisation onto the neighbouring 
serine/threonine residue, resulted in the PSM no longer being identified. This suggests that 
either: cysteine is infact ubiquitinated and is more stable than initially thought, or 
serine/threonine ubiquitination blocks the ability to chemically modify the cysteine 
residues. Interestingly, many of the cysteine ubiquitination sites detected are also sites of 
oxidative PTM in 1% O2 (HIF-1α: C194, HIF-2α: C74 and C195), which could suggest a bi-
functional role for these cysteine residues. For example, 21% O2 ubiquitination promotes 






Lysine acetylation involves the addition of an acetyl group to the positively charged amino 
group of lysine residues, resulting in charge neutralisation. Both HIF-1α and HIF-2α have 
been shown to be regulated by acetylation, having both protein stability and transcriptional 
function roles (Lim et al., 2010 & Dioum et al., 2009). Six separate acetylation sites were 
identified in this dataset, HIF-1α: K674 and K709 and HIF-2α: K379, K385, K685 and K705, 































Table 4.18: Characteristics of Acetylation PTM sites of HIF-1α and HIF-2α.  
  
 
HIF-1α K674 acetylation, by PCAF, was shown to promote transcriptional function by 
enhancing p300/CBP-HIF-1α interactions (Lim et al., 2010). Interestingly, HIF-1α K674 has 











































































































































































































































































































1α K674 might have a dual role, influenced by PTMs, in a mechanism where acetylation 
prevents protein degradation by blocking ubiquitination at this site. Suporting this theory, 
HIF-1α K674 is virtually 100% evolutionarily conserved and acetylation is only identified in 
1% O2. Hypoxia dependent acetylation could thus prevent normoxic ubiquitination and 
degradation, an avenue not explored in the previous publication. 
 
HIF-1α K709 acetylation was shown to directly promote protein stability (Geng et al., 2012). 
Interestingly, 4 separate HTP studies have identified K709 as a site of ubiquitination, 
therefore it can be argued that the 2 PTMs may compete for HIF-1α K709 modification to 
regulate protein stability, as discussed for HIF-1α K674. HIF-1α K709 resides within an 
evolutionarily highly conserved region of ~20 residues, however in all Bony fish there is an 
arginine residue. This variation corresponds to what is used for biochemical mutational 
analysis for acetylation, where lysine residues are mutated to arginine for acetylation-null 
investigations because it maintains the positive charge without the ability to be acetylated 
(Gorsky et al., 2016). 
 
Dioum et al., 2009 showed that HIF-2α was acetylated on K385, K685 (both identified in this 
study) and K741, and that a triple mutant reduced transcriptional function without affecting 
protein stability. However the effect of individual sites was not explored. Both HIF-2α K385 
and K685 have been identified as sites of ubiquitination by HTP studies, which could 
suggest a protein stability role, as discussed for HIF-1α K674, which was not observed by 
Dioum et al., 2009. However, it is possible that the use of different cell lines and treatments 
before analysis could impact HIF-2α stability, with different regulatory profiles for different 
cell lines (Bracken et al., 2006). Interestingly, HIF-2α K685 is only present in mammalian 
species, with all other species having variation to aspartic acid or glutamic acid mutations, 
which are oppositely charged to lysine and may therefore suggest an importance of charge. 
 
Both HIF-2α K379 and K705 acetylation sites are novel and are specific to HIF-2α, aligning 
respectively to a missing region and an alanine residue within HIF-1α. Interestingly, 
evolutionary analysis identifies that HIF-2α K379 has specifically evolved in primate and 
ungulate species only, with remaining mammals having a negatively charged glutamic acid 
residue. All other vertebrate species investigated have a charge neutral amino acid. Overall 
this could suggest a recently developed functional trait that is charge dependent. Similarly, 
HIF-2α K705 is only present in mammalian species, with all other species having a serine 





Lysine and arginine methylation have classically been associated with histone modification 
and gene expression regulation. Methylation has also been identified as an important PTM 
in signal transduction pathways, including the EGFR – ERK pathway (Hsu et al., 2011), and 
for regulation of protein function such as p53, where mono-methylation inhibits function 
and di-methylation activates function through co-factor binding  (Huang et al., 2007), 
reviewed by Biggar et al., 2014. Infact, HIF-1α and HIF-2α have been shown to be 
methylated at K32 and K29, respectively, but has conflicting reported functional effects 
with reports showing inhibition of transcriptional function without affecting their stability 
(Liu et al., 2015) and methylation induced degradation (Kim et al., 2016). Additionally, HIF-
1α methylation at K391 was found to promote PHD-VHL dependent degradation (Lee et al., 
2017), showing the potential importance of this modification in hypoxia signalling. None of 
these sites were identified in this study, however a total of 4 novel HIF-1α and HIF-2α 




























































































































































































































































































































































Our data show that all HIF-1α methylation sites are novel and are present at 21% O2 only, 
suggesting a potential O2 dependent regulatory role. Interestingly, all 3 HIF-1α lysine 
methylation sites (K71, K477 and K532) have been identified as sites for other PTMs, 
suggesting a potential dual function (as discussed previously in the acetylation section 
(4.8.3)). HIF-1α K71 was detected as a site of ubiquitination in two separate HTP studies 
while both K477 and K532 have been extensively investigated in LTP studies as 
SUMOylation and acetylation/ubiquitination sites.  K477 was also identified as a site of 
ubiquitination in our data, therefore was discussed previsouly in section 4.8.2. 
 
LTP studies have shown HIF-1α K532 is ubiquitinated, post PHD Proline hydroxylation, 
resulting in degradation (Tanimoto et al., 2000 & Paltoglou et al., 2007). Additionally, HIF-
1α K532 was shown to be a site of acetylation, by ARD-1 (Arrest Defective protein -1), 
triggering degradation (Jeong et al., 2002 & Lee et al., 2010). However, the role of HIF-1α 
K532 has conflicting evidence, with studies showing that acetylation does not occur 
(Murray-Rust et al., 2006 & Arnesen et al., 2005). Considering the range of reported PTMs 
(ubiquitination, acetylation, and methylation from this study), combined with 100% 
conservation of HIF-1α K532, it is highly likely that K532 has essential regulatory roles which 
are not yet fully understood. The final HIF-1α methylation site is a novel arginine residue 
(R463), which is poorly conserved. 
 
All HIF-2α methylation sites detected in this study (K379, K596, R690 and K705) are novel 
sites. Similarly to HIF-1α, lysine methylation sites were only present at 21% O2, R690 
methylation was identified in both O2 tensions. Evolution analysis shows that HIF-2α R690 
only exists in primates, marsupials and rodents, with remaining mammalian species having 
a Glutamine variation. This variation is used as an acetylation-mimetic mutation to maintain 
side chain structure but removing the charge (Gorsky et al., 2016). Thus, it is interesting as 
methylation does not result in charge neutralisation, like acetylation. Interestingly, both 
K379 and K705 are sites of acetlyation, and were therefore discussed above.  
 
4.8.5. SUMOylation 
Although SUMOylation has been shown as an important PTM that regulates HIF-1α (Bae et 
al., 2004, Berta et al., 2007 and Cheng et al., 2007) and HIF-2α (van Hagen et al., 2010) 
function, no sites were detected within this study. It is possible that the cell line and O2 
treatments used did not result in SUMOylation. However, a more plausible explanation is 
the difficulty in identifying SUMOylation PTMs using MS without targeted approaches 
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(Hendriks et al., 2016, Hendriks et al., 2018 & Tammsalu et al., 2015). SUMO is a protein 
tag, similar to ubiqutin, however it is poorly digested with trypsin and results in a 30 amino 
acid tag attached to the peptide; too large for standard proteomics analysis. 
 
4.9. COSMIC database 
With the advancements of genome sequencing technology, high quality genome sequences 
can be produced and computationally aligned/annotated relatively quickly. This has lead to 
a wealth of data where different cancer samples have been sequenced to identify 
mutational patterns in genes of interest, that may result in amino acid mutation (missense 
mutation). The COSMIC database (Catalogue Of Somatic Mutations In Cancer) is the largest 
repository for such data with over a million partial and >28,000 full genome tumour 
sequence entries (Bamford et al., 2004 & Forbes et al., 2016). The COSMIC database was 
analysed to identify mutations in the HIF-1α and HIF-2α (EPAS-1) genes that result in 
missense mutations, with the aim to identify potential hotspots of mutation that align to 
PTMs identified in this study; potentially pointing to important functional sites worthy of 
prioritising for further investigation. 
 
A total of 50,243 and 48,762 unique tumour samples had been sequenced containing the 
HIF-1α and HIF-2α genes respectively. Considering the importantance of hypoxia, and active 
HIF, in tumour survival and progression, this number of tumours lead to a surprisinly low 
total mutation count of 261 and 357 for HIF-1α and HIF-2α respectively (~0.5% of all 
tumours). For comparison p53 (TP53 gene) has been sequenced in 167,617 unique tumours 
and was found mutated in 41,588 tumours (~25% of all samples), equating to a mutation 
frequency 50 fold greater in p53 than either HIFα genes.  
 
Since the specific aim of this analysis was to identify site-specific mutational hotspots for 
potential PTM effects, only missense mutations (amino acid substitution) were 
investigated, hence synonymous, nonsense, frameshift insertions/deletion and in-frame 
insertion/deletion mutations were removed from the dataset. This lowered the mutation 
count to 190 for HIF-1α and 270 for HIF-2α. The COSMIC database stores mutations of the 
same site to different DNA bases as separate records, thus a highly mutated site to no 
specific residue would not be identified as significantly mutated. Therefore all mutations for 
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a single site were cumulated together and plotted against amino acid position for 
respective protein (Figure 4.14). 

























































































































































































































































Figure 4.14 shows that both HIF-1α and HIF-2α have a mutational hotspot with ~15% of all 
HIF-1α mutations located at K213 + D238, and ~23% of all HIF-2α mutations between 
positions 529-532. Interestingly, none of the PTM sites identified in our study, or in 
published studies, are identified as mutational hotspots in cancer samples. The two 
enriched HIF-1α mutation sites (K213 and D238) are relatively close together and oppositely 
charged, therefore these sites may interact with each other to form an ion pair; hence 
mutation to either can give the same phenotypic effect. HIF-1α K213 and D238 were 
modelled using the crystal structure (PDB: 4ZPR, Wu et al., 2015, Figure 4.15). Figure 4.15 
shows that K213 is situated within a missing region (199-218), however D238 is spatially 
distant from C218 (the closest amino acid in the crystal structure to K213). An alternatively 
theory that Figure 4.15 could suggest is that HIF-1α K213 and D238 are involved with HIF-1β 
binding regulation, both being in close proximity to a HIF-1β α-helix. Interestingly, the HIF-
2α mutational hotspot localises to the prolyl-hydroxylation site (P531) and consensus ‘LAP’ 
motif seen in all known proline hydroxylation sites (Figure 4.14), suggesting that the loss of 
degradation for HIF-2α is an important cancer survival mechanism.  
Figure 4.15: Crystal structure mapping to investigate K213 and D238 cancer mutations of HIF-1α.  
PDB: 4zpr, green = HIF-1α, blue = HIF-1β, red = surrounding amino acids of the deletion encompassing K213 and 





4.10. Binding partners   
MS analysis of the eluted material, before TiO2 phospho-peptide enrichment, allowed for 
total protein analysis to identify Co-IP’d HIF-1α and HIF-2α binding partners. A confidently 
identified peptide count per protein filter was not applied, however identified proteins 
were only kept in the dataset if identified in both replicates. Finally, using the HA-Clover 
only control we created background subtracted lists by the removal of non-specific binding 
partners. All binding partners from each IP and replicate filtering are listed in Appendix 2. 
 
4.10.1. Replicate variability 
Although significant optimisation was performed, including lysis/wash buffer and length of 
washes (Chapter 3), there was relatively low reproducibility in protein identifications (50-
60%) between replicate IPs performed under the same conditions (Figure 4.16). The low 
identity reproducibility is also observed using the HA-Clover only negative control, 
suggesting an analytical repeatibility issue rather than a specific HIFα characteristic. It is 
clear that the HA-Clover only tag, and/or GFP-Traps resin, have their own specific binding 
partners, ‘background’ proteins that are removed from the HIFα list to identify ‘real’ 
binding partners. Nevertheless, the number of unspecific ‘noise’ proteins identified is 







Figure 4.16: Replicate variability of identified proteins post IP of HA-Clover-HIF-
1α, HA-Clover-HIF-2α and HA-Clover only.  
 
4.10.2. O2 dependent binding partners 
Proteins that were confidently identified in both replicates were kept for further evaluation 










































































































































































































































































































































































































































































































For background subtraction, the same filtering was applied to HA-Clover only proteins 
identified and any proteins that were identified in the same O2 tension experiments for 
both HA-Clover only and HA-Clover-HIFα IPs were removed. Post background subtraction, 
HIF-1α had a total of 610 and 571 protein identifications for 1% and 21% O2 respectively, 







Figure 4.17: O2 dependent binding partners for HIF-1α and HIF-2α.  
 
As might have been expected, the HIFα binding partners change significantly as a result of 










































































































































































































































































































































were identified as HIF-1α binding partners (571 vs 610 for 21% and 1% O2 respectively), 
only ~34% of proteins are identified in both conditions; thus ~66% of the proteins identified 
are O2 dependent. More striking is the HIF-2α binding partner data. As previously discussed, 
it could be hypothesised that PTMs and binding partners may play a greater role in 
regulating HIF-2α as its stability is less dependent on O2 tension than HIF-1α. Data here 
indeed suggest this, with >700 proteins identified specifically in 1% O2 compared to 73 at 
21% O2. This ~10 fold increase in the size of the interacting network induced by hypoxia is 
interesting (especially when compared to HIF-1α) and will require additional invesitgation. 
 
4.10.3. Gene Ontology (GO) analysis 
Gene ontology (GO) enrichment analysis was performed to identify which cellular pathways 
interact with HIFα isoforms, in an O2 dependent and independent manner (Huang et al., 
2007 & Huang et al., 2008). For GO annotation enrichment analysis, the DAVID (Database 
for Annotation, Visualisation and Integrated Discovery) tool was used (Dennis et al., 2003). 
Data was stringently filtered for GO-terms of Biological process and Molecular function 
annotations at a Benjamini-Hochberg corrected P-value <0.05 only (Figure 4.18 to Figure 4.21: 
GO Enrichment Analysis of HIF-2α interactors in either O2 tension.Figure 4.21), all GO enrichment data 
in appendix 3). These filtering criteria were applied to provide a broad overview of the 
processes in which HIFα may be involved with and of the specific pathways that may 





Figure 4.18: GO Enrichment Analysis of HIF-1α interactors identified in both O2 tensions.  
GO enrichment analysis was performed in DAVID using the background subtracted list of binding partners 
identified in both O2 tensions (427 proteins). A Fishers exact test is performed for  P-values and were adjusted 
for multiple hypothesis testing using the Benjamini-Hochberg correction and are plotted against fold 
enrichment. The dotted horizontal line represents an adjusted P-value of 0.05. Points are only plotted if the 
adjusted P-value is <0.05 and are labelled if the adjusted P-value is <0.01. Points are labelled with respective GO 














Both O2 tensions 
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Figure 4.19: GO Enrichment Analysis of HIF-1α interactors identified in either O2 tension.  
GO enrichment analysis was performed in DAVID using the lists of background subtracted binding partners 
identified in 21% O2 only (310 proteins), 1% O2 only (235 proteins. A Fishers exact test is performed for  P-values 
and were adjusted for multiple hypothesis testing using the Benjamini-Hochberg correction and are plotted 
against fold enrichment. The dotted horizontal line represents an adjusted P-value of 0.05. Points are only 
plotted if the adjusted P-value is <0.05 and are labelled if the adjusted P-value is <0.01. Points are labelled with 
respective GO annotation and are scaled according to the number of proteins within an annotation. Proteins 






21% O2 only 1% O2 only 
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Figure 4.20: GO Enrichment Analysis of HIF-2α interactors in both O2 tensions.  
GO enrichment analysis was performed in DAVID using the lists of background subtracted binding partners 
identified in both O2 tensions (292proteins). A Fishers exact test is performed for P-values and were adjusted for 
multiple hypothesis testing using the Benjamini-Hochberg correction and are plotted against fold enrichment. 
The dotted horizontal line represents an adjusted P-value of 0.05. Points are only plotted if the adjusted P-value 
is <0.05 and are labelled if the adjusted P-value is <0.01. Points are labelled with respective GO annotation and 
are scaled according to the number of proteins within an annotation. 
Both O2 tensions 
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Figure 4.21: GO Enrichment Analysis of HIF-2α interactors in either O2 tension.  
GO enrichment analysis was performed in DAVID using the lists of background subtracted binding partners 
identified in 21% O2 only (70 proteins), 1% O2 only (677 proteins. A Fishers exact test is performed for P-values 
and were adjusted for multiple hypothesis testing using the Benjamini-Hochberg correction and are plotted 
against fold enrichment. The dotted horizontal line represents an adjusted P-value of 0.05. Points are only 
plotted if the adjusted P-value is <0.05 and are labelled if the adjusted P-value is <0.01. Points are labelled with 
respective GO annotation and are scaled according to the number of proteins within an annotation. Proteins 
identified in 21% O2 only (left hand side) and 1% O2 only (right hand side). 
 
Although GO enrichment analysis was performed on binding partners specifically identified 
in 1% or 21% O2 only, many of the significantly enriched GO annotations are found in both 
O2 tensions (Figure 4.18 and Figure 4.20) and the separate O2 tensions (Figure 4.19 and 
Figure 4.21), for example protein binding and poly(A) RNA binding. The likely explanation 
for this is the broad classification system used by DAVID, thus resulting in many different 
proteins grouped under the same GO annotation. An example of which is proteasomal 
proteins, significantly enriched GO annotations of: proteasomal degradation, protein 
binding, NF-kB signalling, WNT signalling, MAPK cascade, ATPase activity (and more) all 
21% O2 only 1% O2 only 
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consist primarily of the proteasomal proteins with a single differentiating protein to classify 
them as independent groups; NEMO in NF-kB signalling or MAP2K3 in MAPK cascade. 
Therefore, although this analysis may provide some insight into potential functions, further 
more in-depth analysis is needed in respect of actual proteins identified before conclusions 
can be made. Hence only a few GO annotations will be discussed here. Due to issues of 
bioinformatics complexity and time constraints, HIF-1α versus HIF-2α comparisons were 
not performed. 
 
For both HIFα isoforms, the amount of ribosomal proteins identified post background 
subtraction is interesting; with >50 different proteins associated to the ribosome identified. 
Although ribosomal proteins are generally considered background ‘noise’ of the IP, the lack 
of these in the HA-Clover only IPs in comparison to HIFα IPs would suggest otherwise. It is 
undeterminable from this dataset whether HIFα interacts with these proteins either directly 
or indirectly. 
 
Interestingly, the ATPase activity/ATP binding groups conisist of many parts of the 
mitochondrial electron transport chain, including the majority of the ATP-synthase pump. A 
search of the data for mitochondrial proteins (DAVID GO-annotation) highlights a significant 
number of proteins IP’d that are endogenously located within the mitochondria at >100 in 
total (~10% of total proteins identified) for both HIFα isoform, and O2 independently 
binding. This number of internally localised mitochondrial proteins identified would suggest 
that the HIFα proteins may have a fraction of total protein localised into the mitochondria. 
This hypothesis is also supported by some published studies which used biochemical and 
proteomics approaches to show  a sub-population of HIF-1α localised into the mitochondria 
(Briston et al., 2011, Concolino et al., 2018 & Thomas et al., 2019). Although these papers 
only mention HIF-1α,  they do not investigate HIF-2α. Therefore it is possible from the data 
presented here that HIF-2α also localises to mitochondria. Because of these identifications, 
we decided to search the mitochondrial DNA (UniProt accession: NC_012920, Andrews et 
al., 1999) for HREs to suggest whether HIF may have a role in regulating mitochondrial gene 
expression. Interestingly, we identified 20 putative HRE promoter sequences ((A/G)CGTG, 
Schödel et al., 2011), although further investigation is needed to understand whether these 




For HIF-1α, the GO annotations identified are marginally different between protein 
identifications of 21% only, 1% only and both O2 conditions. The potentially more 
interesting GO annotations, such MAPK cascade and NF-kB singalling that are only 
identified in 21% O2, primarily consist of the identical proteins with a single differentiating 
protein (Protesomal proteins with either MAP2K3 or NEMO respectively). Therefore GO 
annotations need further investigation before drawing conclusions, as discussed above. 
 
Significantly more enriched GO annotations were identified for HIF-2α at 1% O2, compared 
to 21% O2, as would be expected given the ~10 fold increase in unique protein 
identifications (73 compared to >700 respectively). Surprisingly, HIF-2α in 21% O2 had 
cytoskeletal proteins specifically enriched, with no equivalent GO annotations in 1% O2 or 
any O2 tension of HIF-1α. The major constituents of the cytoskeletal protein GO annotation 
are: proteins of the Arp2/3 complex, Talin and Tubulin isoforms. 
 
Interestingly, enzymes essential for GPI (glycosylphosphatidylinositol) anchoring are 
specifically enriched by HIF-2α at 1% O2 only: GPAA1, PIGK, PIGS, PIGT & PIGU, all of which 
are located within the Endoplasmic Reticulum (ER) (GPI anchor function and localisation of 
binding partners discovered by: Ohishi et al., 2000 & Ohishi et al., 2001). Predicition tools 
(PredGPI) suggest HIF-2α does not have any sites for GPI-anchoring (Pierleoni et al., 2008). 
This therefore suggests that, upon hypoxic incubation, HIF-2α may become localised into 
the ER. In addition, our data finds that the GO annotation of: ‘ER to Golgi vesicle mediated 
transport’ is also significantly enriched, specifically in 1% O2 and for HIF-2α only. This could 
reflect a potential role of HIF-2α in extracellular vesicle packaging. Aga et al., 2014 has 
shown that HIF-1α can be packaged into extracellular vesicles, which then influence 
surrounding cells to promote cancer progression. However HIF-2α has not been 
investigated for similar function. 
 
Another interesting aspect is the enrichment of telomerase influencing proteins identified 
as HIF-2α specific binding partners; with both ‘telomerase RNA localization to Cajal bodies’ 
and ‘protein localisation to teleomere’ significantly enriched in both O2 tensions. Due to the 
nuclear speckle localisation of telomeres (Abreu et al., 2011 & Lee et al., 2015), it is feasible 
that HIF-2α interaction with proteins associated with telomeres could partially explain the 




Investigating the proteins which constitute these telomere associated GO annotations show 
they consist of identical proteins: RUVB like AAA ATPase’s and 6 Chaperonin containing 
TCP1 subunits (2, 3, 5, 6, 7, 8). The latter are components of the TRiC complex which has 
been shown to regulate PHD3 specifically (Masson et al., 2004). However, PHD3 was not 
identified as a HIF-2α binding partner here, thus the PHD3-HIF-2α association cannot be 
blamed for the HIF-2α-TRiC identification.  
 
4.11. Label Free Quantification analysis of binding 
aaaapartners  
Due to experimental size and setup, label based quantification was not appropiate. 
Therefore a label free approach was used to quantify binding partner fold changes induced 
by O2 tension. As discussed in the introduction (Section 1.1.18.1) Label Free Quantification 
(LFQ) is less accurate than labelling approaches as samples are prepared and analysed 
independently of each other, hence experimental error and variation between runs can 
impact the precision and accuracy of protein quantification (Bantscheff et al., 2012 & 
Bantscheff et al., 2007). Therefore LFQ approaches are reliant on normalisation against 
‘housekeeping proteins’ (Välikangas et al., 2018). However, hypoxia induces large effects in 
gene expression of many house keeping genes (Caradec et al., 2010), that are used as 
housekeeping proteins, combined with IP specifically enriching a subset proteins from the 
proteome in an unknown manner (and thus may include common housekeeping proteins), 
these approaches are not necessarily adequate here. 
 
MaxQuant is an open source software that allows the LFQ analysis of such data. Critically, 
MaxQuant determines the summed protein intensities initially to identify proteins that 
minimally change between conditions, which are used to normalise data to in a process 
termed delayed normalisation (Cox et al., 2014 & Cox et al., 2011). Perseus, also open 
source software, has been designed to aid the extraction of required information from 
MaxQuant outputs and aid in visualisation with a range of tools (Tyanova et al., 2016). 
 
LFQ was based on a minimum of 1 peptide identified at 1% FDR, calculating the area under 
the peak. Peptides were grouped by their unique protein identifier and were only retained 
in the data if they were observed in both replicates of either O2 tension. Peptide intensities 
were averaged to infer protein intensity and normalised to the fold change of HIFα 
proteins, as small abundance differences (<1.2 fold) were found between O2 tensions. Thus, 
the data contains all binding partner interactions, as filtered previously when using 
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Proteome Discoverer, with calculated protein intensities that are normalised to HIFα levels, 
available in Appendix 4.  
 
Importantly, MaxQuant matches peaks between conditions even if one condition lacks an 
identified MS/MS spectra, due to too low intensities. Missing values (undetected m/z 
ratios) are imputed with a fictional number, from a normally distributed dataset that is 
below the lowest intensity recorded from the MS/MS data. Theoretically this should result 
in statistically valid differences, however if intensities are variable and of low intensity it is 
possible that imputed values lead to the loss of significance. Hence data shown from the 
Proteome Discoverer pipeline (Figure 4.17), that requires MS/MS data, have many more 
proteins that are O2 dependently regulated, whereas LFQ data (Figure 4.22 & Figure 4.23) 
has statistically significant fold change differences of data that includes proteins identified 
in both O2 tensions. For example, it is feasible to have a 10 fold change in protein intensity, 




Figure 4.22: LFQ analysis of HIF-1α binding partners in response to O2 tension.  
LFQ was performed using MaxQuant, based on a minimum of 1 peptide identified at 1% FDR in both replicates 
of either O2 tension, with match between runs applied. Peptide intensity was measured by the area under the 
peak and all peptide intensities averaged for protein intensity. Missing intensities were imputed from a normal 
distribution. Protein intensities were normalised to HIF-1α protein intensity. P-values were determined using a 
Students 2-sample t-test. Plot is of –Log10(P-Value) against Log2(fold change), where positive values are enriched 
in 1% O2 and negative values enriched in 21% O2. Dotted lines are at a P-value <0.05 and 2- Fold enrichment. 
Points coloured red are significant at P-value <0.05. Labelled points are significant at P-Value <0.01 and have a 





1% O2 21% O2 
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Figure 4.23: LFQ analysis of HIF-2α binding partners in response to O2 tension.  
LFQ was performed using MaxQuant, based on a minimum of 1 peptide identified at 1% FDR in both replicates 
of either O2 tension, with match between runs applied. Peptide intensity was measured by the area under the 
peak and all peptide intensities averaged for protein intensity. Missing intensities were imputed from a normal 
distribution. Protein intensities were normalised to HIF-2α protein intensity. P-values were determined using a 
Students 2-sample t-test. Plot is of –Log10(P-Value) against Log2(fold change), where positive values are enriched 
in 1% O2 and negative values enriched in 21% O2. Dotted lines are at a P-value <0.05 and 2- Fold enrichment. 
Points coloured red are significant at P-value <0.05. Labelled points are significant at P-Value <0.01 and have a 
fold change of >2. Point size is scaled to the number of peptides identifying a protein. 
 
As suggested, the number of binding partners that are significantly differentially IP’d is 
lower than the Proteome Discoverer pipeline to identify O2 dependent binding partners. For 
example, Proteome Discoverer identified >300 binding partners specific to HIF-1α in 1% O2 
1% O2 21% O2 
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only, compared to <150 identified with LFQ at a P-value <0.05. Interestingly, LFQ shows that 
some binding partners do have very dramatic fold changes induced by O2 tension. For 
example the fold change of greatest statistical significance for HIF-1α (~80 fold, P-value = 
~1x10-7) is ANKRD34B. Greater fold changes do exist, for example HSPA5 (also known as 
BiP) with >1000 fold change between O2 tensions, however investigating the data shows 
both 21% O2 replicates resulted in no identified peptides and are thus has imputed values. 
Therefore, HSPA5 is a true hypoxia regulated binding partner, interesting considering its ER 
specific localisation. 
 
Brief investigation of this LFQ data identifies interesting fold changes from a PTM 
standpoint. VCPIP is a deubiquitinating enzyme (DUB), known to be important in mitosis 
and golgi assembly (Wang et al., 2004), which bound HIF-1α 5 fold greater in 21% O2 than 
1%; a surprising observation considering the role of ubiquitination and degradation. HIF-2α 
binding partner shows an inverted ubiquitination protein associated binding partner 
pattern, with the significantly increased intensities of ubiqutinating enzymes LTN1 and 
HUWE1 in 1% O2, by  ~10- and ~ 4- fold respectively.  Therefore, these data suggest very 
different roles of ubiquitination in HIFα isoform regulation. 
 
4.12. Protein kinase binding partners of HIFα 
As we were particularly interested in phosphorylation as a PTM, we searched the DAVID 
data output by kinases. The kinase data was then filtered down for protein kinases 
specifically (Table 4.20), as the datset contained nucleotide, lipid and sugar kinases as well 
as kinase interacting proteins, such as NEMO. A total of 14 and 19 proteins kinases were 
identified for HIF-1α and HIF-2α respectively. This is perhaps not surprising given the 





























































































































































































Table 4.20 clearly shows that the HIFα binding kinome is influenced by O2 tension, with the 
majority of kinases only identified in a specific O2 tension. This is partly unexpected 
considering the phopshorylation maps of both HIFα isoforms (Figure 4.3) did not differ 
greatly between O2 tensions. However, as discussed, it is likely that some kinases that 
phosphorylate HIFα have not been identified due to their transient nature. Importantly, it is 
impossible to decipher whether the identified kinases are directly binding to HIFα proteins 
or are indirectly immunoprecipitated through a secondary binding partner. 
 
The identification of tyrosine specific kinases is of interest since no tyrosine 
phosphorylation sites were identified from our mass spectrometry analysis. It is possible 
that the level of tyrosine phosphorylation is below the limit of detection for the 
methodology or, alternatively, an indication that HIFα is localised with these kinases in a 
‘primed’ state for the correct signal to enable a rapid response. Additionally, TiO2 is known 
to have limitations in terms of phospho-tyrosine identification, therefore a more targeted 
approach would be useful for these investigations using phospho-tyrosine specific 
antibodies for secondary IPs (Lombardi et al., 2015). Whilst some kinases identified have 
previously been shown to phosphorylate the HIFα proteins, including: MTOR (Land et al., 
2007), GSK3β (Flügel et al., 2007) and CDK1 (Warfel et al., 2013), the majority of the kinases 
identified are novel interactors of HIF-1α and HIF-2α. 
 
All of the HIF-1α 1% O2 only identified kinase interactors were also identified as HIF-2α 1% 
O2 only binding partners. Of the 21% O2 only HIF-1α kinases, both STRAP and MAP2K3 were 
also identified as HIF-2α binding partners, however only in 1% O2. AURKA and GSK3β were 
the only kinases specific to HIF-1α, both identified in 21% O2. Although conflicting, a 
transcriptional relationship has been shown between HIF-1α and AURKA, yet no interaction 
or phosphorylation has been found (Cui et al., 2013 & Fanale et al., 2013). GSK3β has been 
shown to multiply phosphorylate HIF-1α within the ODDD, ultimately leading to protein 
degradation, independently of proline hydroxylation and O2 tension (Flügel et al., 2007, 
Flügel et al., 2012, Cassavaugh et al., 2011 & Mottet et al., 2003), therefore its HIF-1α only 
identification could potentially explain some of the stability differences between HIF-1α 
and HIF-2α. 
 
The HIF-2α specific kinase interactors identified are all novel. Interestingly, PLK1 was 
identified in this study, with the PLK3 isoform previously shown to phosphorylate HIF-1α at 
S657, although HIF-2α was not investigated in this published study (Xu et al., 2010). Here 
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we show that, using HIFα isoform sequence alignments, the known PLK3 dependent HIF-1α 
S657 phosphorlyation site aligns to the novel HIF-2α T626 site, therefore could suggest the 
phosphorylation site for the PLK1 kinase identified. 
 
MET (Rankin et al., 2014 & Vanichapol et al., 2015), NEK7 (Korgaonkar et al., 2008), EGFR 
(Franovic et al., 2009 & Alam et al., 2016) and GAK (a CDK5 associated protein, Herzog et 
al., 2016) are all kinases essential for mitotic cell cycle progression that have been linked as 
target genes of the hypoxic response as part of a feedback loop. None of these kinases have 
been implicated in HIFα regulation, rather identifying expression level changes of stated 
kinases in response to hypoxia.  
 
4.13. Known binding partners  
The current main regulatory pathways for HIFα regulation is the O2 dependent degradation 
and inactivation pathway and transcriptional complex formation, consisting of 7  proteins: 
PHD1-3 (EGLN1-3), FIH-1, HIF-1β and p300/CBP (Ivan et al., 2001, Epstein et al., 2001, 
Bruick et al., 2001, Jaakkola et al., 2001, Semenza et al., 1992, Wang et al., 1995, Lando et 
al., 2002, Lando et al., 2002, Masson et al., 2003, Jiang et al., 1996, Arany et al., 1996 & 
Kallio et al., 1998)). Therefore we searched our data to investigate how these interactions 
change in response to hypoxia, simultaneously validating our findings. This is of particular 
interest as the experimental design used here overexpresses WT HIFα, rather than 




For HIF-1α, HIF-1β (ARNT) was found as a binding partner in both O2 tensions. LFQ however 
identifies, counter intuitatively, that HIF-1β was enriched >6 fold more in 21% O2 than 1% 
O2, and is significant to a P-value <0.05 (hence not labelled in Figure 4.22). For HIF-2α, HIF-
1β was found to be 1% O2 specific using the Proteome Discoverer analysis pipeline, yet 
MaxQuant showed a non-significant no fold change. The latter is likely due to variation in 
the data at 21% O2, with one replicate showing imputed data values (no peptides identified, 
hence removed as an interactor in Proteome Discoverer data) while the second replicate 
shows minimal differences to 1% O2 intensities. Thus the nature of O2 sensitive binding is 






FIH-1 was not identified, in any condition and for either HIFα isoform, although the ‘open’ 
PTM search identified HIFα asparagine hydroxylation. This could suggest highly transient or 
weak interactions of HIFα - FIH-1. 
 
4.13.1.3. p300/CBP  
p300/CBP was not identified in any HIF-1α sample.  For HIF-2α, p300/CBP showed different 
results, depending on the data analysis platform used (similar to HIF-1β). Proteome 
discoverer failed to identify p300/CBP in 21% O2, thereby classifying it as 1% O2 specific 
protein. However, MaxQuant detects >2 fold enrichment of p300/CBP in 21% O2 with a 
significant P-value (<0.01). In these circumstances, it is of greater significance to believe 
Proteome Discoverer data because they require MS/MS spectra and determination of 
primary peptide sequence to identify a peptide, where MaxQuant can, infrequently, 
mistake non-fragmented identical m/z ratios at ther MS1 stage as the same peptide, which 
may not be the case. 
 
4.13.1.4. PHDs 
The PHDs that have been shown to regulate both HIFα isoforms are translated from the 
EGLN genes. For HIF-1α EGLN1 (PHD2) was identified as a binding partner in both O2 
tensions. LFQ found that there was infact a 4 fold increase of EGLN1 in 21% compared to 
1% O2, as may be expected when O2 is a limiting factor. Interestingly, for HIF-2α EGLN1 was 
identified as a binding partner specific to 1% O2, through Proteome Discoverer, and 
supported by LFQ identifying >3 fold more EGLN1 in 1% O2 than 21% O2. The functional 
importance of this is unknown, however would suggest that in early hypoxia HIF-2α may 
experience an increased rate of proline hydroxylation. HIF-1α IPs did not identify any other 
interacting EGLN proteins, likely due to their involvement with rapid HIF degradation. 
Similarly, EGLN2 (PHD1) was not detected by HIF-2α IPs. EGLN3 (PHD3) was identified using 
MaxQuant, however there was no significant quantitative fold change dependent on O2 
tension observed. 
 
Interestingly, searching for prolyl hydroxylases using DAVID identified multiple other 
proline hydroxylases as novel interactors of HIFα proteins, including: Prolyl 4-hydroxylases 
1, and 2 (procollagen-proline, 2-oxoglutarate-4-dioxygenases), Protein Disulfide isomerase 
(Prolyl 4-hydroxylase subunit beta) and Prolyl 3-hydroxylases 1, 2 and 3 (Leprecans), 
referred to by their gene names (P4HA1, P4HA2, P4HB, P3H1, P3H2 and P3H3) from now. 
Although P4HB is a protein disulfide isomerase, and not a proline hydroxylase, it is an 
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essential component of the P4HA1/2 complexes which result in proline hydroxylation. Thus, 
P4HB acts as supporting evidence for the correct identification of these additional proline 
hydroxylases. 
 
P4HA1/2 are localised to the endoplasmic reticulum and hydroxylate proline residues at 
position 4 of the proline side chain (Pihlajaniemi et al., 1991 & Myllyharju, 2003). Their 
primarily known for their function in hydroxylating collagen proteins. However, P4HA1/2 
have been shown to hydroxylate other proteins at conserved A-P-G motifs too, such as 
prion proteins and Argonaute 2 (Gill et al., 2000 & Qi et al., 2008), although this motif is not 
present in either HIFα isoform. HIF-1α has been shown to increase the expression of the 
P4HA1/2 genes in response to hypoxia, which in turn can act as a positive feedback loop to 
promote HIF-1α stability, by limiting the availability α-ketoglutarate, an essential cofactor 
for the EGLN proteins (Epstein et al., 2001, Gilkes et al., 2013 & Xiong et al., 2018). We 
found that HIF-1α had ~6 fold more P4HA2 enriched in 1% O2 than 21% O2, (P-value <0.05), 
while PHB had no fold change and P4HA1 was not identified. For HIF-2α a similar pattern 
was observed with ~4 fold more P4HA2 enriched in 1% O2, while both P4HA1 and P4HB 
were found to have no fold change induced by O2 tension. 
 
P3H1/2/3 hydroxylate proline residues at position 3 of the side chain of Proline residues. 
P3H1 is localised within the ER and basement membrane of cells, while P3H2/3 are both 
localised within the golgi. P3Hs are much less studied in comparison to the PHDs and 
P4HAs, however are known to be highly specific in their hydroxylation of collagen isoforms 
(Vranka et al., 2004, Hudson et al., 2013 & reviewed by Gorres et al., 2010). 
 
4.14. Discussion 
The data presented in this chapter are the first known discovery proteomics analysis to map 
O2 dependent PTMs and binding partners of full length HIFα isoforms from human cells. 
Previous studies have used targeted proteomics approachs and/or recombinant or 
overexpressed fragments of the HIFα proteins to identidy single PTMs from in vitro assays. 
Besides the very low abundance of HIFα proteins in human cells, their primary sequence 
makes mass spectrometry analysis, by canonical tryptic digestion, data limiting; with 
maximal sequence coverage of ~35%. We were able to achieve >90% sequence coverage of 
the HIFα proteins by combining data from different protease digests, a process not 
commonly applied to proteomics due to the cleavage sites of different proteases increasing 
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the chance for 1+ charge state peptide ions, which are suboptimal for MS/MS based 
primary sequence determination. 
 
Although an open PTM search was performed to identify any PTM, the specific focus of this 
study was on phosphorylation, primarily due to the availablity of phospho-peptide 
enrichment strategies from the background of all unmodified/alternative PTM peptides and 
the known roles of phosphorylation in regulating HIFα proteins. All phosphorylation data 
were obtained using an optimised high sensitivity, high resolution MS/MS method to 
maximise peptide fragmentation and phosphorylation site localisation. Phosphorylation 
localisation from MS/MS data was analysed using a statistical software tool (ptmRS), to 
predict the confidence of site localisation. In total, ~50 different PTMs were identified on 
both HIF-1α and HIF-2α, with ~25 of these being phosphorylation at different sites. It is 
important to consider that the level of overexpression required for this in-depth PTM 
analysis may result in artifactual PTMs being identified. Whilst this strategy maintains the 
PHD-VHL pathway, although the rate of HIFα synthesis outweighs the degradation rate, 
therefore could be argued more biologically relevant than proline hydroxylation mutants 
that are traditionally used for O2 independent protein expression. 
 
Combining identified PTMs with phylogeny analysis, I set out to identify potentially 
functionally important PTM sites; highly conserved regions are thought to be more likely to 
have important regulatory roles. Similarly, sites of phopshorylation that show variation 
specifically to negatively charged residues could reflect an important role that has evolved 
to be signalling activated, where residues that are uncharged and non-phosphorylatable 
could reflect the loss of a signalling pathway.  
 
However, with previous knowledge, the phylogeny analysis can also be hypothesis driven. 
For example species that are hypoxia tolerant vs sensitive may have sequence variation to 
aid in adaptions. This is supported by recent studies by anthropologists, where humans that 
have been living at high altitudes for many generations (Tibetan, Andean) have a significant 
enrichment of mutations in HIF-2α. However these were largely within intronic regions 
(Simonson et al., 2010, Yi et al., 2010 &  Beall et al., 2010). Interestingly, our cancer 
genomics database mining also found that the HIFα genes were very rarely mutated (both 
in exonic and intronic regions), although HIFα expression levels and downstream targets 
were generally increased. This suggests that regulatory proteins of HIFα are more prevalent 
to mutation and in turn alter HIFα function, as known for the EGLN genes (Simonson et al., 
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2010 & Bigham et al., 2009). This study also compared HIF-1α and HIF-2α PTMs to 
potentially identify sites/patterns, which could aid in explaining the functional differences 
between isoforms. 
 
4.14.1. PTM data 
It is clear from Table 1.2 & Table 1.3 that the majority of published PTMs of HIFα proteins, 
including phosphorylation, were not identified in this study. There are numerous potential 
reasons for this: 1) past studies generally using in vitro assays and recombinant HIFα 
fragment based approaches which are inherently suspectible to artefacts. 2) HIFα 
regulation, including O2 dependent regulation, is highly dependent on cell type (Bracken et 
al., 2006), thus the use of a single cell line, single hypoxic O2 tension and single incubation 
time could all affect identified PTMs. 3) Only phosphorylation was analysed in depth. Other 
PTMs that may occur at low frequencies may not be identified if they are below the limit of 
detection in these analyses. Interestingly, the main functional domains that share minimal 
sequence homology, thus can be argued to differentiate, HIF-1α and HIF-2α  have distinctly 
different PTM profiles. 
 
4.14.1.1. ODDD 
It is obvious from Figure 4.5 that the ODDD of HIF-1α is hyperphosphorylated, with a total 
of 15 different phosphorylation sites identified. Interestingly, 7 of these phosphorylations 
are O2 dependent and only occur in 21% O2, particularly curious considering the process of 
phosphorylation does not require O2 as a cofactor, like hydroxylases. Additionally, 
considering there are a total of 12 O2 dependent phosphorylation events for HIF-1α, this 
means that 67% of the O2 dependent phosphorylation sites identified are located within the 
ODDD. Overall, this may reflect on three possibilies: 1) the role of phosphorylation in the 
canonical PHD degradation pathway, where phosphorylation may promote PHD association 
and degradation. 2) The complexity of alternative degradation pathways at play, or 3) 
kinases that are O2 dependently regulated have function in the PTM of HIF, for example 
AMPK kinase (Shao et al., 2014 & Hwang et al., 2014). 
 
As a crystal structure of the ODDD is unavailable, sequence based ab initio modelling was 
performed on the region encompassing the densest, and O2 dependent, phosphoylation 
region (475-535). This revealed that all O2 independent sites are internally facing and in 
such close proximity to negatively charged glutamic acid residues (<5 Å) that space-charge 
effects will likely lead to structural rearrangements. Modelling also highlighted that O2 
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dependent phosphorylations are all externally facing, which could potentially act as docking 
sites for binding partners and secondary functions, such as promoting degradation. 
Unfortunately, our data could not decipher whether these PTMs co-exist or are mutually 
exclusive, therefore it is possible that O2 dependent PTMs are mutually exclusive to O2 
independent. Hence, it will be interesting to investigate how mutational analysis will affect 
HIF-1α function. However, this may require mutation of multiple sites for functional effects 
to be observed. To limit the number of mutations required, a ‘Middle-Down’ MS approach 
could be adopted, where HIF-1α is minimally digested, in order to determine the co-
existance of phosphorylation sites on larger peptides (~10 kDa). 
 
Conversely, HIF-2α has few phosphorylation sites within the ODDD, a total of 5, with only 
one O2 dependent site. Therefore, if phosphorylation is linked to protein degradation, it is 
conceivable that the differences in protein stability between HIF-1α and HIF-2α at 21% O2 
could be explained by the different phosphorylation status of the HIFα ODDD. 
 
4.14.1.2. N-Terminal Transactivation Domain 
Before obtaining PTM data, I hypothesised that the NTAD would undergo extensive PTM 
changes due to its role in coordinating HIFα specific gene targeting. However, the opposite 
was observed, where a distinct lack of all PTMs was found in this domain, even though 
~100% of the NTAD was observed by MS for both HIFα isoforms. Infact, HIF-1α  only had 1 
PTM identified: K532 methylation, and HIF-2α had 4 phosphorylations identified: T517, 
T528, S543 and T559, making the NTAD the least dense PTM containing domain of both 
HIFα isoforms. Since the NTAD is the region of least sequence homology between HIFα 
isoforms, it is likely sequence/structural differences within this domain explains the 
differential gene targeting seen by HIFα isoforms, rather than PTM status. However, future 
more in-depth analyses of different PTMs may highlight a significant role of PTMs in the 
NTAD, as PTMs could be at low stoichiometric levels, considering the multiple different 
PTMs of K532 acetylation, ubiquitination and methylation (identified here). 
 
4.14.1.3. Proline hydroxylation sites 
Potentially the most interesting observation from the PTM discovery data is the 
identification of HIF-2α phosphorylation sites in 21% O2 that neighbour all of proline 
hydroxylation sites, including a potentially novel site (P576). The proline hydroxylation sites 
are within highly conserved domains between HIFα isoforms, and consists of an LAP motif. 
However, HIF-2α has single amino acid variations in both of the canonical proline 
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hydroxylation sites that are phosphorylated: (HIF-1α/HIF-2α), P402-A403/P405-T406 and 
P564-M561/P531-T528. Therefore it is feasible that the size and charge differences of HIF-
2α phosphorylated threonine residues, to HIF-1α alanine and methionine residues, could 
explain the 21% O2 protein stability observed by HIF-2α; due to blocking of PHD binding, 
thus removing the hydorxylation and degradation pathway. This would be fairly easy to 
investigate through mutational analysis and western blotting techniques. However, as 
mentioned, shotgun proteomics approaches mean it is undeterminable whether each site 
co-exists or are mutually exclusive, therefore further investigation is required such as by 
‘Middle-down’ approaches. 
 
4.14.2. Binding partner analysis 
The binding partner discovery work presented here will be highly insightful for a 
targeted/hypothesis driven approach. The discovery analysis performed by this study has 
generated a huge quantity of novel data for potential binding partners that may regulate 
HIFα isoforms both O2 dependently and independently. However, IP makes it is impossible 
to determine whether these identified binding partners are the result of direct or indirect 
interactions to the HIFα protein. Thus, without a specific characteristic/hypothesis to filter 
identified proteins, data analysis is difficult to draw meaningful conclusions from. Future 
studies investigating binding partners could easily adopt a cross linking and MS analysis 
strategy to identify peptides that crosslink, and thus must interact (Sutherland et al., 2008), 
to determine direct and indirect binding partners. Additionally, the data presented here 
could be used in network mapping to investigate how proteins interact with each other 
through known interactions (Szklarczyk et al., 2015, Szklarczyk et al., 2017 & Shannon et al., 
2003). Global categorisation, through GO annotation enrichment, and O2 depenecy of 
binding partners was investigated in this study. 
 
4.14.2.1. GO annotation enrichment 
Although it is clear that O2 tension has a significant effect on the binding partner profile of 
both HIFα isoforms, with ~66% of all HIF-1α proteins and a >10 fold increase of HIF-2α 
proteins, GO annotation enrichment analysis was relatively unuseful. The GO annotations 
categorise proteins broadly, thus a single protein is part of multiple GO terms. Hence if a 
specfic protein complex is significantly enriched it can result in multiple different GO 
annotations that consist primarily of identical proteins, as observed here with proteasomal 
proteins. Combined with the strict filtering applied, the vast majority of GO annotations 
that were plotted for Figure 4.18 to Figure 4.21 are identical, yet categorically contain 
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different proteins due to analysis of 21% or 1% O2 only binding partners. Hence, although 
useful for categorising proteins based on function/pathway, manually mining all GO 
annotations (both significant and non-significant) for specific queries will be of greater use, 
as done for kinases and mitochondrial proteins here. 
 
4.14.2.2. O2 dependent protein binding 
Two separate approaches were applied to identify binding partner differences induced by 
O2 tension: an MS/MS driven identification and filtering approach (Proteome Discoverer) 
and a label free quantification (LFQ) approach (MaxQuant). Both strategies have their own 
advantages and disadvantages, with Proteome discoverer providing greater confidence in 
O2 tension classification, by requiring MS/MS and determination of primary sequence, 
while MaxQuant is able to analyse the overlap group (both O2 tensions) for statistically valid 
fold changes. Therefore, further analysis of data can be done in combination of both O2 
dependent outputs and GO annotations when extracting information. This identified some 
interesting observations. 
 
4.14.2.3. Mitochondrial proteins 
It is clear from our data that there is significant enrichment of mitochondrial proteins for 
both HIFα isoforms. It could be argued that upon organelle lysis mitochondrial proteins are 
Co-IP’d in a HIFα specific manner, hence not removed by background subtraction although 
endogenously do not interact, thus are artefactual in nature. However, recent publications 
have shown that HIF-1α may have a sub-population of total protein localised into these 
sub-cellular compartments, although functional aspects are unknown. Therefore, in 
combination of data provided here, it will be interesting to see how the field develops. 
Since many transporter proteins into mitochondria are enriched in 1% O2, it could be 
theorised that HIFα is transported into the mitochondria to upregulate genes of the 
oxidative phosphorylation pathway in an attempt to maximise the efficiency of the limited 
available O2.  
 
4.14.2.4. Kinases 
As a specific focus of this chapter was on phosphorylation, we investigated bound protein 
kinases. However, as stated previously, it is unknown whether these directly bind HIFα or 
are secondary indirect binding partners. Due to the transient nature of kinase function, it is 
likely that many kinases that phosphoylate HIFα will not have been identified. The majority 
of kinases identified are novel HIFα interactors and are generally cell cycle regulators, 
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suggesting an important role of HIF in correct cell cycle progression. It is known that HIF is 
important for cell cycle progression (Goda et al., 2003, Koshiji et al., 2004, Kaidi et al., 2007, 
& Hubbi et al., 2013), however the exact mechanism of regulation is unknown. Therefore, 
the identification of many cell cycle dependent kinases could aid in unravelling this system. 
 
4.14.2.5. PHDs 
Considering the primary regulatory pathway of HIFα proteins, through proline 
hydroxylation, it is highly interesting that we identify novel interactions with additional 
proline hydroxylase enzymes (P4HA1, P4HA2, P4HB, P3H1, P3H2 & P3H3). The biological 
significance of this is unknown, especially considering they are ER/golgi specific localised, 
however the identification of novel proline hydroxylation events in HIF-2α (P137 and P206) 
could suggest a functional importance. 
 
4.14.3. Concluding remarks 
Overall, this chapter contains a significant quantity of novel data for HIF-1α and HIF-2α O2 
dependent and independent regulation, through PTM and binding partner based regulatory 
pathways. However, it is important to consider that the HIF overexpression used might 
have resulted in some artefactual data. We strongly argue that this dataset is the most 
biologically relevant yet, compared to published studies which use fragment based 
approaches, in vitro assays or HIFα proline mutants that are oxygen insensitive, bypassing 
the main regulatory pathway. With the identification of these vast numbers of PTMs and 
binding partners future studies will be needed to validate the findings on endogenous HIFα 
proteins (if suitable antibodies are available), potentially in combination with targeted MS 
techniques (that can result in 100 fold increases to sensitivity). Future studies could also 
investigate how PTM status may change as a function of the severity of the hypoxic 
conditions within the same cell line, or different cell lines, to investigate the full complexity 
of HIFα regulation. 
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Following my discovery of multiple new PTMs, the next step is to functionally characterise 
some of these potentially interesting PTMs, determined from the analyses in Chapter 4, to 
investigate their roles as HIF regulators. Since there was a specific focus on 
phosphorylation, and robust statistical analysis was performed to aid in the confident 
localisation of this PTM, sites of phosphorylation were chosen for initial characterisation 
experiments. 
 
Because phosphorylation is generally dynamic and the regulators that promote/inhibit 
phosphorylation of these identified sites are currently unknown, it is difficult to investigate 
the role of the PTM of interest endogenously. Additionally, phosphorylation is likely to 
occur at a stoichiometric ratio below the levels of total protein (Mann et al., 2002), thus 
complicating the functional analysis and compromising the ability to draw conclusions. Site 
directed mutagenesis (SDM) is a method used to introduce a site-specific mutation into 
DNA that can result in an amino acid change. Using this approach, it is possible to mutate a 
PTM site into residues that mimic or prevent phosphorylation. Figure 5.1 shows an example 
of serine phosphorylation, which introduces a negative charge, hence mutation to aspartic 
acid (a permanently negatively charged amino acid) can mimic the functional characteristics 
of the protein in a completely phosphorylated state. Conversely, mutation of the serine to 
an alanine removes the potential for phosphorylation at a specific site, hence allowing 
investigations of the protein in a completely unphosphorylated state.  
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Figure 5.1: Schematic view of Serine phosphorylation and phospho –mimetic and –null mutations.  
All amino acids are labelled and boxed region highlights the functional group of amino acids. 
 
5.2. Aims:  
The aims of this chapter was to functionally characterise a selection of phosphorylation 
sites identified from Chapter 4. A site-directed mutagenesis (SDM) protocol had to be 
implemented, which could reliably mutate single sites while limiting the risk of random 
mutations through PCR amplification. Once the SDM protocol was optimised, mutational 
strategy used the traditional phospho -mimetic (serine->aspartic acid, threonine->glutamic 
acid) and -null (serine/threonine->alanine) mutations, unless there was a guided mutation 
inferred from evolutionary analysis (Chapter 4). Analogous mutational analysis of HIFα is a 
common strategy to investigate regulatory mechanisms (Table 1.2 & Table 1.3, example 
Mylonis et al., 2008). Once mutants were created, an initial functional screening of mutants 
was performed through a HIF-dependent luciferase-based transcriptional assay. We further 
characterised, Serine-31 (S31) mutations by a range of biochemical techniques to identify 





5.3. Site Directed Mutagenesis (SDM) 
aaaioptimisation:  
SDM is a method used to mutate specific DNA bases, which can result in an amino acid 
substitution in the protein sequence (missense mutation). The most common SDM 
technique uses overlapping primers that contain the mutation, thus creating full-length 
mutant plasmid in a single PCR reaction (Quikchange, Agilent, Liu et al., 2008). However, 
even the highest fidelity polymerases can result in random mutagenesis. A random 
mutation rate of ~0.1% is known for the KOD polymerase used here (McInerney et al., 2014 
& Manufacturers notes). Thus, PCR amplification of the whole HA-Clover-HIFα plasmids (~9 
kBp) could potentially result in 9 random mutations per SDM experiment. These mutations 
are incorporated randomly within the plasmid, therefore it is likely that different random 
mutations will occur for each different SDM plasmid. Problematically, the random 
mutagenesis could occur within the plasmid regulatory regions, such as the strong CMV 
promoter where single base pair mutations can result in large gene expression level 
changes (Alper et al., 2005). Thus, random mutagenesis could significantly affect protein 
expression levels, resulting in the false conclusion that the mutation of interest has a 
protein stability role. Hence, this SDM strategy would require sequencing of the whole 
plasmid to ensure that only the desired mutation is present. 
 
MEGAprimer is a SDM technique that limits the PCR reaction length to the gene of interest 
only, depicted in Figure 2.4. Initially, a primer in the flanking gene region and a mutagenic 
primer are used in a PCR reaction to create a mutated DNA fragment (the MEGAprimer). 
The mutated MEGAprimer is then used with a second flanking primer to amplify the full 
length gene, which is then reintegrated into the vector backbone by restriction digest and 
ligation (Sarkar et al., 1990). We created flanking primers that allow SDM independently of 
HA-Clover-HIFα gene, but rather dependent on the mutagenic primer created. Because the 
vector backbone comes from the WT digested plasmid there is no risk of random 
mutagenesis between SDM plasmids outside of the PCR fragment, hence sequencing is only 
required of the HIFα gene (~2.5 kBp).  
 
Using the optimised SDM protocol, I made phospho –mimetic and –null mutations for HIF-
1α: S31 and S786, and HIF-2α: S345, T528 and S581. For serine and threonine 
phosphorylation, mimetic mutations to aspartic acid and glutamic acid were used 
respectively, due to the extra carbon in the side chain of threonine and glutamic acid to 
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mimic space-charge effects. For all phosphorylation null mutations, except S31, Alanine was 
used as a non-charged nor modifiable analogue. In the case of S31, evolutionary analysis 
identified that all bony fish (Osteichthyes) had a non-phosphorylatable glycine residue at 
position 31 (Chapter 4, section 4.7.1.1), thus serine 31 was mutated to glycine. Once 
cloned, all plasmids were sequenced through the Clover and HIFα genes to ensure that only 
the mutation of interest was present. 
 
5.4. HIF dependent luciferase assay 
Due to the number of mutants and conditions to be tested (2 different mutants for all 5 
sites selected, plus WT and endogenous controls at 1% O2 and 21% O2) we initially used a 
HTP HIF dependent luciferase assay to measure transcriptional function. As HIFα proteins 
are canonically regulated by stability, it is important to note that this assay cannot provide 
information on whether the transcriptional effects observed are due to alteration of 
transcriptional activity, transactivation or protein stability. The assay uses a plasmid 
encoding the luciferase gene under the regulation of three HRE repeats (HRE-Luciferase, 
Coulet et al., 2003). Therefore, the luciferase gene is only transcribed and translated into 
protein if active HIF dimers are present. Thus, luminometry readings of the mutants, in 
comparison to the WT counterpart, allows an initial assessment of the functional effects 
induced by a mutation. 
 
Cells were transfected as described for HRE-luciferase assays using the ‘low’ expression 
level model designed to maintain O2 dependent regulation (Chapter 3). As phosphorylation 
sites under investigation were identified at a 4 hr time point in either 1% or 21% O2, these 







Figure 5.2: Luciferase transcriptional assay of HIFα SDM mutants.  
Cells were co-transfected with 0.5 µg HRE-Luciferase plasmid (Addgene #26731) alongside 50 ng of the stated 
HA-Clover-HIFα plasmid (low expression level model) per 200,000 cells in a 35 mm plate. Cells were incubated 
with transfection mix for 18 hr before media change and incubating in 1% or 21% O2 for 4 hr. Cells were then 
lysed and luminometry readings taken using a BMG Labtech FLUOstar Omega plate reader. Readings were 
normalised against luciferase working solution only readings. Data present for n=2 biological replicates +/- 
standard deviation. 
 
It is important to consider that for endogenous readings it is impossible to distinguish the 
relative effects of HIF-1α and HIF-2α without using knockdown controls. These readings 
were thus primarily used to ensure the assay and hypoxic incubation were working 
correctly. A clear observation from Figure 5.2 is that hypoxia induced an ~1.5 fold 
transcriptional increase of all HA-Clover-HIF-1α plasmids, whilst on HA-Clover-HIF-2α 
plasmids, hypoxia had a very mild transcriptional induction. For comparison, endogenous 
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HIF had an ~5 fold luciferase signal increase induced at 1% O2. The weak hypoxic induction 
of HA-Clover-HIF-2α plasmids could be a result of the low exogenous expression model 
saturating HRE-luciferase binding sites (similar to HA-Clover-HIF-1α at a high expression 
level Figure 3.12). However, this explanation is unlikely since WT readings for HA-Clover-
HIF-1α and HA-Clover-HIF-2α are <1.1 fold different, and a ~1.8 fold greater response is 
observed with HA-Clover-HIF-2α T528 mutants. Alternatively, this could suggest that the 
lack of hypoxic induction in early hypoxia could reflect HIF-2α specific characteristics, such 
as HIF-2α being known to become active in prolonged hypoxia (as reviewed by Koh et al., 
2012). 
 
Because this experiment was for preliminary screening to identify a specific mutant set to 
further focus on, only 2 repeats were performed, thus statistical analysis could not be done. 
From Figure 5.2, the HIF-1α S786 mutations had very little effect on transcriptional 
function, mimicking the WT control within a 1.15 fold difference at both O2 tensions. 
Conversely, the S31D phospho-mimetic mutation of HIF-1α dramatically reduced the 
transcriptional activity by ~5 fold, compared to the WT HIF-1α protein. However, the S31G 
phospho-null mutation is <1.2 –fold different to the WT HIF-1α controls. These data suggest 
that S31 phosphorylation inhibits the transcriptional activity of HIF-1α. Based on structural 
analysis (Figure 4.4), we hypothesised that this transcriptional inhibition could be due to a 
reduced ability of HIF-1α to bind DNA in a phosphorylated state, likely due to charge 
repulsion with the DNA backbone. 
 
A similar, but less pronounced, decrease in luciferase signal was observed with the HIF-2α 
S345D phospho-mimetic mutation compared to the WT HIF-2α (Figure 5.2). An ~40% 
decrease in luciferase signal was observed for S345D in both O2 conditions (Figure 5.2), 
suggesting a possible analogous role of phosphorylation at HIF-2α S345 to HIF-1α S31 in 
causing the decrease in transcriptional activity. However, based on structural analysis 
(Figure 4.8) we hypothesised that HIF-2α S345 phosphorylation might regulate 
transcriptional activity by the reduced ability to bind HIF-1β. 
 
Considering that the T528 and S581 mutations were selected based on their close proximity 
to the known proline hydroxylation site (P531) and a potentially novel hydroxylation site 
(P576), it is interesting that the mutation of these sites to either their phospho-mimetic 
(glutamic acid and aspartic acid respectively) or phospho-null (alanine) mutations both 
resulted in an increase in transcriptional activity by ~50%. Our initial hypothesis was that 
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phosphorylation at a site in such close proximity to the proline hydroxylation sites may 
block the function of PHD enzymes, thus increasing protein stability and luciferase signal. 
However, these data could suggest a dual role for the hydroxyl group of serine/threonine 
residues, for example, the unmodified hydroxyl group of the serine/threonine could be 
required for effective targeting of PHDs and subsequent proline hydroxylation. Hence, 
mutation to the phospho-null alanine residue also inhibits this degradation of HIF-2α, thus 
increasing luciferase signal. Where phosphorylation (aspartic acid/glutamic acid) prevents 
PHD binding, thus also increasing luciferase signal 
 
5.5. Exploring the mechanism of HIF-1α S31 
aaaiphosphorylation-induced transcriptional 
aaaiinhibition 
As stated, the luciferase assay, does not allow the determination of whether the observed 
results are because of direct transcriptional effects, or through alteration of protein 
stability or change in binding partners/transactivation. Therefore, we first determined 
whether S31 mutations affected protein stability Figure 5.3 (A)). Figure 5.3 (A) shows that 
there is no significant difference in protein stability between WT, S31G and S31D HA-
Clover-HIF-1α. Normalisation against the β-actin control shows that the S31D and S31D 
mutations are ~1.4 fold and ~1.2 fold more intense than the WT protein (based on 
densitometry analysis, data not shown). Hence the transcriptional inhibition of S31D is not 
















 Figure 5.3: Biochemical assessment of WT HA-Clover-HIF-1α and S31 phospho –mimetic (S31D) and -null 
(S31G) mutations.  




To check if transcriptional efficiency is chronically reduced by S31D mutation, rather than a 
transient effect, two strategies were employed: 1) A low expression model time course over 
24 hr of 1% O2 incubation (Figure 5.3 (B)) and 2) a large overexpression using the high 
expression model (Figure 5.3 (C)). Both Figure 5.3 (B) and (C) show conclusively that S31D 
dramatically reduces the luciferase signal, to levels comparative to the non-transfected 
endogenous control, while the S31G mimics the WT overexpression profile. For 
comparison, after 24 hr incubation at 1% O2 using the low expression levels, the HIF-1α WT 
and S31G proteins were ~5 fold greater, and significantly different, to the S31D mutation. 
The S31D mutant does not significantly differ from the endogenous control. Using the high 
expression level, the HIF-1α WT and S31G proteins resulted in an >50 fold increase in 
luciferase response compared to the S31D. To ensure the S31D mutation had a 
physiological effect on endogenous target gene expression, Real-Time quantitative PCR (RT-
qPCR) was performed on the following hypoxia inducible genes: GLUT-1, PHD2 (EGLN1), 
VEGF and PHD3 (EGLN3) (Figure 5.3 (D)). Figure 5.3 (D) shows that the HIF-1α S31D 
mutation results in a statistically significant reduction in expression of both GLUT-1 and 
VEGF in comparison to the WT control (P-value <0.05), to levels that are comparable of the 
non-transfected control. However, no significant difference was observed in the mRNA 
levels of PHD2 and PHD3 with HIF-1α S31D compared to the WT control. 
 
Overall, the data presented here suggest that the phosphorylation of HIF-1α at position 
S31, inferred from S31D mutation, completely inhibits the transcriptional function of HIF-1α 
in a protein stability independent manner. However, the potential mechanism for the 
transcriptional inhibition is unknown and could be explained by: 1) the impairment of 
binding to known essential cofactors, such as HIF-1β. 2) The impairment of binding to a 
novel binding partner. 3) Differential localisation, such as nuclear exclusion, or 4) direct 
DNA binding inhibition through charge repulsion. These scenarios are explored below. 
 
5.5.1. Investigating S31 binding partners 
To investigate how the binding partners were altered by S31 phosphorylation (exploring 
both scenarios (1) and (2) above), the WT, S31D or S31G plasmids were expressed at the 
low expression level and immunoprecipitated for analysis of their binding partners(Figure 




Figure 5.4: Visual depiction of binding partner differences between HA-Clover-HIF-1α WT, S31D and S31G. 
IPs were performed using HeLa cells transfected with the low level expression model of indicated plasmid. Data 
represents binding partners only identified in both replicates post background subtraction. Numbers reflect 
total number of proteins in each segment, circles and overlaps scaled respective to number. A) Venn diagram of 
WT, S31D and S31G binding partners. B) Venn diagram of S31D and S31G binding partners. 
 
As Figure 5.4 (A) shows, ~70% of the total number of proteins identified were common 
between the WT, S31D and S31G HIF-1α proteins. A list of protein identifications for each 
HIF-1α protein is provided in appendix 5. Importantly, HIF-1β was identified as a binding 
partner for all HIF-1α mutants. Similar to the experiments presented in chapter 4, FIH-1 and 
CBP/p300 were not identified in any sample. Thus, it does not appear that the reduced 
transcriptional function of S31D is the result of failing to form the active transcription 
complex. 
 
Therefore, the data was analysed for potentially novel binding partner changes induced by 
phosphorylation. It is highly likely that the expressed WT HIF-1α protein will be in an 
unknown state of equilibrium between S31 phosphorylated and unphosphorylated protein 
forms. Thus, if S31 phosphorylation is responsible for promoting, or inhibiting, the 
interaction with an essential unknown binding partner, the WT dataset would preclude its 
identification. Hence a focused analysis was performed, comparing HIF-1α S31D and S31G 
binding partners only (Figure 5.4 (B)). Theoretically, direct comparison of the S31D and 
S31G will identify binding partner differences arising as a function of phosphorylation, 
allowing me to hypothesise the functional role played by phosphorylation. A list of all 






Table 5.1: Binding partner differences between S31D and S31G.  
Identifications were present in two biological replicates post background subtraction, using HeLa cells 










Figure 5.5: GO pathway enrichment analysis of S31D vs S31G.  
Identities from Table 5.1 used in DAVID GO annotation analysis, Biological process and Molecular function 
annotations filtered for only. A Fishers exact test was performed, plotted annotations are of a Benjamini-
Hochberg adjusted P-Value < 0.01. Left hand side = S31D only proteins identified, right hand side = S31G only 
proteins identified. 
 
Table 5.1 contains >150 different proteins. To identify functional protein categories and 
signalling pathways associated with these unique binding partners, the data were analysed 
through Gene Ontology enrichment analysis using DAVID (Figure 5.5, Dennis et al., 2003), 
as performed in chapter 4. Figure 5.5 shows that more functional categories were 
significantly enriched for in S31G IPs. However further investigation found that multiple 
annotations consisted of the same proteins and were categorically labelled as different GO 
terms, similar to previously discussed in Chapter 4. Interestingly, S31G has three 
significantly identified annotations for GTP related proteins (GTP binding, small GTPase 




(Table 5.2). These GO annotations, and related proteins, were not identified in S31D even 
when relaxing stringency of confidence. Thus, this data suggests that unphosphorylated S31 
(S31G) is associated with a GTP signalling cascade that is essential to trigger HIF-1α 
dependent transcription, and is blocked by S31 phosphorylation (S31D). 
 
Table 5.2: Identified GTP binding proteins that bind specifically to S31G, and not S31D.  
Table includes the UniProt accession code, Gene Name and description of protein. 
 
The downstream regulation post Ras signalling (reviewed by: Downward, 2003) includes 
many protein kinases known to influence HIF-1α activity, including ERKs (Minet et al., 
2000), GSK3β (Flügel et al., 2012) and mTOR (Land et al., 2007). Therefore, it is possible that 
a Ras-dependent pathway promotes HIF-1α dependent transcription through secondary 
phosphorylation sites. This possibility was not explored due to the poor sequence coverage 
by MS analysis in the neighbouring region of HIF-1α, as discussed in Chapter 4. Additionally, 
it is possible that the Ras-dependent signalling pathway that interacts with HIF-1α is 
indirect and results in the modification or transactivation of a novel HIF-1α binding partner, 
in turn promoting HIF signalling; these options remain to be explored. 
 
Although the binding partners comparison, between S31G and S31D mutants, revealed 
some interesting potential upstream signalling mechanisms, it did not provide a definitive 
explanation for the functional mechanism underpinning the transcriptional inhibition 
induced by a phospho-mimetic mutant of S31 phosphorylation (S31D). The role of S31 







5.5.2. S31 phosphorylation and Nuclear localisation 
The third hypothesis was explored by confocal microscopy to visualise the correct nuclear 
localisation (Figure 5.6 (A)). For nuclear localisation studies, the high expression level of HA-
Clover-HIFα was used for WT, S31D and S31G plasmids. Figure 5.6 (A) shows that, whilst 
highly overexpressed, the WT HIF-1α protein remained exclusively expressed in the nucleus 
as a homogenous distribution. The same observation was observed for both HIF-1α S31D 
and S31G mutants, thus mis-localisation of the S31D phospho-mimetic mutant is not 
















Figure 5.6: Nuclear localisation and DNA binding efficiency characteristics of HIF-1α S31 WT, S31D and S31G. 
HeLa cells transfected with either WT, S31G or S31D HA-Clover-HIF-1α plasmids at the high expression level. A) 
Nuclear localisation analysis, Microscopy analysis at 63X magnification with images taken at brightfield and 488 
nm fluorescence excitation using a Zeiss LSM 780 microscope. B) DNA binding efficiency, determined through 
CHIP and RT-qPCR analysis of the KDM2A HRE promoter. Ct(NT) = Negative control using the HA-Clover only 
plasmid. A Student t-test was performed, * = P-value < 0.01, NS = not significant. Data of n=3 biological 
replicates +/- standard error. Performed by Dr Michael Batie, from the Prof Rocha group. 
 
5.5.3. Direct DNA binding inhibition 
The ability of WT, S31D and S31G HA-Clover-HIF-1α proteins to bind DNA was measured by 
Chromatin Immunoprecipitation (CHIP) (Figure 5.6 (B)), experiments performed by Dr 
Michael Batie, from the Prof Rocha group). The high expression level of HA-Clover-HIF-1α 
was used to exacerbate functional differences observed, because it is known that the S31D 
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mutant protein maintains its transcriptional inhibition at high expression levels (Figure 5.3 
(C)). 
 
Analysis of the KDMA2 HRE promoter was used as a well-known HIF-1α regulated promoter 
(Batie et al., 2017), which works well for HIF-CHIP experiments. CHIP analysis (Figure 5.6 
(B)) shows that the WT HA-Clover-HIF-1α resulted in a significant ~4 fold greater DNA 
binding signal at the KDMA2 promoter than compared to the HA-Clover only (Ct(NT)), and 
anti-mouse, off-target antibody negative controls (P<0.01). The S31G mutant shows a 
similar DNA binding pattern as the WT, consistent with the luminometry and qPCR 
experiments, but exhibited large variability (Figure 5.6 (B)). The S31D mutation resulted in 
almost identical DNA binding signal to the negative control, and was significantly different 
to the WT plasmid (P<0.01). These data are consistent with the luciferase reporter assays 
and RT-qPCR data. Additionally, the DNA binding with HIF-1α S31D was not significantly 
different to either of the negative controls performed (HA-Clover only and anti-mouse IPs), 
highlighting how little DNA was bound to HIF-1α S31D. 
 
Overall, these data suggest that phosphorylation at S31, as determined using the S31D 
phospho-mimetic mutation. It was determined that S31D prevents active HIF dimers from 
binding to DNA, and therefore inhibits transcriptional activation, without affecting HIF-1α 
protein stability, the HIF-1α - HIF-1β binding interactions or nuclear localisation. Combined 
with the identification that the S31D mutant lacked GTPase proteins, it is possible that an 
unknown GTP dependent pathway has a role in promoting the association of HIF – DNA 
through an unknown mechanism, either directly or indirectly. 
 
5.6. Discussion 
In this chapter we used a SDM protocol to specifically create phospho -mimetic and –null 
mutants of identified phosphorylation sites from Chapter 4. Of the mutants generated, the 
HIF-1α S31 phospho-mimetic mutation (S31D) exhibited the greatest disruption to a 
luciferase based transcriptional assay, and thus was further characterised. S31 has 
previously been identified as a phosphorylation site for PKA when using recombinant HIF-
1α fragments in an in vitro kinase assay (Bullen et al., 2016). Using a S31 phospho-null 
mutation of the fragment, to an alanine residue, Bullen et al., 2016 determined that there 
were no effects on protein stability when expressed in human cancer cells lines, and this 
mutant was not investigated further. This is in agreement with our data which show that 
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the stability of full-length HIF-1α is not affected by the S31G phospho-null mutation. 
However, data presented in Chapter 4 suggests a potential role in DNA binding, thus 
regulating transcription in a manner that is independent of protein stability, this was not 
investigated by Bullen et al., 2016. 
 
Interestingly, the phospho-mimetic aspartic acid mutation was completely transcriptionally 
inactive while the phospho-null glycine mutations resulted in generally marginal sub-level 
expression in all luciferase and RT-qPCR experiments, but exhibited large variations in 
measurement. A potential explanation for variability could be that a mutation to a glycine 
residue creates a consensus sequence for neighbouring PTM sites that experience PTM in a 
cell cycle dependent manner. Hence, the variation in cell cycle stage of cultured cells could 
explain the increased variability observed. This could be investigated by the use of cell cycle 
stalling agents, such as hydroxyurea, nocodazole, mimosine or thymidine blocking (Jackman 
et al., 2001, Bostock et al., 1971 & Koc et al., 2004), prior to hypoxic incubation and gene 
transcription. 
 
Investigating a potential cause of transcriptional inhibition by HIF-1α S31D by binding 
partner analysis identified that 10 separate GTPase proteins were specifically purified with 
the phospho-null HIF-1α S31G mutant, suggesting a phosphorylation induced lack of 
GTPase binding. From data presented here, there are two equally valid mechanisms that 
could explain the GTPase and DNA binding inefficiency correlation: 1) GTPases are essential 
for loading of active HIF onto the DNA, through unknown mechanisms. Consequently 
phosphorylation at HIF-1α S31 prevents GTPase binding and subsequent DNA binding. 2) 
Active HIF associates with the DNA together with GTPase proteins stabilising/activating 
transcription. The reduced DNA binding resulting from HIF-1α S31 phosphorylation thus 
simultaneously decreases GTPase protein binding. 
 
There is emerging evidence that a class of GTPase proteins (Rho GTPases) have a regulatory 
role in gene expression by promoting secondary interactions within the nucleus (Phuyal et 
al., 2019). Cdc42 is a rho GTPase protein identified here as a binding partner for the non-
phosphorylatable HIF-1α S31G mutant. Cdc42 is a well characterised protein, known to 
have multiple roles as an activator of various cell signalling pathways involved with cellular 
polarity (Melendez et al., 2011 & Etienne-Manneville, 2004). Thus, it is possible that Cdc42 
activates HIF-1α in a S31 non-phosphorylated state (S31G) for DNA binding by direct 
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mechanisms or indirectly, through a secondary protein interactors becoming activated 
(such as a kinase). Such a role in hypoxia based signalling has not yet been identified. 
 
The major constituents of the GTPases identified to bind S31G and WT HIF-1α are the Ras-
related Rab proteins. Rab proteins are known for their intracellular organisation roles, 
targeting proteins to specific membrane bound organelles (Hutagalung et al., 2011 & 
Wandinger-Ness et al., 2014). Rab32, Rab1 and Rab10 are involved with mitochondrial 
fission and ER vesicle formation respectively, an interesting observation due to the large 
quantity of mitochondrial and ER specific proteins identified in Chapter 4 (>10% of all 
proteins). Rab5 has roles in nuclear-cytoplasmic shuttling of effector proteins (such as PI3K) 
or sequestration of proteins to regulate gene expression, rather than direct protein binding 
(Schwartz et al., 2007 & Wandinger-Ness et al., 2014). Since Rab proteins can 
simultaneously act as scaffolds (Wandinger-Ness et al., 2014), and the fact that it is 
impossible to determine whether binding partners identified by Co-IP are direct or indirect, 
it is possible that a novel HIF binding partner may utilise Rab proteins for nuclear shuttling 
and activation. Thus, if the novel protein was blocked from interacting with HIF-1α by S31 
phosphorylation it could explain the loss of transcriptional function and the Rab protein 
binding. It would be interesting to investigate how Rab protein known-down experiments 
could influence the hypoxic response. 
 
Although the HIF-1α S786 mutations seemed to have no overall effect on transcription, it is 
possible that the luciferase assay failed to identify a transcriptional effect due to the nature 
of the experiment. HIF-1α S786 is situated within the CTAD which is essential for p300/CBP 
binding, and is functionally involved with chromatin remodelling for gene expression 
(reviewed by Chan et al., 2001). Therefore, it is possible that if p300/CBP binding is 
inhibited that endogenous gene expression regulation may be affected, while extra-nuclear 
plasmid DNA (not included in the chromatin and devoid of histone proteins) could remain 
unaffected. Thus, analysis of the S786 mutants through RT-qPCR should be performed 
before disregarding functional transcriptional outcomes. 
 
The HIF-2α S345 was selected because crystal modelling predicted a potential role in HIF-1β 
binding. HIF-2α S345 phospho-null mutation (S345A) had no effect on transcriptional 
response compared to WT, while a phospho-mimetic (S345D) mutation resulted in a large 
decrease in luciferase response. This could suggest that HIF-2α S345 phosphorylation 
weakens the HIF-1β binding strength, as predicted from modelling, thus limiting the 
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transcriptional efficiency of the HIF-2α protein by failure to form the active dimer. This 
could be investigated relatively simply through IP and western blotting for HIF-1β, however 
due to time restraints was not investigated further here.  
 
It is interesting that mutation to phospho –null, or –mimetic mutations of either HIF-2α 
T528 or S581 phosphorylation sites, which neighbour LAP proline hydroxylation sites, 
resulted in ~1.5 fold increase in transcription. One hypothesised explanation is that the 
hydroxyl group of the threonine/serine residue in an unmodified form is an essential 
component of a motif to target a secondary modification that results in the reduced 
transcriptional efficiency, through either protein stability or transactivation. Thus, mutation 
to a charged (glutamic acid/aspartic acid) or hydrophobic (alanine) residue abolishes the 
inactivating secondary PTM, hence stabilising HIF-2α transcriptional signal independently of 
physiochemical properties introduced by phosphorylation. With the creation of HIF-2α 
T406 phospho -mimetic (T406E) and -null (T406A) mutants, neighbouring the remaining 
known proline hydroxylation site, it will be interesting to investigate whether similar 
observations are identified to T528 and S581 mutations. We hypothesise that the increased 
HIF-2α transcription observed by these mutations, are due to protein stability, therefore 
multi-site mutational analysis may have synergistic effects. Thus, it is possible that the 
phosphorylation pattern of the HIF-2α T406/T528/S581 sites in 21% O2 (Chapter 4) could 
explain the observed 21% O2 stability of HIF-2α, while HIF-1α is rapidly degraded.  
 
Overall, using S31 as an example, this chapter highlights how a single PTM can dramatically 
alter the functional status of the HIFα proteins. In the context of drug development, HIF 
targeting in tumour progression is a major research interest with current approaches using 
HTP screening techniques to identify novel drugs (reviewed by Semenza, 2003 & Masoud et 
al., 2015). Problematically, the functional aspect of drug-based inhibition is lost and can 
lead to drugs with various side effects. A more targeted approach is preferable but requires 
mechanistic understanding of essential signalling pathways that regulate the hypoxic 
response, so that drugs can be designed to bind to specific regions of the protein, or the 
regulatory enzyme for specific functions and/or modifications to be altered. Thus with ~100 
different novel PTMs identified, it is not only exciting for the field of hypoxia regulation, but 









6.1. Final discussion 
This thesis describes the development and utilisation of tools to investigate the regulation 
of HIFα proteins by hypoxia in an unbiased manner. I was able to identify an in-depth 
phosphorylation map (~25 phosphorylation sites) for each of the HIF-1α and HIF-2α 
proteins, with the majority of phosphorylation sites identified being novel. Furthermore, an 
open PTM search (all possible PTMs) identified a potential further 25 PTMs per HIFα protein 
(additional to phosphorylation) including acetylation, methylation and irreversible cysteine 
oxidative modification. Combined with domain and evolutionary analysis of ~250 different 
vertebrate species, we were able to identify several interesting aspects from isoform 
differences and evolutionary conservation/variation, which we used to guide the 
investigation of potentially interesting phosphorylation sites (discussed in Chapter 4). Using 
mutational analysis, I determined that HIF-1α S31 phosphorylation inhibits transcriptional 
activity, independent of protein stability mechanisms, but rather through preventing the 
ability to bind to DNA. Additionally, I was able to identify many more binding partners of 
HIFα proteins than previously defined and evaluated their O2 dependent binding by label-
free quantification proteomics approaches. I used GO annotation enrichment analysis to 
identify O2 dependent cellular processes interacting with HIFα proteins to further 
understand the cellular processes that regulate these. There are several points to consider 
to guide future experimentation, discussed below. 
 
6.1.1. Novelty of the approach 
We have overexpressed full length HA-Clover tagged proteins to investigate the HIFα PTM 
status and binding partners. Such a strategy has the obvious drawback that HIFα expression 
is under a strong, exogenous CMV promoter and thus lacks endogenous DNA based 
regulatory mechanisms. Additionally, it is well-documented that purification tags, 
particularly larger tags such as GFP/Clover (~27 kDa, approximately 25% of the HIFα protein 
size), can influence protein function/localisation (Weill et al., 2019). However, it is 
important to consider that countless studies have utilised GFP tagging of proteins to 
investigate protein function by proteomics and microscopy techniques (Trinkle-Mulcahy et 
al., 2008, Lipinszki et al., 2014, Kubitscheck et al., 2000 & Soboleski et al., 2005), including 
for HIFα protein investigation (Jiang et al., 2001, Mylonis et al., 2006, Mylonis et al., 2008, 
Kalousi et al., 2010, Bagnall et al., 2014 & Taylor et al., 2016). These studies still constituted 




To ensure physiological relevance of the experimental system, we have used microscopy 
and transcriptional assays to confirm that HA-Clover-HIFα proteins had the correct nuclear 
localisation and were functionally active as transcription factors. Thus, in comparison to 
previous studies using recombinant fragment-based in vitro assays to determine PTMs in a 
targeted approach (Table 1.2 & Table 1.3), my methodology provided a much more 
biologically relevant representation of the HIFα signalling systems. 
 
One important focus of this thesis was to identify molecular features that could explain the 
observed differences between HIFα isoforms, such as sub-nuclear localisation and O2 
dependent stability. A discovery proteomics approach was adopted, primarily focusing on 
phosphorylation because of the availability of enrichment tools. However, from this study 
and other published studies, it is clear that HIFα proteins are subjected to multiple other 
types of PTM. Antibody based enrichment strategies are available for other PTMs. Whilst 
they are less easy to adopt than the TiO2 phosphorylation enrichment used in this study, 
they permit the enrichment of other PTMs, and thus could be used to provide a full in-
depth PTM map of HIFα proteins. This will allow the field to fully decipher the regulatory 
pathways of HIFα.  
 
In total, ~50 PTMs have been identified in this study for both HIF-1α and HIF-2α, which is of 
a similar order to the number of PTMs identified for endogenous p53. p53 has 86 different 
characterised PTMs and ~20 other PTMs have been identified in HTP MS studies (data 
obtained from PhosphoSitePlus (Hornbeck et al., 2015 & Hornbeck et al., 2012)). Therefore, 
although validation of the HIFα PTMs on endogenous proteins will be vital, this study 
provides an essential starting point to further understand HIFα regulation and its 
implication in signalling networks. 
 
Interestingly, few of the previously identified HIFα PTMs were identified in our dataset, 
thus posing an intriguing question for the hypoxia field: has the previously used 
methodology generated high rates of false positive data for both PTM identification and 
binding partner discovery? Two arguments could provide an explanation to the apparent 
discrepancy: 1) cell line specific regulatory mechanisms, and 2) the ‘hypoxia’ conditions 
used. Bracken et al., 2006 have shown that the protein expression levels and transcriptional 
profiles of HIFα isoforms vary considerably between cell lines, O2 tension used and whether 
hypoxia mimicking agents are used (specifically the iron chelator DFX). Hence the multiple 
different cell lines used, combined with different hypoxia conditions (many publications 
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using different hypoxia mimicking drugs, at different concentrations and for different 
incubation times), could explain some of the differences observed. Therefore, further 
experimentation following this study should: 1) validate the data in a range of cell lines and 
conditions, 2) investigate the dynamics of PTMs and binding partners, and 3) functionally 
characterise the hypoxia regulatory network.  
 
6.1.1.1. Validation of data 
Due to the discovery nature of these experiments, and the enormous quantity of cells 
required to obtain sufficient amount of HIFα proteins for robust MS analysis of the 
complete protein sequence, combined with a lack of good antibodies for IP, analysis of 
endogenous proteins would have been infeasible. However, now that the PTMs have been 
identified it will be possible to determine the exact m/z ratio of specific modified peptides 
and use a targeted MS approach (selective reaction monitoring (SRM)), increasing 
sensitivity up to 100 fold (Lange et al., 2008). Thus, theoretically, endogenous HIFα could be 
used to validate identified PTMs. Furthermore, an SRM pipeline could simultaneously be 
easily applied to previously published PTM sites by the in silico determination of proteolytic 
peptides and respective m/z ratios. However, for endogenous protein IP this would require 
the development of better antibodies, particularly for HIF-2α. Alternatively, CRISPR/Cas9 
technology could be used to insert a tag of interest into the genome, therefore maintaining 
endogenous expression mechanisms. 
 
6.1.1.2. Expanding the regulatory network 
It will be of interest to repeat the discovery proteomics aspect in different cell lines to 
investigate whether different cell lines have different HIFα signalling pathways. This could 
be further extended into investigation of hypoxia time courses and severity of hypoxia 
treatment. For example, prolonged (chronic) hypoxia is known to downregulate HIF-1α and 
promote HIF-2α signalling (Koh et al., 2012 & Uchida et al., 2004). Hypoxia severity is an 
interesting question, because cultured cells incubated under prolonged physiological levels 
of O2 (3-5%) are known to stabilise HIF-1α (Carrera et al., 2014). Therefore, it may be 
possible to compare regulatory mechanisms from a more endogenous regulation system to 
hypoxic cancers with 0.5-1.5% O2 (Table 1.1). Additionally, it will be interesting to 
investigate O2 independent mechanisms of HIFα stabilisation, such as in response to Insulin-
like Growth factor signalling (IGF2, Feldser et al., 1999), Epidermal growth factor receptor 
signalling (EGFR, Peng et al., 2006) or inflammation (Palazon et al., 2014), which all have 




6.1.2. HIF-1α versus HIF-2α 
From the PTM data obtained here, there are several noticeable patterns of interest 
(discussed in Chapter 4). The most striking observation is the possible role of 
phosphorylation in the O2 dependent degradation for both HIFα isoforms. It is clear that the 
HIF-1α ODDD is hyperphosphorylated, particularly in 21% O2 (4.7.2). Considering emerging 
evidence of the requirement of other PTMs for the efficient proline hydroxylation and 
degradation (Lee et al., 2017), it is possible that phosphorylation contributes to the O2 
dependent degradation of HIF-1α. Conversely, we predict that the phosphorylation status 
of HIF-2α may be, in some part, responsible for its O2 dependent stability. We find that for 
HIF-2α, there is a phosphorylation site adjacent to both canonical proline hydroxylation 
sites, and a novel third LAP motif. We further showed that mutation of any of these sites 
resulted in ~1.5 fold increase in transcriptional output. However, this requires further 
investigation, and evaluation of protein stability. 
 
It is important to consider that utilising a ‘Bottom-Up’ proteomics approach makes it is 
impossible to understand the co-regulation of PTM sites, unless identified on the same 
proteolytically generated peptide. Therefore a ‘Middle-Down’ proteomics approach could 
be adopted, where a minimally cleaving protease is used to produce large peptides of ~10 
kDa in size (Cristobal et al., 2017). This will allow the determination of combinations of 
PTMs before investigating PTMs using multi-site mutational analysis. This is particularly 
important when considering the potential roles of HIF-1α ODDD hyperphosphorylation, 
where multiple sites may co-exist and provide a degree of synergism between PTMs, 
therefore complicating the identification of functional roles by single site mutational 
analysis. However, multi-site mutational analysis of so many sites will likely result in off 
target effects, as structural and polarity changes in amino acids could have additive effects. 
Therefore, it will be important to investigate the co-existence of PTMs in a combinatorial 
fashion to define the PTM pattern and identify the mutants required for multi-site analysis. 
 
To investigate the binding partners we decided not to include benzonase, a DNA digesting 
enzyme, because DNA and long non-coding RNAs (lncRNA) are known to regulate binding 
partner interactions (reviewed by Siggers et al., 2014 & Schmitz et al., 2016). Recent data 
identifies that a lncRNA has an important role in stabilising HIF-1α protein, by preventing 
PHD2 binding (Chen et al., 2019). However, there is a possibility that chromatin DNA bound 
to HIF will Co-IP, resulting in the identification of proteins which do not interact with active 
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HIF but rather are associated with DNA. Therefore, the IP experiments could be repeated in 
the presence of benzonase to identify protein interactions that do not require DNA 
scaffolding mechanisms. Although this study is the first discovery style experiment for HIF 
binding partners, it was reliant on overexpression with a large IP tag. Therefore, it could be 
argued that the rate of false positive binding partners identified could be high, even though 
measures were taken for background subtraction. We were able to use the low level 
expression (near endogenous levels) to detect binding partners of mutants (5.5.1). 
Therefore, with optimisation and scaling, it will be easily possible to IP endogenous HIF-1α 
(and HIF-2α if an adequate antibody is found) for the detection of protein interactors of 
endogenous proteins. If further experiments are performed to identify endogenous HIFα 
binding proteins, they should strongly consider a reversible crosslinking IP strategy (Smith 
et al., 2011), because many protein interactors will be stimuli specific and highly transient, 
particularly when considering modifying enzymes. Such a strategy, will allow to obtain a 
more in-depth interactor map. 
 
The fact that >100 proteins (~10% of all proteins) identified for both HIFα isoforms were 
mitochondrial in nature is interesting. The validity of this discovery is supported by a 
number of published studies demonstrating a sub-population of HIF-1α localised in 
mitochondria (Briston et al., 2011, Concolino et al., 2018 & Thomas et al., 2019). 
Additionally, it has been shown that mitochondria have a role in the stabilisation of HIFα 
proteins through the development of ROS, and may act as a secondary O2 sensing 
mechanism to PHDs (Guzy et al., 2005 & Chandel et al., 1998). Overall, this could raise an 
interesting question: does HIF have a role in regulating mitochondrial DNA? Indeed, when I 
searched the mitochondrial DNA (UniProt accession: NC_012920, Andrews et al., 1999) we 
identified 20 putative HRE promoter sequences ((A/G)CGTG, Schödel et al., 2011). Using an 
annotated gene map of mitochondrial DNA will provide initial insight to whether these 
identified HREs are in proximity to functional genes, and may be HIF regulated, or whether 
they are intronic in nature. This will be an interesting avenue to pursue. It is likely that 
fluorescent tagging for live cell microscopy, previously used to investigate sub-cellular 
localisation, will struggle to identify HIFα in mitochondria as they may likely be below the 
limit of detection. Therefore, a proteomics approach that employs sub-cellular fractionation 
to purify mitochondria before lysis, potentially coupled with an SRM targeted approach, 




6.1.3. Evolutionary analysis 
Our evolutionary analysis was performed on HIFα sequences from vertebrates only, for 
reasons explained in Chapter 4, including the fact that invertebrate species do not have 
specialised O2 delivery systems. However, more advanced invertebrate species do infact 
have complex O2 delivery systems including dense vasculature networks and haemoglobin 
based O2 transport systems, for example in crab and squid species (Birk et al., 2018 & Alter 
et al., 2015). Although these ‘HIF-1α’ proteins are larger than human HIFα (~1000 vs ~850 
residues) they are much smaller than insect HIFα proteins (~1500) and could reflect the 
evolution of developing specialist O2 delivery systems. A more directed approach to 
investigating HIF-1α evolution could potentially be adopted by combining a knowledge 
based, selective inclusion of invertebrate species, especially considering that very early 
invertebrate jellyfish species have HIF-1α homologs (Wang et al., 2014). Additionally, the 
bHLH and PAS domains are common domains in many proteins, therefore it would be of 
interest to investigate how the respective domains have evolved between proteins to 
identify potential regulatory differences and PTM sites of interest. 
 
From the sequence alignments performed here, it is clear that both HIFα isoforms are 
highly evolutionarily conserved, highlighting their functional importance. However, the 
inhibitory domain is poorly conserved between isoforms and among vertebrate species, 
generally only conserved within families. Interestingly, Bony fish species show extensive 
variation in this region, with all species, except for hypoxia tolerant Carp, missing the first 
~50 residues, which is serine/threonine rich in human with 15 different residues. 
Unfortunately, from our study this serine/threonine rich region was unanalysable by MS, 
even using multiple different proteases, therefore it would be of interest to investigate this 
further using different proteolytic strategies to identify if phosphorylation has a significant 
role here. The inhibitory domain could possibly be viewed as an evolutionary ‘hot pocket’ 
for mutations, to both distinguish between HIFα isoforms and provide slightly altered 
function between phylogenetic families.  
 
6.1.4. Outlook and future perspective 
Whilst we have discovered many novel PTMs and binding partners in this work, it has posed 
many new questions, including: 1) The functional meaning of the PTMs and interactions 
identified. 2) Whether the PTM status may be transient/dynamic and its robustness as a 
result of different hypoxic incubations/treatments and cell lines. 3) The potential role of 
HIFα in mitochondria, and 4) The accuracy and relevance of previously used methodologies 
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to study HIF PTM status and regulatory roles. Overall it appears that the canonical proline 
hydroxylation pathway is not the only pathway to act on HIFα. However, unravelling the 
functional outcomes post PTM will require extensive further work. The results of further 
characterising HIFα regulation/signalling might make it possible to target hypoxic cells in 
tumours in a selective manner, by inhibiting (or promoting) modifying enzymes. If this can 
be achieved, it would prevent the blanket inhibition of HIF signalling, which is likely to have 
various side effects for hypoxic adaption elsewhere in the body.  
 
Finally, our data suggest that the signalling pathways regulating HIF function may be orders 
of magnitude more complex than the current understanding, opening up multiple avenues 
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